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Abstract 
Aim: Chemokines are signalling molecules that mediate the migration of immune cells 
and are involved in tumour progression, invasion, and metastasis. CXCL8 and 
CXCL10 are responsible for the recruitment and activation of leukocytes to the site of 
inflammation. The aberrant expression of CXCL8 or CXCL10 and their receptors was 
identified in multiple cancer types where they contribute towards cancer progression. 
The aim of this thesis was to characterise the role of these two chemokines in cancer 
cell migration and associated cellular morphological changes, as well as identifying 
the main signalling pathways involved in these processes, which could be utilized as 
desirable targets for therapeutic intervention to prevent cancer progression. 
Methodology: To investigate the migratory effect of CXCL8 and CXCL10 on cancer 
cell lines, several migration assays were used, such as time-lapse imaging, 
chemotaxis, wound healing, and Boyden chamber. The expression of the 
correspondent receptors of both chemokines was observed using 
immunofluorescence assay. To investigate the downstream signalling pathways 
involved in the chemokine-induced migration and cytoskeleton rearrangement, a 
number of small molecule inhibitors were used. The effect on the release of 
intracellular calcium was also assessed for some of the inhibitors. 
Results: We identified a role of CXCL8 and CXCL10 signalling in the migration of 
THP-1, MDA-MB231, PC3 and MCF-7 cells. Using small molecule inhibitors to target 
signalling molecules revealed a difference in the pathways utilised by CXCL8 to 
induce migration in the two cell lines: PC3 and MDA-MB231 cells. The major signalling 
pathways investigated are Pi3K/AKT, Raf/Rac/MEK/ERK, DOCK1/2/5, FAK/Src, 
Arp2/3, PKA, PKC, PKD, and β-catenin. Inhibitors like LY294002, AKTi, ZM336372, 
SL327, PD89059, BS203580, EHT1864, CPYPP, PF562271, Bosutinib, CK666, 
CID755673 can inhibit the migration of both MDA-MB231 and PC3 cells which could 
be further investigated as universal inhibitors. Other inhibitors like L779450, FH535, 
and H89 were cell-type specific. Furthermore, the effect of PKC on the migration and 
cytoskeleton rearrangement was cell-type and chemokine specific. 
Conclusion: In this thesis we confirmed the migratory effect both CXCL8 and 
CXCL10 have on different cancer cell lines. The signalling pathways involved in the 
chemokine-induced migration varied between the cell lines. These potential signalling 
molecules that were identified require further investigation to establish their vitality as 
potential cancer treatment.  
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1 Chapter 1: Introduction 
 Cell migration and cancer metastasis 
Metastasis is the spread of cancer cells from the primary tumour site to distant organs, 
and is considered the main reason for cancer morbidity and mortality [2]. The 
molecular mechanisms involved in the process of cancer cells metastasizing are not 
well understood due to their complexity. Mainly it includes the tumour detaching from 
the primary site, intravasating into the vascular or lymphatic circulations, escaping 
immune attack, invading the vascular basement membrane and extracellular matrix 
(ECM) to extravasate at distal capillaries, invading and proliferating by gaining 
epithelial characteristics in distant organs [3]. Several hypotheses aimed to explain 
the process and origin of metastasizing cancer cells. One of which addressed the Go 
or Grow hypothesis, stating that cell division and migration are temporally exclusive 
phenomena, and cancer cells defer proliferation for cell migration [4]. It is proposed 
that cells cannot undergo cytoskeletal changes and genetical modulation to perform 
both cell division and migration simultaneously [4], [5]. In other words, proliferating 
cells have less migratory attitude, and migrating cells have less proliferative 
behaviour. However, with their heterogeneous properties, cancer cells tend to have a 
mixed phenotype of moderate levels of migration and proliferation concurrently [6], 
[7]. As for the ability of primary tumour cells to gain migratory abilities brings up the 
epithelial-mesenchymal transition (EMT) phenomena.  
EMT is characterized by the phenotypic and morphological changes 
encountering epithelial cancer cells leading to their transformation into mesenchymal 
cells during tumour metastasis [8]. During EMT, tumour cells surrounding the 
epithelial cells and matrix lose their polarity and adhesive features to give a more 
elongated, spindle-like, fibroblastic-like shape, thus improving the ability of cells to 
migrate and invade [9]. EMT undergoes differential expression of several epithelial 
and mesenchymal molecular cancer markers, such as the activation of transcriptional 
repressors of E-cadherin gene in the downstream signalling, including down-
regulation of epithelial markers such as α-catenin, β-catenin and γ-catenin leading to 
the loss of the epithelial phenotype, while an upregulation of mesenchymal molecular 
markers such as N-cadherin, vimentin, and fibronectin [10]. Therefore, EMT has been 
considered as a potential drug target with inhibitors of receptor tyrosine kinases 
reaching to Phase III clinical trials [11].  
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Moreover, whereas EMT requires prolonged and extensive gene transcription 
changes, mesenchymal-amoeboid transition (MAT) or amoeboid-mesenchymal 
transition (AMT) undergo a rapid alternation to the motility behaviour that suppress or 
enhance the activity of certain pathways involved in the metastasis process [12].  
The mechanism of migration recruited by cells after EMT can be categorized 
into one of the two categories: single and collective migration [13]. The classic opinion 
about metastasis seeding begin with a single colonial growth tumour cell from the 
primary tumour, that goes through a sequence of complicated events compromising 
the basic tumour transmission models, such as EMT and migratory cancer stem cells 
to arrive to its distant site [14]. However, the current paradigm is suggesting that 
seeding requires collective migration which is probably one of the main modes of 
migration during metastasis of many solid tumours [15]. Indeed, emerging evidence 
showed a significant difference in the mechanics between the two types of migration 
[15]. Single cells can circulate as individual circulating tumour cells (CTCs) and use 
two main modes of migration, amoeboid and mesenchymal. Amoeboid migration is 
described by blebbing, rounding, weak adhesions, and rapid migration, while 
mesenchymal migration is described by strong fibres, polarization, and actin 
meshwork including leading and trailing edge [16], [17]. Amoeboid migration is a more 
flexible and squeezing-into-gaps kind of pattern that does not involve degrading the 
ECM. The amoeboid tumours usually have hematopoietic or neuroectodermal origins, 
involving leukaemia, lymphoma, and small cell lung carcinoma, and most other 
tumour types [18], [19]. In contrast, the migration of mesenchymal cells generates the 
path as cells degrade the surrounding ECM using proteolysis to allow them to move 
through [12]. This migration pattern is also adopted by collective CTC and not limited 
to single CTCs [20]. The mesenchymal migrating tumours are often from tumours of 
the connective tissues, including fibrosarcoma or breast cancer cells [21]. Certain cell 
types may alternate between migration types at different points in time obtaining 
hybrid phenotypes as they circulate the microenvironment [20], [22]. Moreover, 
collective cells migration are detected in early stage cancer patients, have high 
invasive capacity, associated with worse clinical outcomes and have high survival 
response to chemotherapeutics than the single CTCs migration [23]. Collective CTCs 
can migrate in a verity of modes including sheets, strands, tubes, and clusters (Figure 
1). They differ to single CTCs mainly by maintaining connection via cell-cell junctions 
during movement and exhibiting collective polarization, mechanical coupling, and 
cytoskeletal kinetics [14]. Therefore, tumour cells undergo EMT, MAT, and AMT 
assuming different migration modes depending on the environment [12], [24].  
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Figure 1. The different motility modes adopted by tumour cells upon 
detachment from the primary tumour. Cells can spread individually, or 
collectively as multicellular groups based on specific cell-cell junctions. During the 
process, cells change morphology to adjust to the environment between an 
amoeboid and mesenchymal phenotype. Image is taken from [20]. 
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Cell migration is initiated and maintained by signalling pathways that regulate 
cytoskeletal dynamics [25]. In general, cytoskeleton dynamics interact with cell 
surface receptors that engage with the surrounding environment; consequently, the 
cytoskeleton operates as an engine, and the receptors behave as its transmission 
[20], [25]. The process starts with a migratory signal that causes the cell to polarize. 
During polarization, the front and rear ends of the cells change in structure  [26]. Some 
of the vital regulators of this process are Rac and Cdc42, which reside at the leading 
edge of the cell, while Rho gathers at the sides and rear end of the cell [27] (Figure 
2). The polarization of elongated mesenchymal migrating cells starts with assembling 
actin-rich protrusion like lamellipodia and filopodia at the leading edge [28]. 
Lamellipodia form a dendritic-like endings, branched and cross-linked actin network 
that sway across a broader stretch of the membrane, while filopodia are formed of 
parallel bundles of actin filaments that can sense signals from the surrounding 
environment [28]. During protrusion formation, lamellipodia are made by the Arp2/3 
complex, which  resides near pre-existing filaments, responsible for forming new actin 
filaments that branch off [29]. Rho GTPases modulate WASP/WAVE, which in turn 
regulate the action of Arp2/3 complex [30], [31]. Rac is necessary for lamellipodia 
extension, promoted by growth factors, cytokines and ECM components [32]. 
Although actin reorganisation is regulated by Rho GTPases, Pi3K are considered 
crucial for cell polarity and defining the leading edge of the cell [33]. This is suggested 
to be controlled by a positive feedback loop between Rho and Pi3K, which are 
required for efficient cell migration [34]. Extension of protrusions happens alongside 
the assembly of focal adhesions that attach the actin cytoskeleton to the ECM [35]. 
This process is mediated by adhesion molecules, such as integrins, Arp2/3, formins, 
cofilin and cortactin [16]. These molecular structures along with contractile actin stress 
fibres serve as traction areas to push the cell, and as sensors to translate signals from 
the ECM to the inside of the cell [12]. Assembled integrins give rise to the focal 
adhesions that then recruits EMC proteolytical enzymes such as metalloproteinases 
(MMPs) to perform pericellular ECM remodelling to lay out the path for migrating cells 
[36], [37]. The disassembly of adhesions is modulated by Src, FAK and phosphatases 
[38]. It is thought that this pathway stimulates Rac and Erk which are responsible for 
adhesion turnover [39]. In contrast, as mentioned before, in the amoeboid migration 
style, cells assume a rounded shape with ability to squeeze and glide through matrix 
barriers having contractility abilities, without involving MMPs and integrins [24]. Thus, 
with metastasis being a multistage process during which cells pass through different 
migration styles, it is vital to have a full understanding of the signalling molecules 
orchestrating the migration process to manage tumours spreading.
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Figure 2. Assembly of actin filament network. Cell migration comprises cell polarization and protrusion of the leading edge (driven by 
lamellipodia and filopodia). Lamellipodium requires Rac for its assembly and stimulation of membrane ruffling, and it is comprised of a branched 
actin filament network, which are nucleated by Arp2/3 complex [29]. Filopodium are highly regulated by Cdc42 and is constructed of parallel 
bundles of Fascin cross-linking in the filopodia [40]. The cell will then attach the leading edge to the substrate with focal complexes, which develop 
into focal adhesions. Focal adhesions are integrin-based structures that anchor the ends of stress fibres [41]. Stress fibres are composed of thick 
antiparallel contractile actin filaments. They mediate strong attachments to the substrates and require Rho for their assembly [41]. Cell body 
contraction is driven by forces generated by actomyosin interactions [42]. Myosin II creates contractile forces implicated in driving actin network 
translocation [43]. RhoA is capable of stimulating myosin II through ROCK [25]. Rho activates tail retraction and forward sliding of cell rear [44].
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 Chemokines and chemokines receptors 
 Chemokines 
Chemokines are a family of small secreted proteins that are structurally related to 
cytokines and are distinguished from other chemoattractants by their specificity to 
leukocytes subsets [45]. The chemokine system is a large one that is currently known to 
include more than 50 chemokines and 20 chemokine receptors [46] (Figure 3).  
 
Figure 3. Illustration of chemokines and their respective cognate receptors. Multiple 
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They are small (6-14 kDa) molecular chemoattractants comprising structurally 
related and secreted proteins of 67-127 amino acids in length [48]. NMR and X-ray 
crystallography studies have revealed a lot about their structures. All chemokines feature 
a remarkably conserved tertiary structure containing a disordered N-terminus (signalling 
domain) of 6-10 amino acids which functions as an important domain in all characterised 
chemokines [49]. This region is followed by a structured core domain of a long N-loop, a 
310 helix, a three stranded antiparallel β-sheet, an α-sheet at the C-terminal tail, and 
disulfide bonds for the stabilisation of the structure of the chemokine monomers  [49]. 
Chemokines are classified into four subgroups based on the location of the two initial 
cysteine residues attached to the N terminal of each chemokine: CXC, CC, CX3C, and 
C chemokines (C represents the cysteine and X represents the non-cysteine amino 
acids) [50]. CXC chemokines are further subdivided into ELR- and ELR+ according to 
the presence or absences of the three motif amino acids: Glutamic acid-Leucine-
Arginine, that proceed the first cysteine residue on the N-terminus [51] (Figure 4). 
 
Figure 4. A schematic of a chemokine structure. Representation of an N-terminal, 
N-loop residues, three stranded antiparallel β-sheet, and an α-sheet at the C-terminal 
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Chemokines are known to form dimers and oligomers, alone, in solution or when 
interacting with glycosaminoglycans (GAGs). CC dimerization occurs through the N-
terminus where this domain becomes buried in the β-sheet of the other protomer [53]. 
While CXC ligands, for example CXCL8, form dimers by the interaction of residues from 
the first β-strand from one subunit to the same region of a second subunit, giving one 
extended six-stranded β-sheet which binds to the α-helix at the end of the C-terminus 
[54]. The different dimers motifs of CC and CXC ligands were primarily thought to define 
the affinity of interaction with the respective chemokine receptor [55], however, it is 
hypothesized that chemokines bind with their receptors as monomers, at least when 
directing cells motility [49], [56], [57]. For example, monomeric mutants of CXCL8 were 
found to recruit and stimulate neutrophils in vitro as efficiently as wild type, consistent 
with the data suggesting receptor interaction as a monomer [58], [59]. The monomeric 
form of CCL2 was also found to be sufficient for receptor binding and activation [60]. 
Nonetheless, oligomerization was still found to be involved in some crucial cellular 
functions independent of direct receptor interaction, such as binding to GAGs [61]. The 
latter interaction facilitates the secretion of chemokines from cancer cells, T cells, 
maintaining chemokine stability and signalling [62]. Notably, binding to GAGs appeared 
to be important in establishing a cell surface gradient to facilitate directional migration, in 
vivo, although this is not necessarily the case in vitro [63], [49]. Hoogewerf and 
colleagues confirmed that cell surface GAGs promote polymerization of chemokines, 
resulting in their elevated concentration which promotes their effect on their receptors 
[64]. Loss of GAGs significantly reduce the affinity of cells to chemokines [65]. 
Furthermore, binding to GAGs can protect some chemokines against processing by 
specific proteases [66]. For instance, Metzemaekers et al. [67] found that NH2 proteolytic 
cleavage of CXCL9, CXCL10 and CXCL11 mediated by dipeptidyl peptidase IV/CD26 is 
protected by CXCR3 binding to GAGs, while this GAGs interaction also interferes with 
the receptor signalling. Consequently, the two states of monomers or oligomers share 
the significance in enabling chemokines function either by binding to the respective 
cognate receptor or with GAGs, accordingly. 
Indeed, It is suggested that chemokines can promote each other’s functions by 
forming heterodimers [68], [69], a process referred to as “chemokine cooperativity” [70]. 
Cooperative chemokines compete for binding with GAGs, thus elevating the effective 
free chemokines concentration that can bind their receptors [64]. Indeed, heterodimers 
formation is found to be thermodynamically favoured among various chemokines such 
as CXCL4, CXCL8, CXCL1 and CXCL7, CCL5, CCL2, and CCL8 [69]. For instance, 
CXCL4 binds to CXCL8 which attenuates CXCL8-stimulated signalling in CD34+ human 
hematopoietic progenitor cells, promote CXCL8-stimulated chemotaxis, and induce the 
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anti-proliferative effect of CXCL4 on endothelial cells [71], [72]. Therefore, the function 
of chemokines can be influenced by the formation of heterodimers which can have 
substantial biological implications.  
Although one of the main characteristics of chemokines is their ability to induce 
direct migration in a process called chemotaxis, they also have shown more complex 
physiological functions; having homeostatic roles in haematopoiesis, stimulating 
adaptive immune responses and immune surveillance [73], [74]. The expression of 
chemokine receptors was reported in the skin, intestinal mucosa, and lungs for their role 
in continuously invigilating any abnormal activity [49]. Chemokines are classified into 
inflammatory or homeostatic chemokines, although, few of them were identified to have 
dual-functions [75]. Inflammatory chemokines are expressed by leukocytes, and regulate 
the recruitment of monocytes, neutrophils, and other effector leukocytes from the 
circulation to the infected and damaged tissue [48]. The expression of inflammatory 
receptors is reported to be temporary within the inflammation area until the situation is 
resolved [49]. The other class of chemokines are homeostatic chemokines which are 
constitutively expressed [76]. They are needed for the constant regulation of cell 
migration required by the immune system and processes that are involved in the 
progressive movement and patterning of cells, such as in T and B cells development to 
particular secondary sites of the lymph nodes [48]. Lymphocytes also require 
haemostatic chemokines for regular immune monitoring [76]. Dual-function chemokines 
engage in immune defence by being activated in inflammatory conditions and target non-
effector leukocytes at sites of leukocyte development and immune surveillance [74]. This 
type of chemokine was identified to have a role in T-cell development in the thymus and 
recruitment to inflamed tissue [74]. 
Furthermore, chemokine expression has been associated with many pathologies 
including cancer. Indeed, malicious cancer cells take advantage of the chemokine 
system in order to survive, progress, metastasize and colonise at distance areas, as well 
as promote the immune suppression [77]. Moreover, the aberrant expression of 
chemokines and their receptors has been documented  to correlate to different 
pathologies [78] such as: autoimmune, vascular, pulmonary disorders relating to 
psoriasis, atherosclerosis, rheumatoid arthritis, multiple sclerosis, asthma, sepsis, 
inflammatory bowel disease, transplant rejection or HIV (as reviewed by [49]).  
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 Chemokine receptors 
Chemokine receptor structure: Chemokine receptors belong to class A 
rhodopsin-like family of G-protein coupled receptors (GPCRs) or seven-transmembrane 
(7TM) receptors, with three intracellular and three extracellular hydrophilic loops [79]. 
They are close in size (about 250 amino acids in length), have an acidic N-terminal end 
exposed outside the cell and an intracellular C-terminus containing serine and threonine 
residues facing the cytosolic side. The first two extracellular loops of the receptor have 
a pair of conserved cysteines that allow the formation of a disulphide bridge between 
these loops [80]. The extra disulphide bond is expected to keep the membrane-spanning 
segments arranged in a circle to maintain the 3D structure of the receptor [81]. G-proteins 
are coupled to the C-terminal domain of the receptor which, when activated, signal to 
multiple distinct intracellular signalling cascades, while the N-terminal determines ligand 
binding affinity [82].  
 Ligand-receptor activation 
Ligand binding structure: Structural and functional studies indicate that all 
chemokines bind to their receptors using the same two sites, N-terminal and N-loop 
(binding domain) residues of the ligand to the N-terminal and one or more extracellular 
loops of the receptors [52]. The first step of ligand-receptor binding involve the core 
domain of the ligand, including the N-loop, binding with the N-terminus (site I) and the 
extracellular loops of its receptor, this binding area is referred to as the “chemokine 
recognition sites” [83] and triggers receptor activation. Notably, the term “chemokine 
redundancy” [84] has been associated with the ability or “promiscuity” of one chemokine 
to bind to multiple types of its receptors, both canonical and atypical ones, to exert similar 
or different actions based on the context [85], [85]. In the second step, the flexible N-
terminus (triggering domain) of the ligand binds with the second recognition site buried 
in the cavity formed by the extracellular loops of the transmembranes domains III to VII 
(Figure 5). This process induces a change to the receptor conformation that initiates 
receptor activation followed by signal transduction [86]. Consequently, the N-loop 
residue is important for receptor selectivity and binding affinity, and N-terminal residues 
are significant for binding affinity and receptor activation [52]. Truncation of the N-
terminus often leads to the chemokine losing its agonist activity, where the chemokine 
still binds to the receptor in high affinity but acts as an antagonist [61], [83], [87], [88]. On 
the other hand, some chemokines that are highly present in the plasma membrane [89] 
possessing long N-terminal extensions could demonstrate elevated agonist activity 
levels by sequential N-terminal proteolytic processing [87]. 
G-proteins in receptor activation: G-proteins consists of three subunits α, β 
and γ. Upon receptor stimulation, GPCR undergo conformational changes that expose 
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the intracellular sites involved in the interaction with heterotrimeric G-proteins. The Gα 
subunit is bound directly to the receptor intracellular loops, while Gβ subunit bind to Gγ 
in a tight complex. Ligand-receptor interaction leads the dissociation of GDP-bound Gα 
subunit to be exchanged and replaced with GTP [90]. Gα-GTP then separates from the 
receptor and the Gβγ heterodimer. The two G-protein complexes then stimulate various 
downstream effectors that ultimately lead to cellular responses such as cytoskeleton 
rearrangement, cell migration, integrin upregulation, release of oxidative species and 
phagocytosis [91]–[94]. 
 
Figure 5. A model of chemokine ligand-receptor binding. The N-loop of the 
ligand interacts with the N-terminus of the receptor (site I), and the N-terminal of 
the ligand interact with the receptor extracellular loops and transmembrane 
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 Receptor desensitization and internalisation 
Internalisation and desensitisation are two regulatory methods cells use to regulate the 
level of the receptor expression and to prevent continuous signalling. Indeed, stimulation 
with elevated amounts of the chemokine may exhibit receptor internalisation rather than 
the initiation of Gαi activation as well as, prolonged exposure to chemokines could lead 
to the downregulation of the receptor from the cell surface [96]–[99]. In desensitization, 
the receptor becomes refractory to the constant stimuli signalling. Moreover, endocytosis 
is a cellular activity mainly responsible for membrane receptor internalisation, where the 
receptor is physically removed from the cell surface and form an endosome. Notably, 
endocytosis could lead to total cellular receptor reduction through receptor 
downregulation [100]. Three families of regulatory molecules are involved in tightly 
controlling receptor desensitization: second messenger dependent protein kinases, G 
protein-coupled receptor kinases (GRKs) and β-arrestins. GRKs along with protein 
kinase (A) and protein kinase C (PKC) specifically phosphorylate the activated receptor 
which in turn recruit β-arrestins that are ubiquitously expressed and lead receptor 
desensitization, endocytosis and signalling [101], [102]. 
Activated chemokine receptor binds to β-arrestins which are adaptor proteins that 
act by interacting with phosphorylated serine/threonine residues on the C-terminal tail of 
the receptor [103]–[105]. Recruited β-arrestins block any further G-protein coupling by 
sterically inhibiting the receptor and G-protein interaction. The conformational changes 
of the receptor due to interaction with β-arrestins promotes endocytosis which is 
generated by the coordinated contact of β-arrestins with clathrin, adaptor protein (AP-2) 
and phosphoinositides [106], [107]. The complex ultimately leads the receptor to be 
recycled or degraded via lysosomes formation (Figure 6). 
Accumulating evidence suggest that along with the β-arrestins being an adaptor 
protein binding to endocytosis machinery to terminate signals, they could also function 
as scaffolding proteins that activate several signalling pathways such as Src [102], and 
components of MAPK, ERK, JNK, and p38 cascades [108]–[111]. β-arrestins can confer 
different enzymatic activities upon the receptor, which may results in signals that 
modulate different cellular responses such as being involved in the regulation of the actin 
cytoskeleton [112]–[115]. For example, Luttrell et al. [116] found that β-arrestins can 
interact with GRKs and cytosolic tyrosine kinase c-Src, resulting in Src recruitment to the 
β-arrestins-clathrin-coated pit complex, thus initiating mitogenic signals from the 
activated receptor. Further studies showed the involvement of Src recruitment by β-
arrestins to be associated with tyrosine phosphorylation of dynamin [117], stimulation of 
ERK/MAPK pathway [109], [116], and activation of neutrophil degranulation [118]. 
Serving as a scaffold, β-arrestins can trigger the activation of JNK3 pathway [119].  
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As for the role of β-arrestins in chemotaxis, receptor desensitization and recycling 
are important for maintenance of cellular polarity required by chemotaxis [111], [120]. β-
arrestins can serve as scaffolds to localize molecules involved in cytoskeleton 
rearrangement associated with chemokines-induced cell migration [121]. In a review by 
DeFea [121], it was argued that β-arrestins may prefer terminating the coupling of the 
receptor with G-proteins in the back of the cell while the front of the cell being heavily 
polarized in the direction of the chemoattractant gradient. Additionally, the importance of 
β-arrestins in chemotaxis downstream of multiple receptors was linked to apoptosis, 
inflammation as well as cell migration [111], [122]–[125]. 
 
Figure 6. β-arrestin-dependent desensitization and internalisation of GPCRs. 
Chemokine activation of the GPCR leads to G-protein dissociation and stimulation of 
downstream signalling cascades. GPCRs are phosphorylated by GRKs leading to the 
recruitment of β-arrestins [126]. β-arrestins act together with clathrin and AP-2 complex, 
which associate the receptor to clathrin-coated pits. The GTPase, dynamin, regulates 
the release of the clathrin-coated pits. Clathrin-coated vesicles are formed, and the 
receptor is then internalized into endosomes. Dephosphorylation of the receptors leads 
to their degradation through formation of lysosomes or resensitization and recycling 
moving back to the cell surface. Beyond the function of β-arrestins in regulating receptor 
endocytosis, they can recruit c-Src and initiate mitogenic signals from activated receptors 
[116]. Recruitment of Src kinases might also modulate receptor endocytosis, trigger 
ERK1/2 stimulation, and regulate exocytosis [102]. β-arrestins can also serve as scaffold 
for JNK3 pathway [119] or trigger the assembly of MAPK activation and subsequently 
ERK1/2 signalling [102], [109]. 
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 CXCL8 and CXCR1-CXCR2 axis 
CXCL8, also known as interleukin (IL-8), is a proinflammatory CXC chemokine that was 
first reported in 1987 for its activation and recruitment of neutrophils and granulocytes to  
sites of inflammation [127], [128]. Its history goes back to Peveri et al. [129] who showed 
that LPS-activated monocytes produce a protein called neutrophil activating factor 
(NAF), which leads to the stimulation of neutrophil exocytosis and respiratory burst by 
binding to specific cell surface receptors. NAF was purified and sequenced and later 
called IL-8 or CXCL8 [128]–[130]. 
CXCL8 acts by binding to its cognate receptors CXCR1 and CXCR2. This 
chemokine is barely detected in normal tissues or unstimulated cells [131]–[133]. 
However, CXCL8 receptors are expressed on the surface of leukocytes including 
neutrophils, monocytes, macrophages, basophils and T-lymphocytes and endothelial 
cells [134]. The expression of CXCL8 is rapidly induced by hypoxia, cytokines (such as 
tumour necrosis factor α (TNF-α), IL-1β, and IL-6), growth factors, and 
pathophysiological stresses mediated by transcription factors (such as nuclear factor-кB 
(NF-кB) and activator-protein-1 (AP-1)) [135]–[137]. Hypoxia and stressed tumour 
microenvironments use NF-кB to induce macrophages to secrete CXC chemokines 
[138]. Indeed, cytokine-mediated stimulation of NF-кB is considered the leading 
mechanism for transcriptional induction of chemokines. Specifically for CXCL8, 
transcription is regulated through NF-кB as well as other transcription factors including 
API and NF-IL-6 [139]–[141].  
Moreover, the effect of autocrine/paracrine signalling of CXCL8 on the elevated 
expression levels of CXCR1 and CXCR2 has been reported in many cancer cells, 
suggesting a positive role of this chemokine on the cancer microenvironment [142], [143]. 
For instance, CXCL8 induces the angiogenic responses in CXCR1 and CXCR2 
expressing endothelial cells [144], and the recruitment of neutrophils to the tumour 
microenvironment through its paracrine activity [137]. Simultaneously, in melanoma 
cells, stimulation with CXCL8 promotes cancer cell proliferation, survival, and migration 
via an autocrine activity [145]. Indeed, CXCL8 acts as an autocrine growth factor in liver, 
pancreas, and colorectum cancer [146]–[149]. Autocrine signalling according to Oladipo 
et al. [150] may have adverse prognostic effects in breast cancer, on the other hand, the 
positive role of CXCL8 in immune infiltrate may have good prognostic implications. 
Taking it together, the aberrant expression of CXCL8 have been noted to be associated 
with advanced stages of cancer and a poor prognostic marker for malignant disease, 
however, its complex role in the tumour microenvironment and its role as a prognostic 
and/or predictive cancer biomarker requires further investigation. 
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 Activation of CXCR1 and CXCR2  
CXCR1 and CXCR2 belong to the vast family of GPCRs, which bind extracellular ligands 
and consequently initiate intracellular signalling. Both CXCR1 and CXCR2 are highly 
homologous, sharing 76% sequence and bind to CXCL8 with similar affinities [151], 
[152]. The most divergent regions between the two receptors are the N-terminal 
(extracellular) and C-terminal (intracellular) regions [151]–[154]. CXCR1 is stimulated 
upon the interaction with CXCL8 or granulocyte chemotactic protein-2, whereas CXCR2 
is stimulated by CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, granulocyte 
chemotactic protein-2, and growth-regulated oncogenes [143], [155], [156]. Both 
receptors internalize through the recruitment of arrestins, with CXCR2 showing an extra 
phosphorylation-independent internalizing mechanism [102], [157]. Notably, CXCR2 
undergoes internalisation rapidly (∼95% after 5-10 min) with slower recovery (∼35% 
after 90 min) relative to CXCR1 which internalizes slowly (∼45% after 1 hr) and recovers 
rapidly (∼100% after 1hr and 30 min) [98], [103], [158]. Indeed, a study by Richardson 
et al. [103] found that the C-tail of phosphoryl-deficient and C-terminus deleted mutants 
of CXCR1 and CXCR2 is crucial for receptor phosphorylation and arrestin recruitment, 
yet, it is not sufficient to account for the differences in receptor internalisation and 
recycling. These difference in receptor trafficking seem to be substantial for determining 
the ability of the receptors to stimulate specific leukocyte responses, including respiratory 
burst and cross-regulatory and exocytotic signals [158].  
Furthermore, CXCL8 can exist in monomer or dimer forms that could bind with 
CXCR1 and CXCR2 with different affinities and potencies to regulate various cellular 
events [159]. CXCL8 forms dimers at micromolar concentrations (Kd ≈ 10 µM) and binds 
to its receptors at a nanomolar concentration (Kd ≈ 1 nM), proposing that monomers are 
sufficient for receptor activation [59], [160]. Existing in a monomer form was found to be 
more active than dimers for events like intracellular calcium mobilization, 
phosphoinositide hydrolysis, chemotaxis, and exocytosis [161]. The rate of monomer-
mediated regulation of CXCR1 was greater for these intracellular events, whilst for 
CXCR2, both monomeric and dimeric CXCL8 can potentiate these events at a similar 
rate [161]. Therefore, it is worth considering the distinct properties of the monomer and 
dimer forms of CXCL8 and its receptors, and their role in orchestrating immune cells 
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Inhibitors of CXCR1 and CXCR2: because of the therapeutic potential 
associated with the inhibition of CXCR1 and CXCR2, several small molecule inhibitors 
have been developed to target these receptors. Amongst some of CXCR1 and CXCR2 
antagonists are Reparixin, SCH527123, and SB225002. Reparixin is a non-competitive 
allosteric blocker of CXCR1 and CXCR2 activation. Mutation analysis and molecular 
modelling revealed that this antagonist binds to a pocket in the transmembrane allosteric 
region of CXCR1 and blocks CXCL8-induced intracellular signal transduction without 
affecting receptor bindings [162]. SCH527123 is another CXCR1 and CXCR2 antagonist 
that is highly potent and features non-competitive allosteric properties with a Kd= 49 pM 
towards CXCR2, and Kd= 3.9 nM towards CXCR1 [163]. Moreover, SB225002 is a potent 
antagonist that inhibits CXCL8 binding to CXCR2 with an IC50= 22 nM and binding to 
CXCR1 with IC50 > 150-fold higher than CXCR2. Further details about the effect of these 
antagonists are discussed in chapter 3.  
 CXCL8 involvement in cancer 
As mentioned earlier, an increased expression of CXCL8 and/or its receptors has been 
characterized in cancer cells, tumour-associated macrophages, infiltrating neutrophils, 
and endothelial cells, indicating the vital role this axis plays in the tumour 
microenvironment. CXCL8 was the first chemokine detected to stimulate melanoma 
cancer cells chemotaxis and hepatotactic migration [164]. Following this, it was reported 
that the binding of CXCL8 to its receptors promotes the proliferation and migration of 
melanoma cells and MCF-7 breast cancer cells [147], [165]. Additionally, Zuccari et al. 
[166] reported elevated expression levels of CXCL8 in neoplastic mammary tissues 
compared to normal tissues. Other cancers that demonstrated association with elevated 
levels of CXCL8 are melanoma [137], breast [167], thyroid [168], gastric carcinoma [169], 
ovarian [165], prostate [170], and lung cancer [146]. Consequently, there is strong 
correlation between high levels of CXCL8 and  invasive metastasis with an increased 
risk of recurrence  [171], [172].  
 CXCL8 involvement in angiogenesis 
In the 1990s, Folkman demonstrated that certain activated signalling cascades within 
tumour cells could promote surrounding blood vessels to grow [173]. A tumour could 
acquire its own blood supply by forming a network of blood vessels around itself and 
then growing around those vessels, a phenomenon that Folkman referred to as 
angiogenesis [173]. Angiogenesis is involved in multiple conditions such as wound 
healing, embryonic development, chronic inflammation, and the progression of cancer 
[173]. During wound healing, endothelial cells undergo ECM proteolysis, increased local 
migration, proliferation, and the development of new capillary all while maintaining the 
equilibrium of angiogenic and anti-angiogenic regulators [174]. Tumour angiogenesis 
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exploits the same signalling cascades used by wounds to form new blood vessels, which 
unlike the balanced state of wound healing, favours the upregulation of angiogenic 
factors and downregulation of anti-angiogenic factors [175]. Upon ligand-receptor 
binding, angiogenesis starts by secreting matric metalloproteinases (MMP2 and MMP9) 
to break down the ECM where it will begin initiating and growing the capillaries. Studies 
found that CXCL8 promotes the proliferation of endothelial cells and capillary tube 
organisation, whereas neutralizing antibodies against CXCR1 and CXCR2 inhibited this 
process [142], [176]. CXCL8 mimics vascular endothelial growth factor (VEGF), 
transactivates VEGF-R2, and induce angiogenesis [177]. Moreover, CXCL8 promote 
avβ3 upregulation that has a role in endothelial cell survival and tumour migration during 
angiogenesis [178]. In vivo cancer models with depleted CXCL8 or its receptors showed 
a reduction of tumour growth associated with decreased microvessel density [179]. For 
example, depleted CXCR2 in mouse models with prostate or pancreatic cancer had 
lower tumour angiogenesis and less tumour growth [180]. A similar study found that in 
vivo CXCR2-/- mice with lung cancer had decreased the angiogenic activity presented by 
lower vascular density [179], [181]. Moreover, blocking CXCL8 and its receptors could 
reduce angiogenesis of metastatic melanoma [137], [143]. 
 CXCL8 involvement in metastasis 
In addition to the local effects of chemokines on leukocytes and tumour, it is confirmed 
that cancer cells can utilise chemokines, such as CXCL8, to enable metastases [143]. 
For example, CXCL8 serum level could be a helpful prognostic marker for metastatic 
breast cancer [182]. Indeed, several studies suggest that tumour metastasis is facilitated 
by the binding of CXCL8 to its receptors enabling EMT, cell migration, and cell seeding 
at secondary sites [183], [184] (Figure 7). CXCL8 produced in the inflammatory 
microenvironment, exasperates the inflammatory state, and enables cancer cells to 
proliferate and migrate to secondary tumour sites. Notably, CXCR1 and CXCR2-
expressing neutrophils are attracted to the cancer site following a CXCL8 gradient 
produced by cancer cells. Neutrophils release enzymes that enable ECM remodelling 
which facilitate cancer cells migration and entry to the vascular bed, leading them to 
metastatic sites [185]. Furthermore, it was also established by Christiansen and 
Rajasekaran. [186] that cells which lose their epithelial differentiation and assume 
mesenchymal features become more invasive, motile, gain cancer-stem like features, 
and have more resistance to chemotherapeutics. In addition, the effect of stress on 
stromal cells leads to the secretion of CXCL8 which could be involved in the invasiveness 
and/or metastasis of tumour cells [187]. 
 
37 | P a g e  
 
Thereafter, guidance and direction of organ-specific metastasis to the lymph 
nodes and to other sites will be mediated by the cells expressing CXCL8 and/or its 
cognate receptors [133]. For example, the liver was found to be  amongst the primary 
sites of breast cancer recurrence where Khazali et al. [188] found that hepatic stellate 
cells and their derived CXCL8 could stimulate breast cancer growth and proliferation. 
Further data show that CXCL8 is implicated in osteolysis and the  stimulation of 
osteoclastogenesis correlated with metastatic breast cancer [189], [190]. High levels of 
CXCL8 mRNAs were reported in association with distant lymph node metastasis, poor 
survival and quick relapse of NSCLC [191], [192]. Also, implantation of pancreatic 
adenocarcinoma cells into the pancreas of nude mice led to the formation of liver 
metastasis correlated with elevated expression of CXCL8 [193]. Taken together, 
developing therapeutic approaches to inhibit metastasis requires a full understanding of 
the mechanism by which primary tumours utilize CXCL8 to migrate to metastatic sites 
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Figure 7. Involvement of CXCL8 in cancer metastasis. (1) Primary tumour growth 
initiated in the breast (2) gain invasion and migratory properties to intravasate the blood 
stream. (3) CXCL8 exerts a chemotactic action on CXCR1 and CXCR2-expressing 
immune cells which further produce CXCL8 and guide their infiltration to the blood 
stream. (4) Circulating tumour cells (CTCs) expressing the receptors as well as the 
immune cells will extravasate the blood stream to distant organs, such as the liver [188] 
or bones [190], [194]. Moreover, CXCL8 may also promote angiogenesis by inducing 
endothelial cells’ (ECs) migration or chemotaxis [142], [195]. CXCL8 promotes epithelial-
mesenchymal transition (EMT) of tumour cells which enhance the metastatic 
dissemination and secretion of angiogenic factors [196], [197]. Endothelial cells 
expressing CXCL8 receptors are thought to stimulate the angiogenic effect in a paracrine 
manner [144], whereas the proliferation, survival and migration of tumour cells is 
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 CXCL10 and CXCR3 axis 
CXCL10, also known as interferon “gamma-induced (IFN- γ) and protein of 10 kDa” (IP-
10), is one of the first identified chemokines that is secreted by multiple cell types [198]. 
ELR+ CXC chemokines such as CXCL8 mediate neutrophil attraction and angiogenesis 
as discussed earlier, however, CXCL10 is an ELR- CXC chemokine that attracts 
lymphocytes and exert anti-angiogenic effects by binding to its receptor, CXCR3 [199], 
[200]. Indeed, CXCL10 together with CXCL9 and CXCL11 share the property of being 
predominantly induced by IFN-γ, which is itself mediated by IL-12 cytokines [201]. IFN-γ 
is produced by a wide range of cells, such as endothelial cells, fibroblasts, keratinocytes, 
monocytes, and T lymphocytes [202], [203]. T helper-1 cells recruitment could mediate 
IFN-γ and TNF-α secretion, which promotes the production of CXCL10 from various cell 
types creating an amplified feedback loop which sustains the autoimmune process [201]. 
Secretion of CXCL9, CXCL10, and CXCL11 can also be induced by LPS, TNF-α, 
proinflammatory cytokines, IFN-α and IFN-β, depending on the cell type [204].  
 Activation of CXCR3 
CXCR3 has three splice variants generated by the alternative gene splicing of three 
different exons: CXCR3-A, CXCR3-B, and CXCR3-Alt. Although CXCR3 expression is 
linked to cancer progression as mentioned earlier, some studies did not account for the 
different isoforms of CXCR3, which were reported to have opposite effects [205]. Each 
of these variant CXCR3 receptors were found to stimulate distinct intracellular signalling 
cascades proposing that they have non-redundant roles in immune responses [206]. The 
term biased agonism is associated with CXCR3 due to the ability of different ligands to 
bind CXCR3 and preferentially stimulate some signalling cascades while inhibiting others 
[207]. Former studies claimed that the specificity of each CXCR3 splice variant to induce 
particular downstream signalling pathways is cell-type specific [205], [206].  
CXCR3-A is a 368 amino acid protein that is considered to be the most abundant 
variant in cells [208]. Notably, CXCR3-A is the predominant form expressed on T cells 
[209]. This form activates Gαi, induce arrestin recruitment, and initiate phosphorylation 
of ERK1/2, p38 MAPK, JNK, and Pi3K/AKT signalling cascades [208], [210]–[214]. 
CXCR3-A stimulate intracellular calcium release, DNA synthesis, actin polymerization, 
promote endothelial cells proliferation, and mediate Th1 cell chemotaxis [205], [215], 
[216]. Indeed, CXCL9 and CXCL10 use the C-terminal and the third intracellular loop of 
CXCR3 to induce chemotaxis, calcium flux, and the internalisation of CXCR3-A, 
processes that are identified to be mediated by arrestins [217] (Figure 8),while CXCL11 
predominantly induces a C-terminal independent cascade [218]. Upon stimulation, β-
arrestin form a core scaffolding complex that is thought to stimulate the phosphorylation 
of ERK1/2 [219].  
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Figure 8. Schematic representation of CXCR3-mediated signalling pathways. 
CXCR3 is expressed on T-lymphocytes, natural killer (NK) cells, monocytes, vascular 
smooth muscle cells (VSMC), endothelial cells (EC), dendritic cells (DC), epithelial cells 
(EP), and tumour cells (TC) [198], [205], [220]–[223]. The coupling of CXCL10 to 
CXCR3-A activates Gαi that inhibits adenylyl cyclase and decrease cAMP, which induce 
calcium flux. CXCR3-induced chemotaxis is mediated by Src, Pi3K/AKT, and p38 MAPK 
which is also linked to cell migration, invasion, proliferation and metastasis [210]–[212], 
[216]. Activation of CXCR3-B leads to Gαs coupling enabling the activation of p38 MAPK 
that promotes apoptosis by inhibiting ERK [224]. This pathway mediate the anti-
angiogenic effect of CXCR3-B [225]. The anti-proliferative effect of CXCR3-B is due to 
Ras activation [222]. CXCR3-B signalling also triggers PKA (cAMP-dependent), which 
inhibits m-calpain activation (not shown in figure) and blocks cell migration [226]. 
CXCR3-Alt specifically binds to CXCL11 and has a moderate effect on inducing 
chemotaxis and calcium flux [227]. It has shown that it activates signalling such as 
ERK1/2 and AKT phosphorylation [227], [228], with no specified role in cells proliferation 
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On the other hand, CXCR3-B, a 415 amino acid protein, has a longer  N-terminal 
tail consisting of 51 amino acid that replaces the four most N-terminal residues of 
CXCR3-A [229], [230]. CXCR3-B expression is debated in the literature regarding which 
G-proteins it interacts with. For example, CXCR3-B interacts with Gαs to activate adenylyl 
cyclase and increase cAMP concentration leading to the inhibition of cell proliferation, 
migration, chemotaxis, and apoptosis induction [212], [223], [231], [232] (Figure 8). 
Nonetheless, a study reported that CXCL11 (but not CXCL9 or CXCL10) interact with 
CXCR3-B and activate Gαi at a concentration of 100 nM, while all three chemokines 
failed to signal through Gαs in receptor-transfected HEK293T cells [206]. Another study 
found that CXCR3-B demonstrated no measurable Gαi or Gαs activity [233]. Furthermore, 
Campanella et al. [234] argued that CXCL10 induce its anti-proliferative effect on 
endothelial cells independent of CXCR3, instead it binds to GAGs. Moreover, it has been 
previously demonstrated that CXCL10 has a higher binding affinity to CXCR3-B relative 
to CXCL9 and CXCL11, whereas the affinity is similar between these ligands towards 
CXCR3-A [205]. Endothelial [205], epithelial [221] and tumour cells [222], [223] showed 
expression of CXCR3-B, which has led to the assumption that this variant is preferentially 
expressed on these cells  [234]. Alongside CXCL9, CXCL10, and CXCL11, platelet 
induced chemokines CXCL4 and CXCL4L1 also bind to CXCR3-A and CXCR3-B [235].  
The third CXCR3 splice variant, CXCR3-Alt, consists of 267 amino acids and is 
a result of  posttranscriptional exon skipping which misses several transmembrane 
domains that are characteristic of GPCR [227]. It is identified to be co-expressed with 
CXCR3-A at very low levels [203], [215], [227]. The biological role of CXCR3-Alt is not 
well known, although expression of CXCR3-Alt coincided with the upregulation of 
CXCL11 [236]. In addition, CXCR3-Alt was reported to have elicit the signalling of 
ERK1/2 and AKT phosphorylation [227], [228]. The binding of CXCL11 to CXCR3-Alt 
demonstrates a moderate induction of chemotaxis and calcium flux, suggesting 
involvement of pertussis toxin sensitive Gαi [227], however no effect on cell proliferation 
was reported [237].  
Taken together, an additional layer of complexity is added to the chemokine 
system defined by the biased agonism emphasizing the importance of considering the 
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 CXCL10 involvement in cancer 
Several studies have reported that CXCL10 is overexpressed in multiple human 
diseases such as infectious diseases, chronic inflammation, and tumour progression 
[237]. Specifically, CXCL10 is involved in the recruitment of leukocyte to inflamed sites, 
exacerbating inflammation and leading to substantial tissue damage [201]. CXCL10 
binds to the CXCR3 chemokine receptor and exert signalling effects in both a paracrine 
and autocrine fashion [203], [238], [239]. CXCL10 induction is predominantly based on 
the C-terminus of CXCR3, which is vital for receptor internalisation, chemotaxis and 
calcium flux [217]. CXCR3 is present on normal plasma cells and multiple myeloma cells 
enabling migration/chemotaxis to the bone marrow [223]. Moreover, CXCL10 is found in 
significant amounts in cancer like melanoma [240], [241] and malignant B lymphocytes, 
where it triggers chemotaxis and contribute to cell proliferation and survival [242]. On the 
other hand, CXCL10 appear to have a dual role in cell proliferation, because when bound 
to CXCR3 it acted as an efficient inhibitor of endothelial cell proliferation and this effect 
is counteracted with anti-CXCR3 antibodies [205]. 
Moreover, CXCR3 ligands promote the migration and invasion of MDA-MB231 
breast cancer cells, with neutralizing anti-CXCR3 antibody inhibiting this effect [243]. 
Additionally, the invasiveness of breast (MCF-7, T47D) and lung (A549) cancer cells 
were also stimulated by CXCR3 ligands [244]. Studies found that CXCL10 can activate 
T-lymphocytes tumorigenesis and metastasis [245]–[248]. Furthermore, CXCR3 
expression is associated with breast [249], osteosarcoma [250], ovarian carcinoma 
[228], B-cell lymphoma [251], and colon metastasis [252], [253], having a role in the 
tumour progression or acting as a useful diagnostic marker. Simultaneously, endothelial 
cell production of CXCL10 along with VEGF can promote cancer metastasis, within the 
tumour microenvironment or via autocrine interaction of CXCL10 axis on tumour cells 
[238], [254]. 
In contrast, elevated production of CXCL10 was reported in tumours that 
presented spontaneous regression and impaired angiogenesis [255]. Thus, CXCL10 has 
been identified as an anti-angiogenic factor that inhibits human NSCLC [245] and human 
microvascular endothelial cells [205], this is potentially mediated via CXCR3-B 
interaction [222]. Previous studies have debated whether the anti-angiogenic effect 
CXCL10 exerted is through binding to CXCR3 or GAGs. Indeed, it was confirmed that 
the tumour anti-angiogenic activity induced by CXCL10 or CXCL11 is CXCR3-dependent 
[256], [257]. Altogether, the role of CXCL10 in tumour progression is rather complex and 
relies on the cell type and the CXCR3 isoform expressed. 
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 Signalling pathways involved in chemokine signalling 
Cascades with aberrant signals in the context of cancer could be the driving force for 
sustaining the life of tumour cells [258]. The human genome has about 500 kinases 
which can attach phosphate tags, for example γ-phosphate of ATP, to serine, threonine 
or tyrosine residues in a process called phosphorylation [258]. Phosphorylation is 
required for intracellular and extracellular signals transmission throughout the cells and 
to the nucleus thus, works as a ‘molecular master switch’ [259]. Indeed, researchers 
have considered kinases to be pivotal in coordinating signals responsible for cellular 
responses and hypothesized that signal transduction therapy may be valid for targeting 
cancer [260]. 
Kinases phosphorylation is carried out when they target specific amino acids in 
the destined proteins. For instant, tyrosine kinase phosphorylates tyrosine, and 
serine/threonine kinases phosphorylate serine and threonine. Both kinases have a 
catalytic core with a glycine-rich N-terminal ATP-binding pocket and a central conserved 
aspartic acid residue required for its catalytic activity [261]. Tyrosine kinases are 
classified into receptor and non-receptor tyrosine kinases. Receptor tyrosine kinases are 
transmembrane proteins that have a ligand binding extracellular domain, and a catalytic 
intracellular kinase domain [261]. Non-receptor tyrosine kinases are located in the 
cytosol, nucleus, and in the inside surface of the plasma membrane. Therefore, kinases 
can behave as receptors on the membrane of the cell or as an intracellular signal 
regulator to launch a chain of cellular responses [262].  
Tremendous effort have been invested in developing specific protein kinase 
inhibitors as therapeutic agents for perturbed cellular behaviour [263]. The US FDA 
approved 52 small molecule protein kinase inhibitors, so far [264]. Kinase inhibitors are 
classified based on their targeting of the ATP-binding site, with the kinase adopting a 
conformation mimicking the ATP binding ability. The ATP-binding pocket lies in the 
protein kinase domain. This domain is positioned in a deep cleft and held in place via 
hydrogen bonds formed between the ATP adenine ring and the kinase hinge ring. This 
kinase hinge ring is bound by the N-terminal lobe, and C-terminal lobe [262]. The enzyme 
activity is controlled by a conserved activation loop which is tagged by a conserved DFG 
motif at the start of the loop and ending with an Ala-Pro-Glu motif [265]. Protein kinase 
inhibitors possess a high ATP-competitive affinity to compete with the elevated 
intracellular concentration of ATP and efficiently block kinase function [266]. 
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Tyrosine kinase inhibitors are a class of anticancer medications that inhibit the 
action of one or more of the tyrosine kinases. They can operate in four different 
mechanisms. Type I and type II inhibitors compete with the ATP pocket of the kinase in 
its active or inactive state, respectively [267]. Indeed, type I kinase inhibitors bind in and 
around the binding site of the adenine ring of the ATP and mimic its interaction with the 
hinge site of the protein [268]. This type targets the ATP-binding site of the kinase in the 
active form, which is recognized by its open conformation of the activation loop. This is 
associated with the “DFG-in” conformation of the activation loop which is characterized 
by its positioning of the aspartate-phenylalanine-glycine at the beginning of the activation 
loop [269]. Type II inhibitors bind to the DFG-out inactive kinase conformation and target 
the allosteric site of the ATP pocket [270] (Figure 9). The allosteric site is formed of an 
additional hydrophobic pocket presented by the DFG-out adjunct to the adenine region 
[269]. The amino acids in the allosteric site are less conserved relative to those in the 
ATP binding site, which proposes that it may be easier to achieve kinase selectivity with 
type II inhibitors [271], [272]. Moreover, Type III inhibitors occupy an adjacent allosteric 
pocket residing on the outside the ATP pocket without competing with it. Type IV 
inhibitors interfere with the surfaces that are important for protein-protein interactions 
[273].  
 
Figure 9. Binding sites of type I and II protein kinase inhibitors.  Ribbon diagram of 
a) type I inhibitor binding to the adenine site with DFG-in conformation, whereas b) is 
type II inhibitor shows binding to the DFG-out inactive kinase conformation and target 
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Although, the ATP active site possess a highly conserved nature making it 
challenging to selectively target type I and II inhibitors, the pharmaceutical industry field 
have encountered big advances in the progression of selective protein kinase inhibitors 
[272], [274], [275]. Indeed, development of small molecule kinase inhibitors that can 
activate or inhibit specific kinase signalling cascades propose new opportunities for 
pharmacological manipulation of protein kinase function (Table 1).  
Table 1. List of some FDA-approved tyrosine kinase inhibitors. Table taken from 
[267].  
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 Pi3K/AKT pathway 
Activation of GPCRs by extracellular stimuli transmit the signal across the plasma 
membrane into intracellular signalling events [276]. The binding of the chemokine to its 
receptor induces a conformational change in the receptor that activates various small G 
proteins that regulate downstream effector pathways. The active conformational change 
facilitates the exchange of bound GDP to GTP of the Gα subunit, which are grouped into 
Gαq/11, Gαi/o, Gαs and Gα12/13, and dissociate from Gβγ subunits [277]. Chemokine 
receptor activation promote intracellular signalling through both Gα and Gβγ subunits, 
which can stimulate distinct, complementary, or antagonistic cascades [278]. One of the 
pathways that gets activated through either Gα or Gβγ subunits is the Pi3K/AKT 
signalling pathway (Error! Reference source not found.). Gβγ can directly bind and 
activate Pi3K. Direct activation of Pi3K/AKT cascade through Gα has not been precisely 
measured but this activation is made via transactivating integrins, receptor tyrosine 
kinase and other growth factor receptors [279]. 
 CXCL8 signalling has attracted a lot of attention because of its involvement in 
cancer angiogenesis, survival, proliferation, and tumorigenesis [280]. One of the widely 
studied signalling pathways is the Pi3K-associated pathway. This pathway has been 
proven to be significant for the cells ability to sense a chemokine gradient and guide the 
directed migration in response to chemokine receptor activation in multiple cell types 
[281] (Error! Reference source not found.). Pi3K works on maintaining cell polarity 
and defining the leading edge of cell migration [34]. Indeed, this lipid/protein kinase was 
reported to be crucial for CXCL8-induced chemotaxis of neutrophils, causing an increase 
of phosphorylation of its substrate serine/threonine kinase AKT [282]. 
AKT activation is involved in modulating cell survival, growth, angiogenesis, and 
migration [283]. Jiang and colleague found that CXCL8 stimulated the invasion of 
osteosarcoma cells by regulating the Pi3K/AKT signalling cascade [284]. Furthermore, 
studies have shown that CXCL8 promoted the migration of chondrosarcoma cells by 
elevating integrin β3 expression via Pi3K/AKT signalling [285]. In oestrogen receptor-
negative breast cancer, CXCL8 is involved in leptin-mediated EMT, increased integrin 
β3 expression and promotes cell invasion all through the activation of Pi3K/AKT 
signalling [94], [286].  
NF-кB is a transcription factor that is involved in stimulating the expression of 
CXCL8 [155]. Indeed, Pi3K/AKT signalling promotes CXCL8 expression in human lung 
epithelial cells by stimulating IKK and NF-кB proteins [287]. Also, CXCL8 potentiate NF-
кB activation through EGFR-transactivated AKT signalling in human ovarian cancer cells 
[288]. The production of CXCL8 was elevated through the betacellulin-EGFR-Pi3K-AKT 
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and ERK pathway in NSCLC A549 cells, which was involved in the development of an 
inflammatory microenvironment with consequences on lung cancer proliferation and 
migration [289].  
Accumulating evidence have used LY294002, the well-established potent 
pharmacological inhibitor of Pi3K to advance our knowledge in the importance of this 
signalling pathway [290]–[292]. LY294002 significantly reduced CXCL8-induced cell 
migration in neutrophils and L1.2 cells overexpressing CXCR2 [282], [293]. In androgen-
independent prostate cancer cells, CXCL8 induced the activation of mammalian target 
of rapamycin (mTOR) via PLD-dependent and Pi3K/AKT and MAPK-dependent 
pathways, and using Pi3K inhibitor, LY294002, attenuated the rate of cells proliferation 
[294]. Moreover, treatment of colorectal adenocarcinoma HT-29 cells with LY294002 
downregulated LPS-induced CXCL8 expression [295]. Due to the inhibitory effect of Pi3K 
inhibitor, LY294002, on MAPK signalling in CXCL8-induced neutrophils, Takami et al. 
[296] suggested a model of Pi3K being upstream of MAPK. Another study using NSCLC 
cells found that Pi3K/AKT and c-Jun (a member of MAPKs) were involved in human 
papillomavirus-16 oncoprotein induced VEGF and CXCL8 expression in the cells, 
leading to angiogenesis in vitro [291]. Additionally, a study found that since Pi3K/AKT 
and MAPK are implicated in inducing the angiogenic effect of CXCL8 and VEGF in breast 
cancer cells, blocking these dominant signalling pathways rather than the chemokine 
might be more tumour-specific, eliminating potential side effects [297]. This study also 
reported that LY294002 treatment inhibited the expression of CXCL8 and VEGF in breast 
cancer cells with constitutively stimulated AKT. Simultaneously, Pi3K can induce VEGF 
expression by activating HIF-1, ERK1/2, and NF-кB to induce tumour angiogenesis [298], 
[299]. Indeed, Pi3K/AKT, mTOR and their effectors HIF-1α and VEGF function in 
controlling angiogenesis, where PTEN, a Pi3K inhibitor, mediate the inhibition of 
angiogenesis by regulating these effectors [300], [301].  
In all, these studies demonstrate that CXCL8 utilizes the Pi3K/AKT signal 
transduction pathway to induce a range of effects favouring cancer progression.   
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Figure 10. Induction of Pi3K/AKT signalling upon CXCL8 binding to CXCR1 and 
CXCR2. CXCL8 activates mTOR via Pi3K/AKT and PLD which produce an effect on 
cyclin D1 that regulates proliferation in androgen-independent prostate cancer cells 
[294]. Pi3K and c-Jun were found to be involved in inducing angiogenesis in CXCL8-
induced NSCLC cells [291]. Pi3K was reported to be crucial for neutrophil migration in 
response to CXCL8 gradient [282]. Moreover, IKK and NF-кB stimulation via Pi3K/AKT 
leads to the expression and release of CXCL8 in lung epithelial cells [287]. Potentiation 
of NF-кB mediates transcription of antiapoptotic genes and also activates Pi3K/AKT and 
MAPK [294] that is crucial for cell survival [296], a response that is elevated in hypoxic 
cells [302]. In addition, NF-кB is involved in CXCL8 and VEGF-induced angiogenic effect 
that is mediated through Pi3K/AKT and MAPK [297]. Pi3K inhibitor, LY294002, blocks 
signals associated with survival, proliferation, migration, and  angiogenesis  [282], [293]–
[297]. Moreover, loss of Pi3K/AKT inhibitor, the tumour suppress gene PTEN, leads to a 
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 The Ras/Raf/MEK/ERK, and p38 MAPK pathway 
CXCL8 signalling modulates the activity of MAPK signalling pathway that comprise 
several serine/threonine kinases [143]. MAPKs are evolutionarily conserved protein 
kinases that link and transmit extracellular signals responsible for regulating major 
cellular responses such as, survival, growth, differentiation, migration, and apoptosis 
[304], [305]. Aberrant MAPK signalling has been associated with cancer progression. 
For example, many MAPK cascades are involved in stress signalling related to hypoxia, 
substrate detachment, inflammation, and metabolic stress [306]–[308]. Therefore, the 
importance of this protein kinase in sensing and processing stress signals is established 
[304]. These characteristics associated with stress-induced kinases are linked to cancer, 
inflammation, DNA damage response and apoptosis [305], [307], [308]. The best 
characterized pathway of these kinases is the Ras/Raf/MEK/ERK pathway (Figure 11). 
Pi3K has been identified as a mediator for coupling CXCL8 to MAPK signalling in 
neutrophils [309]. The Ras/Raf/MEK/ERK and Ras/Pi3K/PTEN/AKT cascades interact 
with each other to regulate growth and often tumorigenesis [310]. 
The Ras/Raf/MEK/ERK pathway pairs signals from the cell surface and transmit 
them to transcription factors, which sequentially regulate gene expression [311]. Upon 
stimulus binding, Ras exchange GDP for GTP which induce conformational change 
causing its activation. This in turn enables Raf to be recruited to the cell membrane. 
Indeed, Ras is a small GTP-binding protein that is considered a common upstream 
molecule in many signalling pathways such as Raf/MEK/ERK, Pi3K/AKT, and 
RalEGF/Ral [312]. Studies have shown that different mutation frequencies in Ras that 
cause its constitutive stimulation is often linked to human cancer (as reviewed [310]). 
The Raf family have a role in modulating cell proliferation, differentiation, and 
apoptosis upon induction with cytokines [313]–[316]. This family consists of A-Raf, B-
Raf, and C-Raf (also known as Raf-1). The A-Raf member has a weak effect on ERK 
activation [316] and yet was a crucial stimulus for hematopoietic cells growth [311]. The 
role of C-Raf has been questioned since the discovery of B-Raf, where the latter 
appeared to be a much potent activator of MEK relative to C-Raf and A-Raf [314], [317]. 
C-Raf may have a function in blocking the activity of apoptosis promoters and could itself 
be activated by B-Raf [317]. Indeed, B-Raf gene mutation seemed to be involved in 
inducing proliferation and transformation [318]. Therapeutic intervention by targeting B-
Raf with RNA interference have shown that depleted oncogenic B-Raf in cancer cells 
abrogate ERK activity, inhibit proliferation and induce apoptosis [319], [320]. Knall et al. 
[309] found that Pi3K inhibition block CXCL8-induced stimulation of  
C-Raf and B-Raf, causing an inhibition of MAPK stimulation. Conversely, another study 
found that the inhibition of Pi3K with LY294002 led to an upregulation of B-Raf activity 
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[321]. Thus, it is suggested that there could be more than one mechanism controlling the 
activation of Raf. Simultaneously, other signalling molecules interact with the 
Ras/Raf/MEK/ERK cascade to enhance or inhibit their activity with a potential crosstalk 
between the Raf/MEK/ERK and Pi3K/AKT. Notably, the growth of hematopoietic cells 
was inhibited by targeting both signalling pathways [322], with further interactions 
between the two pathways being reviewed in [312]. Therefore, the abnormal signalling 
in cancer could be due to mutations in upstream membrane receptors, Ras and B-Raf 
as well as genes in other pathways such as, Pi3K, PTEN and AKT, which can control 
Raf activity [310]. 
ERK1/2 induction in response to extracellular signals is suggested to have a dual 
effect on cancer cells by either enhancing or inhibiting their progression depending on 
the context and strength of stimulation [304]. CXCL8 induces rapid and transient 
phosphorylation of ERK1/2 and Pi3K in neutrophils [323]. The role of ERK1/2 activation 
by CXCL8 in neutrophil migration is not well understood [282], [309], [324]. CXCL8 
signalling activates the MAPK pathway which in turn enables the downstream 
phosphorylation of ERK1/2 that has been detected in cancer cells. For example, this 
pathway promotes cell proliferation and survival in prostate [294], ovarian [165], NSCLC 
[325], pancreas [326], and colon [149] cancer cells. The activation of ERK-MAPK 
proposes that there is a pathway connecting CXCL8 signalling to the stimulation of E2F 
and activator protein transcription factors, whose main role is to regulate the transcription 
of genes involved with cell proliferation [299], [327], [328]. Moreover, MEK inhibitors 
PD98059 and U0126 inhibit the release of adenovirus serotype 7 upon stimulation with 
CXCL8 via inhibition of ERK pathway in a dose-dependent manner [131]. Another study 
found that PD98059 and p38 MAPK inhibitor, SB203580, block CXCL8 expression, 
whereas JNK inhibition only partially inhibit CXCL8 secretion/expression in human 
oesophageal epithelial cells [329]. This study also added that MAPK and PKC signalling 
are important for regulating acid-mediated CXCL8 expression through NF-кB, where the 
inhibition of the NF-кB may exhibit a potential therapeutic target for oesophageal 
inflammation. In addition, reported data had suggested that ERK inhibition in lung cancer 
stimulates glycogen synthase kinase 3β, possibly leading to β-catenin degradation, 
which causes inhibition of cancer progression and migration [330].  
The p38 MAPK pathway is identified as a regulator for inflammation and 
modulating stress responses and can be stimulated by CXCL8 [331]. For instance, the 
p38 MAPK inhibitor, SB203580, inhibits IL-1β-stimulated CXCL8 mRNA expression and 
protein production in Caco-2 and HT-29 cells [332]. Another p38 MAPK inhibitor, 
SB202190, blocks TNFα and LPS-stimulated CXCL8 mRNA expression in monocytes 
[333]. Furthermore, using RWJ 67657, which is also a p38 MAPK inhibitor, caused the 
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abrogation of transcription and production of CXCL8 in monocyte-derived macrophages 
in a dose-dependent manner [334]. Moreover, p38 MAPK, plays an important role in the 
post-translational regulation of CXCL8, and its inhibition with SB203580 blocks TNFα-
induced CXCL8 secretion [332]. CXCL8 was also found to have induced the migration 
and invasion of head and neck squamous cell carcinoma by stimulating p38 MAPK/ERK-
NF-кB pathway and reducing JNK [335].  
Overall, this highlights the link between CXCL8 activation of the 
Ras/Raf/MEK/ERK as well as p38 and JNK (MAPKs) and their involvement in cancer. 
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Figure 11. The Ras/Raf/MEK/ERK pathway and intracellular signalling. The 
pathway is initiated with receptor activation upon ligand binding, such as CXCL8. 
Ras resides in the plasma membrane and facilitates the exchange of GDP to GTP. 
Ras recruits the Raf family to the cell membrane. Raf phosphorylation activated 
MEK which subsequently phosphorylated ERK1/2. In turn, activated ERK1/2 
produce a wide range of cytosolic and nuclear responses resulting in migration, 
proliferation, and survival [131], [336]. For example, MEK inhibition with PD98059 
supressed CXCL8-activated neutrophil chemotaxis [324]. Moreover, PC3 cells 
stimulated with CXCL8 promote the proliferation via induction of ERK1/2 and p38 
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 Rho GTPases and DOCK1/2/5 pathway 
Amongst other signalling pathways is the Rho family GTPases that are key regulators of 
the actin cytoskeleton [337]–[341]. This family belongs to Ras superfamily of small 
GTPases and among its well-characterized molecules are Rho (A, B, C isoforms), Rac 
(1, 2, 3 isoforms) and Cdc42 (Cdc42Hs, G25K isoforms) [341]. These proteins play a 
role in regulating the actin cytoskeleton by modulating the formation of lamellipodia, 
filopodia, and stress fibres, respectively [341] (Figure 12). Rho GTPases regulate 
cellular processes by working as a switch based on their GDP or GTP-bounding form. 
Guanine nucleotide exchange factors (GEFs) catalyse the exchange of GDP with GTP, 
while GTPase-activated proteins (GAPs) conversely hydrolyses GTP to GDP [338]. In 
their GTP-bound conformation, Rho GTPases activate downstream effector proteins 
involved in the cytoskeleton rearrangement, migration, proliferation, transformation and 
differentiation [338]. CXCL8 binding to CXCR1 induce rapid stimulation of Rho resulting 
in a cytoskeleton response in microvascular endothelial cells, whereas binding to CXCR2 
cause a retraction of endothelial cells mediated by Rac [342]. Thus, signalling of CXCL8 
induces the polymerization and subsequently the retraction of the actin cytoskeleton. 
Further evidence demonstrate the dynamic, time-dependent regulation of Rho, Rac, and 
Cdc42 activity upon application of exogenous CXCL8 on prostate cancer cells, proposing 
that all three proteins are significant mediators of CXCL8-driven cancer cell migration 
and invasion [143]. Moreover, a study confirmed that the chemotactic role of CXCL8 on 
endothelial cells is mediated by p38 MAPK, which is potentially a downstream activator 
of Rac1/Cdc42 and RhoA GTP binding proteins [343]. RhoA, Rac1 and Cdc42 showed 
elevated levels of expression in breast cancers [344].  
The role of Rho GTPase in cancer development has been widely investigated. 
This family is involved in stimulating cell cycle progression and regulation of gene 
transcription, revealing its pro-oncogenic characters, such as inducing Ras-induced 
transformation [345], and promoting neovascularisation [346]. Since this family has a 
role in modulating cell body contraction by regulating actin-myosin contractility and 
forming stress fibres [340], their inhibition was found to block the migration of 
macrophages [339]. Indeed, Rho absence can cause an inhibition of the cell tail 
detachment through reduced actin-myosin contraction [347]. Furthermore, Rho activity 
can be blocked downstream of cadherins resulting in a more migratory phenotype [348]. 
The expression level of RhoA and RhoC is generally elevated in cancer, whilst RhoB is 
downregulated and so is inversely linked to cancer aggressiveness [349]. RhoA is 
involved in cancer cell proliferation and survival due to its constitutive activation which 
can promote transformation [350]. In fact, RhoA is a crucial regulator of amoeboid and 
mesenchymal motility [337]. This happens through the RhoA-ROCK pathway inducing 
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actomyosin-based cortical contractility resulting in amoeboid blebbing leading to its 
motility, and also causing tail retraction in mesenchymal migration [351]. RhoA and its 
downstream target ROCK are also involved in cancer extravasation, based on 
experimentation using chemical inhibitors [337], [352]. Indeed, Pi3K activating Rho leads 
to ROCK, Myc phosphorylation and thrombospondin-1 repression. The latter is an anti-
angiogenic factor that when repressed through RhoA is implicated in promoting breast 
cancer angiogenesis [349].  
The expression of Rac1, Rac2 and Rac3 is elevated in some tumours [349]. 
Accumulating evidence suggest that Rac1 is expressed in a vast number of cancer 
causing malignant transformations [349]. With this in mind, Rac1 appears to be mutated 
in some cancers, such as meningiomas, astrocytomas and pituitary adenomas, leading 
to its overexpression and further increasing the survival of the tumours [353]. Rac1 may 
promote cancer cell proliferation by regulating the cell cycle. For instance, Rac1 was 
shown to promotes the expression of cyclin D1, and stimulation of cell transformation in 
vitro [354]. Moreover, DOCK1/2/5 is characterized as a major regulator of Rac in 
neutrophils, thus, blocking it has inhibited chemotaxis migration of neutrophils [355]. 
DOCK2 binds to Rac and mediate GTP-GDP exchange reaction. Inhibition of DOCK2 is 
thought to be an attractive target for inflammatory-related pathologies [356].    
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Figure 12. Illustration of the involvement of Rho GTPases in tumour progression. 
From the loss of the polarity and directionality to the disruption of the adherent junctions 
leading to tumour increased migration, proliferation and remodelling of the ECM, and 
induction of angiogenesis, the Rho protein family plays an important role in maintaining 
the integrity of the cells, and their abnormal expression is highly associated with tumour 
development (Image taken from [349]). 
It is well documented that cells require Cdc42 for their polarity and directed 
migration, otherwise they would migrate randomly [357]. Cdc42 controls the polarity by 
relocating the microtubule-organising centre and Golgi apparatus at the front of the 
nucleus in the direction of the leading edge resulting in the growth of microtubules and 
transfer of vesicles towards this region [358]. The relation between Cdc42 and cancer 
appear to be tissue specific. For example, an elevated expression level of Cdc42 was 
found in breast cancers and hardly detected in corresponding normal tissue [344], [359], 
[360], whereas the absence of Cdc42 promoted the progression of liver cancer [360]. 
Indeed, Cdc42 was reported to induce the invasion and metastatic activity of breast 
cancer cells [361]. Moreover, Cdc42 inhibitor, ZCL278, was found to have inhibited the 
migration of PC3 cells [362] as well as suppressed the invasion and migration of 
pancreatic cancer cells [363]. 
The primary target for Cdc42 and Rac are the WASP/WAVE family of Arp2/3 
complex activators [364]. Rac uses WAVE signalling to induce lamellipodia extension 
[365], and Cdc42 interacts with WASP causing the stimulation of Arp2/3 complex leading 
to dendritic actin polymerization [366]. The stimulated Arp2/3 complex allows the rapid 
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polymerization of actin and the formation of the branched filaments present in 
lamellipodia [366]. 
Overall, Rho GTPases are involved in the multiple stages of cancer progression, 
with a primary role in actin cytoskeleton rearrangement associated with cell migration 
and invasion, but also modulating other cellular responses, such as cell survival and 
proliferation. Small molecule inhibitors seem to be evolving in targeting these kinases 
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 Src and FAK signalling 
The non-tyrosine kinases Src and FAK are crucial intermediates in the CXCL8 signalling 
pathway [367] (Figure 13). As previously discussed, CXCL8 stimulates members of Rho 
GTPases family which could lead to the stimulation of Src and FAK [143]. The induction 
of Src and FAK protein kinases is associated with cells proliferation and migration [368], 
as well as the development of metastatic phenotypes by Src [369]. Their chemotactic 
effect is facilitated by phosphorylating substrates involved in focal adhesion and 
migration [370]. FAK and Src play a crucial role in the development of solid tumours by 
stimulating EMT which correlates with metastatic phenotypes (review by [371]). Cells 
missing these two kinases appear to have greater adhesions and reduced mobility [372]. 
For example, fibroblasts lacking Src or FAK showed lower levels of spreading, decreased 
motility rates and seemingly elevated numbers of adhesions [373], [374]. Src stimulation 
appears to increase the growth and invasion of tumours and decrease apoptosis [369]. 
Moreover, CXCL8-activated rat basophilic (RBL) cells induces FAK phosphorylation and 
re-localization, which is linked to increased cell spreading and migration [143], [375], 
[376]. Further evidence suggest a role of FAK and Src in the growth of prostate cancer 
cells besides their chemotactic effect [367]. Actin cytoskeleton rearrangement 
downstream of Src contributes to growth factor and integrin signalling, for instant, cellular 
Src facilitate EGF-activated cellular motility, morphology, and stress fibres reorganisation 
[377]. Inhibition of the two kinases using anti-Src and anti-FAK antibodies have shown 
inhibited proliferation, angiogenesis and metastasis in human tumours [371]. Therefore, 
targeting Src and FAK for cancer therapy might produce promising outcomes by 
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 PKC and PKD signalling 
The binding of chemokine to its receptor activates G protein which in turn activates PLC 
enzymes (Figure 13). Gα, particularly Gαq and Gα11 activates PLCβ, while Gβγ activates 
PLCγ. PLCβ cleaves the membrane phospholipid phosphoatidylinositol-4,5-biphosphate 
(PIP2) into 1, 3, 5- inositol triphosphate (IP3) and diacylglycerol (DAG) [378]. IP3 releases 
calcium from its intracellular stores, and DAG in the presence of calcium activates 
membrane-bound PKC [379], [380]. PKCs are a multifunctional proteins serine/threonine 
kinases. The family of PKC consists of 15 isoforms classified into three categories based 
on their second messenger requirements. Conventional PKCs (α, βI, βII, γ) requires DAG 
and calcium; novel PKCs (δ, ε, η, θ) requires DAG only and atypical PKCs (ζ, ι (λ)) are 
not directly activated by the PLCβ signalling pathway, therefore, does not require DAG 
or calcium for activation [381]. Instead, atypical PKCs can be stimulated by lipid 
components like PIP3 [382], phosphatidic acids [383], arachidonic acid, and ceramide 
[384], [385]. PKCs are fundamental components in intercellular networks that mediate 
vast number of cellular processes. They can affect the morphology of  cells thereby 
regulating processes such as cell migration [386]. PKC seem to also affect intracellular 
calcium release as reported in CCL3-induced CHO.CCR5 cells and THP-1 cells [387]. 
PKCα was significant for CXCL12-activated Jurkat and MCF-7 cells migration, while 
PKCζ is not important [388]. Conversely, PKCα was found to be crucial for PC3 cells 
migration according to data generated by using PKC inhibitor staurosporine [389]. 
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Figure 13. G protein-dependent pathways involved in chemokine intracellular 
signalling. Upon receptor activation, Gαq activates PLCβ, which hydrolyses PIP2 to 
yield the two second messengers; IP3 and DAG. IP3 opens the IP3 dependent Ca2+ 
channel on the endoplasmic reticulum realising Ca2+. DAG, in the presence of Ca2+ 
activates membrane-bound PKC, which in turn can activate PKD [390]. The 
PLC/PKC/PKD signalling pathway contribute to neutrophil chemotaxis [391]. 
Additionally, PKC and PKD are important for the migration of CXCL12-activated 
PC3 cells [389]. Gβγ dimer could also activate PLCβ and IP3 resulting in PKC 
activation [392]. Gαs and Gαi act through adenylyl cyclase (AC), which regulate the 
concentration of cAMP, thereby stimulating PKA. Gα12/13 activates Rho dependent 
pathways [393], [394]. Rho GTPases could lead to the activation of Src and FAK 
upon CXCL8 binding [143]. The latter is involved in regulating the actin cytoskeleton 
and its interaction with the ECM [143]. In addition, Gαi could activate Src leading to 
MAPK, Pi3K and FAK [395], [396]. CXCL8 was reported to induce FAK-Src-cortactin 
signalling in prostate cancer cell lines [143] and was correlated with an elevated cell 
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All PKCs consist of a regulatory and a catalytic domain joined together by a hinge 
region. The catalytic domain is highly conserved in the different PKC subsets, and the 
regulatory domain leads to the distinguished cellular responses between the isoforms, 
which are typically similar within the classes [381]. In cPKCs and nPKCs, the C1 domain 
sense phorbol 12-myrisate 13-acetate (PMA) and DAG, while in aPKC, the does not bind 
PMA and DAG [398]. The C2 domain serves as calcium-dependant phospholipid binding 
modules in cPKCs, whereas this domain does not bind calcium in nPKCs [381]. APKC 
lacks the C2 region and is activated, in part, by interaction with the Cdc42-GTP-Par6 
complex through PB1 (Phox and Bem1) domain [399]. PKCs are regulated by two distinct 
mechanism: by phosphorylation which regulates the active site along with the subcellular 
localisation of the enzyme, and by second messengers, which induce the association of 
PKC membrane leading to pseudosubstrate exposure [398] (Figure 14). 
 
 
Figure 14. Structure of PKC isoforms. PKCs consist of an N-terminal regulatory 
domain comprising a pseudosubstrate (PS), two C1 domains (C1a and C1b) and a C2 
domain. The C-terminal domain has a V5 region that is distinguished amongst the 
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 The PKD family are serine/threonine kinases with a similar homology to PKC, 
and comprise of three isoforms: PKD1, PKD2, and PKD3. Similar to PKCs, DAG and IP3 
are crucial activators of PKD, as well as growth factors and PKC isoforms [400] (Figure 
13). Induction of PKD through oxidative stress is reported, where the activation is partly 
pursued through PKC-mediated activation loop phosphorylation and partly via Src-
mediated PKD tyrosine phosphorylation, therefore, PKD has been identified as a sensor 
of oxidative stress [401], [402]. The family of kinases seem to have a vital role in 
regulating cellular processes including cell growth, protein trafficking, and lymphocyte 
biology [403]. Moreover, PKD isoforms are expressed in neutrophils, and they are 
important facilitators of their chemotaxis [404]. Accumulating evidence indicate the role 
CID755673 play in inhibiting all the three PKD isoforms and associated PKD cellular 
responses [405]. For example, this inhibitor reduced the migration speed of CXCL12-
stimulated PC3 cells where cells also assumed an elongated appearance with PKD 
inhibition [389].  
 In all, although some studies have shed light on the importance of PKC and PKD 
in cancer progression, little is known about their role in chemokine-driven migration. This 
could be due to the complexity of the two protein kinases associated with their different 
isoforms which could exhibit different cellular responses (discussed further in chapter 5). 
To add to this complexity is the lack of specific inhibitors for the different isoforms of the 
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 Research objectives 
Chemokines are a large family of small cytokines that are known for their essential role 
in mediating the directed migration of leukocytes and cancer cells [239]. Chemokine 
signalling contribute to cancer progression and metastasis, and their expression in both 
primary tumours and metastatic sites is associated with poor prognosis in cancer patient 
[85]. Pharmacological disruption of chemokine receptor mediated processes could be 
utilized for therapeutic intervention in cancer. However, the effort of targeting a 
chemokine or a chemokine receptor for the aim of limiting cancer cells from 
metastasizing has not been very promising in clinical trials [406]. This is mainly due to 
the redundancy of the chemokines generally binding to multiple receptors, subsequently 
yielding varied responses. It is also due to the inappropriate target and dosing selection 
[407]. Therefore, there is a need to further understand the role of chemokines and their 
receptors to find alternative strategies to manage their dysregulation in cancer.  
 The role of CXCL8 signalling in cancer progression has been widely studied. 
CXCL8 binds to CXCR1 and CXCR2 and is involved in various steps of cancer 
progression including growth, proliferation, and migration [408]. Likewise, elevated levels 
of CXCL10 have been reported in a range of diseases such as inflammatory, 
autoimmune disorders, and cancer [201], [237]. The expression of these chemokines 
and their effect could be cell-type specific [409], therefore, it is challenging to be 
conclusive with the outcomes they generate on cancer cells. The aim of this thesis is to 
expand our knowledge in the effect of these two chemokines in cancer cell migration. To 
accomplish this, the following experimentation will be undertaken: 
 Chapter 3: Characterise cancer cell response to CXCL8 and CXCL10. Primarily, 
the expression of the corresponding receptors of CXCL8 and CXCL10 will be explored. 
This will be followed by investigating the role of these two chemokines in inducing cancer 
cell migration in leukemic (THP-1 and Jurkat), breast (MCF-7 and MDA-MB231) and 
prostate (PC3) cancer cell lines. 
 Chapter 4: Examine the involvement of different signalling pathways in CXCL8-
activated cancer cell migration. Small-molecule inhibitors will be used to target the 
different signal transduction molecules. The effect of these inhibitors for inducing cellular 
morphology changes will also be studied. 
Chapter 5: The role of PKC in directing the migration of CXCL8 and CXCL10-
activated cells was the aim of this chapter. PKC inhibitors were used to address the 
cytoskeletal rearrangement, cell migration, as well as the release of intracellular calcium 
in MDA-MB231 cells and PC3 cells. 
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2 Chapter 2: Materials and Methods 
 Cell lines and tissue culture 
 Acute monocytic leukaemia cell line THP-1 
THP-1 cells are derived from the peripheral blood of a one-year old male donor 
diagnosed with acute monocytic leukaemia. THP-1 cells were purchased from the 
American Type Culture Collection (ATCC) (Teddington, UK). They were cultured in RPMI 
1640 growth media (Corning, Biosera) supplemented with 10% v/v Foetal Calf Serum 
(FCS) (Invitrogen), 100 μM non-essential amino acids (Gibco) and 2 mM glutamine 
(Invitrogen). They were used at 60x104 cell / mL. 
 Human breast adenocarcinoma cell line MCF-7 
MCF-7 cells are a mammalian epithelial cancer cells that are derived from the pleural 
effusion of a 69-years old Caucasian woman with metastatic breast adenocarcinoma. 
This cell line is characterized as being non-invasive, with low metastatic ability, and are 
positive for oestrogen and progesterone (as reviewed by [410]). MCF-7 cells were 
cultured in DMEM (Corning, Biosera) supplemented with 10% v/v FCS (Invitrogen), 100 
μM non-essential amino acids (Gibco) and 2 mM glutamine (Invitrogen). 
 Human breast cancer cell line MDA-MB231 
MDA-MB231 cells are a human epithelial breast cancer cell line that is derived from a 
51-years old Caucasian female with metastatic breast adenocarcinoma. This cell line is 
highly aggressive, invasive, negative for oestrogen and progesterone expression, and 
poorly differentiated triple-negative breast cancer cells. MDA-MB231 cells were cultured 
in DMEM (Corning, Biosera) supplemented with 10% v/v FCS (Invitrogen), 100 μM non-
essential amino acids (Gibco) and 2 mM glutamine (Invitrogen). 
 Human Prostate cancer cell line PC3 
PC3 cells are human epithelial cancer cells that are derived from a 62-years old 
Caucasian male suffering from bone metastasis of grade IV of prostate cancer. They are 
androgen insensitive and considered as a useful study model because of their 
aggressive migratory behaviour [411]. PC3 cells were obtained from ATCC (Teddington, 
UK) and were cultured using RPMI (Corning, Biosera) supplemented with 10% v/v Fetal 
Calf Serum (FCS) (Invitrogen), 100 μM non-essential amino acids (Gibco) and 2 mM 
glutamine (Invitrogen). 
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 Leukemic T-lymphocyte Jurkat cell line 
Jurkat cells are human T lymphocytes cells derived from the peripheral blood of a one-
year-old male suffering from acute T cell leukaemia. Jurkat cells were obtained from the 
American Type Culture Collection (ATCC) (Teddington, UK) and were cultured using 
RPMI (Corning, Biosera) supplemented with 10% v/v Foetal Calf Serum (FCS) 
(Invitrogen), 100 μM non-essential amino acids (Gibco) and 2 mM glutamine (Invitrogen). 
The previous cell lines were used to allow a comparison with different cancer types. They 
were used extensively for their migration ability [1], [388], [389]. 
 Routine tissue culture procedures for cell lines 
Both adherent and suspension cell lines were cultured in 75 cm2 flasks (Corning) in a 
humidified incubator at a temperature of 37oC with 5% CO2. Adherent cell lines would be 
used when they are confluent enough, reaching around 80-90% confluency. Prior to 
using the cells, they would undergo detachment from the flask they are incubated in. For 
MDA-MB231 and PC3 cells, they would be washed with 4 mL PBS (1.5 mM potassium 
phosphate monobasic, 3 mM potassium phosphate dibasic, 150 mM NaCl; pH 7.2, at 
room temperature), then incubated with 2 mL 0.25% Trypsin/EDTA (Gibco). MCF-7 cells 
would be detached with PBS/EDTA. Cells would be incubated for around 10 mins at 
37oC with 5% CO2. Flasks would then gently be tabbed to suspend the cells. To harvest 
the cells, they would be centrifuged at 800 g for 5 mins, discarding the supernatant, and 
the pellet resuspended in the relevant growth medium. Cells’ wellbeing would be 
detected microscopically, and haemocytometer would be used for counting them.  
Suspension Jurkat cells would be used after one day of passaging them or until 
they reach the density of 1 x 106 /mL, as they proliferate fast. THP-1 cells take around 2-
3 days to be ready for performing experiments on them. Prior to the purpose of using the 
cells, they would be centrifuged at 800g for 5 mins and the pellet resuspended in relevant 
growth media. 
For cells’ freezing to be cryopreserved, 1 X 106 of cells would be centrifuged, 
pellet resuspended into 1 mL of 10% v/v DMSO in FCS and transferred into cryotubes. 
To slow down the sudden freezing process, cryotubes would be wrapped in multiple 
tissue layers and frozen at -80oC for at least 24 hrs before long-term storage in liquid 
nitrogen at -196oC.  
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 Migration assays 
 Wound healing assay 
The migratory potential of cells in the presence of CXCL8 was investigated by wound 
healing assay. 24 well plates were marked on its outside bottom surface with two parallel 
lines (with permanent marker) to form a reference point when analysing images of wound 
closure. Cells would be harvested, centrifuged, washed, and resuspended in growth 
media at a density of 6 x 105 cells per mL. Cells were seeded into the prepared 24 well 
plates, and 1 mL of cells would go in the wells, and incubated at 37°C, 5% CO2 for 24 
hrs till they form a monolayer with minimum gaps. Three scratches across the marked 
lines were introduced to each of the wells, with a sterile pipette tip. Afterwards, the media 
would be removed and very gentle washing with PBS to remove debris from scratch 
induction or any dead cells. Cells were then immersed with 200 µL serum deprived media 
and the scratches made were imaged with duplicates for each treatment using an 
inverted Leica DMII fluorescence microscope in bright field at 10X magnification. As a 
reference point, the parallel lines drawn on the bottom of the well were used to refer to 
the same spot across different time-points. Chemokines and inhibitors or antagonists 
were added to the wells at their working concentrations. After 24 hrs of incubation with 
the compounds, media would be removed and cells would be hydrated with PBS (100 
µL), images were taken again. To quantify the effect of the treatments on the wound 
healing process, before and after images of 0 and 24 hrs time-points were analysed and 
compared using Microsoft PowerPoint by measuring the width of wounds. Results were 
presented in a ratio where 1 indicates no migration and any number lower indicates 
migration. The experiment was repeated four times.  
 Chemotaxis migration assay using ChemoTx® plate 
Suspension cells were tested for their directed migration ability using ChemoTX 5 μm 
pore chemotaxis plates (ChemoTx® System from Neuro probe Inc, USA). The lower 
chambers of the chemotaxis well plate was blocked with 30 μL 1% BSA blocking buffer 
(in simple RPMI) for 30 mins at room temperature. Chemokines were diluted in 0.1% 
BSA working buffer (in simple RPMI) at 1 nM for CXCL10 and 5 nM for CXCL8, 
depending on the experiment. Then 31 μL of the diluted chemokine was loaded on the 
wells. THP-1 or Jurkat cells were collected, centrifuged and diluted in working buffer to 
a concentration of 25 x 104 cell /mL. Cells were incubated with the inhibitor treatment or 
vehicle for 30 mins at 37 °C before loading. 20 μL cells were then administrated on to 
the top chamber of the polyvinylpyrrolidone-free polycarbonate filter (5 μm pores). The 
chemotaxis plate was incubated at 37 °C, and 5% CO2 for 5 hrs to allow cells to migrate. 
The filter was then removed and 10 μL from the wells was loaded onto a Neubauer 
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haemocytometer and counted, demonstrating the number of migrating cells. All the 
experiments were repeated at least three times. 
 Transwell migration assay using Boyden chamber 
Transwell migration assay was conducted using Falcon 8.0 µm pore size cell culture 
inserts (Thermo Fisher Scientific). Initially, adherent MDA-MB231 cells were harvested, 
and resuspended in simple DMEM media containing 0.1% BSA to a density of 1x106 per 
well. Inserts were positioned in a 24 well plate. Cells were treated with an equivalent 
amount of antagonists prior to loading for 30 mins at 37 °C and 5% CO2. 200 μL of cell 
solution was poured on top of the filter membrane into the inserts and incubated for 10 
mins at 37 °C and 5% CO2, for cells to settle. 600 μL of simple media with 0.1% BSA 
was added to the lower chamber with equivalent amount of chemokine (10 nM for 
CXCL8) and incubated for 24 hrs at 37 °C and 5% CO2. Culture media was removed and 
replaced with 300 μL DMEM with 0.1% BSA, in addition to 4 μM Calcein AM (Cambridge 
Biosciences) for 45 mins. Inserts were removed from the plate and with a cotton swab, 
the top remaining cell suspension was removed. Inserts were transferred into fresh wells 
containing 0.25% Trypsin/EDTA and incubated for 10 min at 37°C, and 5% CO2. Cells 
that have migrated over the 24 hrs hour will be detached by the Trypsin/EDTA. 200 µL 
of the detached cells in the bottom chamber were transferred to opaque reader plate 
(Thermo Fisher Scientific) and measured at a ratio of the fluorescence detected at 
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 Agarose Spot Migration Assay 
The agarose spots solution was initially made by melting 0.5% of low-melting point 
agarose (Sigma- Aldrich, Germany) in PBS. The mixture was heated and stirred until 
complete dissolution, then cooled down to 40°C. The chemokine required was diluted in 
0.1% BSA in PBS, then added into the agarose solution to give a stock concentration of 
1 µM. The control sample contained 0.1% BSA in PBS added in equivalent volume to 
the agarose solution. 
Prior to the addition of the spots, a 35 mm plate was marked across with a marker 
pen and labelled with the position of where the samples were going to be spotted (Figure 
15). 2 mm was cut off a 200 µL pipette tip followed by the transfer of 10 µL of the viscous 
molten agarose solution with the chemokine into the position labelled and the control 
spot was added to the other side. The plate was then left to cool at 4°C for 5 min for the 
spots to settle. Adherent cells at a number of 1.7x105 were suspended in 1 mL of 
complete media and gently placed over the agarose spots. The liquid tension will prevent 
the spots from crushing. After 4 hrs of incubation, the medium was replaced with 0.1% 
FCS in DMEM and incubated overnight at 37°C and 5% CO2. Visualisation was 
performed using an inverted Leica DMII fluorescence microscope. Cells that invaded the 
agarose spot were analysed by imagining different fields of the spot to cover the whole 
circumference and cells were counted using Fiji/ImageJ.  
 
Figure 15. Schematic representation of agarose spot migration assay. Cells were 
seeded, and two agarose spots were loaded on a 35 mm petri dish, with or without the 
chemokine. After overnight incubation, migrating cells towards the agarose spot were 
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 Oris migration assay 
PC3 and MDA-MB231 cells were harvested using a relevant agent and resuspended in 
RMPI or DMEM growth media, respectively, to a density of 5x104 /mL per well. Pipette 
100 µL of the cell suspension into one side of the Oris™ Seeding Stopper (Platypus 
Technology). The cells were left to adhere overnight at 37°C and 5% CO2. The role of 
the gel stoppers is to generate a detection empty area for the cells to settle around 
(Figure 16). Afterwards, the medium was removed, and the gel stopper was removed 
as well gently with a sterile tweezer. 100 µL of relevant fresh medium was added along 
with 10 nM CXCL8, CXCL9, CXCL10 or CXCL12 and incubated overnight at 37°C and 
5% CO2. Medium was removed and 100 µL of PBS was added with 4 µM calcein to stain 
the cells for 45 mins in the incubator at 37°C and 5% CO2. Wells were then washed and 
replaced with 100 µL PBS. For imaging purposes, light field or fluorescence microscopy 
was used to take images of the cells migrating with inverted Leica DMII fluorescence 
microscope. However, for quantification, cells that migrated were measured by limiting 
the reading area to the detection zone by applying an Oris™ Detection Mask and the 
ratio of the fluorescence detected was measure at 530nm/ 410nm using BMG Labtech 
Fluorostar Optima plate reader (BMG Labtech, Germany).  
 
 
Figure 16. Steps of Oris™ Migration Assay. Cells grown around a gel stopper 
attached to the wells. After cells adherence, the chemoattractant was added with the 
removal of the gel stopper. Cells would migrate towards the centre of the detection zone. 
Images or quantification of the detection area using calcein was used for analyses of the 
migrating cell. Schematic is taken from [412]. 
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 Time-lapse cell migration assay 
The effect of CXCL8 and CXCL10 on the migration speed of the cells was observed 
using time-lapse video microscopy. MDA-MB231 and PC3 cells were seeded out in a 
24-well plate in complete RPMI and DMEM media, respectively, for 24 hrs at 37 °C. 
Equivalent concentrations of the inhibitors (as indicated in Table 4) were added to the 
cells followed by the addition of CXCL8 (10 nM) or CXCL10 (10 nM). Using Carl Zeiss 
AxioVision Rel. 4.8 software, time-lapse images were taken every 4 mins for 10 hrs at 
10x objective in a controlled chamber of 37°C, and 5% CO2. Time-lapse videos created 
were analysed using Fiji/ImageJ software where 10 cells in each video were tracked 
manually throughout the video frames. The speed sum of each individual cell was 
averaged over the course of experiments - sum of the distance of 10 cells/ time (10 hrs) 
= Speed All the experiments were repeated at least four times. 
2.2.6.1 Cell morphology analysis 
From the previous time-lapse migration assay experiments, the videos generated were 
reanalysed for the observation and quantification of the cellular morphology. Cell 
morphology was measured using Fiji/ImageJ. The last frame of the videos indicating 10 
hr of cells migration was screenshotted. Using the free hand drawing option, cells were 
drawn around and measurements of area, aspect ratio and circularity were made using 
the Analyse and Set measurement options. Subsequently, these parameters were 
averaged for 70 cells per image per experiment and the experiments were repeated at 
least three times.  
2.2.6.2 Cell proliferation analysis 
Upon performing the time-lapse migration assay to test for the speed of migrating cells 
towards the CXCL8 or CXCL10, the videos generated were reanalysed for the 
observation of the mitotic behaviour of the cells. Two images were obtained by taking 
screenshots of 0 hr time-point and 10 hrs time-point from the time-lapse videos (section 
0) using Fiji/ImageJ. Screenshots were obtained using the slice remover function from 
the tool’s menu. Subsequently, the pointer clicker was customized to give a red cross 
mark on the cells counted and added to the region of interest manager to keep track of 
the number of cells. Thereafter, the number of cells in the picture frame were compared 
between the treated and control cells. 
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 MTS cytotoxicity assay 
MTS assay was performed using a CellTiter 96 AQueous Non-Radioactive Cell 
Proliferation Assay (Promega). 100 µL cells were seeded at 1 x 105 mL-1 in complete 
RPMI medium for PC3 or THP-1 cells, and DMEM for MDA-MB231 and MCF-7 cells in 
a round (for suspension cells) or flat (for adherent cells) bottomed clear 96 well plate 
(Sterilin Ltd, UK). Treatment of antagonists or inhibitors were added to the cells and 
incubated at 37°C and 5% CO2. To validate the toxicity of the treatments on the cells, 10 
µL of the MTS reagent (3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) was added to each well and incubated for 2 hrs. Cytotoxicity 
of the test compounds will be decided on the viability of the cells over the incubation 
period. The viability of cells is defined by the metabolism of the MTS reagent to formazan, 
which is read at 490 nm, and compared to the compound-tested cells. 
 
 Calcium flux 
Cells were harvested and centrifuged at 800 g for 5 min. The supernatant would be 
removed, and cells would be washed twice with calcium flux buffer (148 mM NaCl, 5 mM 
KCl, 2.5 mM CaCl2, 10 mM HEPES, 1 mM glucose, pH 7.4, stored at 4°C), and re-
suspended in 1 mL of the calcium flux buffer. Cells were treated with the required 
concentration of the antagonist or inhibitor and loaded with a final concentration of 4 µM 
Fura-2 dye (Invitrogen). They were then incubated at 37ºC and 5% CO2 for 30 mins. 
Thereafter cells were centrifuged and washed twice to remove excess Fura-2, then re-
suspended in 1 mL calcium flux buffer. 100 µL of cells were added to a 96 well black 
plate (ThermoFisher Scientific) before calcium flux assessment using BMG Labtech 
Fluorostar Optima plate reader. (BMG Labtech, Germany). The Fluorometer injection 
was previously washed with H2O few times, then primed with the chemokine. The fluxes 
in intracellular calcium release were characterised by radiometric analysis of alterations 
in fluorescence sequentially stimulated at an excitation and emission wavelengths of 340 
nm (bound Fura-2) and 380 nm (unbound Fura-2) and measured at 510 nM. Data was 
analysed as the difference of fluorescence before stimulation at 340 nM and after 
stimulation and after stimulation at 380 nM using BMG Optima software. 
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 Imaging Techniques 
 Phalloidin actin stain 
Cells were harvested after reaching around 90% confluency. MDA-MB231, PC3, and 
MCF-7 cells were seeded onto 12 well plate with glass coverslips and 1500 mL growth 
media. Inhibitors were added with or without CXCL8 or CXCL10 (10nM) to the wells and 
left to incubate for 10 hrs at 37°C and 5% CO2. Afterwards, the media was removed, and 
cells were washed gently in PBS (stored at 4ºC). Cells were fixed with 500 µL of 4% 
paraformaldehyde for 10 mins. Cells were then washed again with 1 mL PBS (4ºC), and 
permeabilized with 200 µL 0.1% Triton x-100 solution (FischerBiotech) for 10 mins. They 
were then washed again with 1 mL PBS (4ºC) and stained with 1:100 Phalloidin-iFlour 
488 Conjugate (Abcam) in PBS and left to incubate in the dark for 30 mins at 4 ºC. If 
required, nucleus stain of the cells happened after washing the wells twice with 1 mL 
PBS (4ºC) and stained with DAPI (4’,6 diamidino-2-phenylindole) (Sigma Aldrich) at 
1:5000 for 5 mins at 4 ºC. Final washing of excess stain with 1 mL PBS (4 ºC) followed 
by extracting the coverslips gently with tweezers and mounting on a glass slide with DPX 
(ThermoFisher Scientific). Coverslips were mounted onto glass slides with DPX 
mounting media (Fisher Scientific). Stained cells were then imaged using inverted Leica 
DMIL fluorescence microscope.  
 
 Immunofluorescence staining 
MDA-MB231 and PC3 cells were harvested in a relevant agent after reaching around 
90% confluency. MDA-MB231 and PC3 cells were seeded onto 12 well plate with glass 
coverslips and 1500 µL growth medium. Cells were fixed with 500 µL of 4% 
paraformaldehyde for 10 mins, while being incubated at 4 °C. After incubation cells were 
washed with 1 mL PBS (4ºC) and blocked with primary antibodies of IL-8RA (CXCR1) 
antibody (SC-7303, Santa Cruz); IL-8RB (CXCR2) antibody (SC-7304, Santa Cruz), or 
CXCR-3 (H-1) antibody (SC-133087, Santa Cruz) at 1:100 dilution. Well plate was 
incubated for 1 hr at 4°C in the dark. Afterwards, cells were washed with 1 mL PBS (4ºC) 
and incubated with the corresponding secondary antibodies of Alexa Fluor 488-
conjugated goat anti-mouse IgG (Abcam, Cambridge, MA) at a ratio of 1:1000. Cells 
were further washed with 1 mL PBS (4ºC) and incubated with DAPI (Sigma Aldrich) at 
1:5000 for 5 mins at 4 ºC. Coverslips were mounted onto glass slides with DPX mounting 
media (Fisher Scientific). Final washing of excess stain with 1 mL PBS (4 ºC) followed 
by extracting the coverslips gently with tweezers and mounting on a glass slide with DPX 
(ThermoFisher Scientific). Stained cells were then imaged using inverted Leica DMIL 
fluorescence microscope. 
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THP-1 cells were harvested and centrifuged and the same process was applied 
to them except they were stained in their eppendorfs instead of in a well plate. 40 µL of 
the stained cells were loaded on the mounting buffer DPX (ThermoFisher Scientific) on 
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 Chemokines, antibodies, and small molecules 
Table 2. List of chemokine and their cognate receptors. Chemokines were made 





























Chemokines Supplier Chemokine Receptor 
CXCL8 
(IL-8) 
Gift from K. Schmitz  













PeproTech CXCR4, CXCR7 
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Table 4. List of small molecule inhibitors. 
Inhibitor Target Supplier Working conc 
L779450 Raf Abcam 100 nM 
ZM336372 Raf Santa Cruz 1 μM 
PD98059 MEK Abcam 25 μM 
SL327 MEK Abcam 1 μM 
SB203580 p38 MAPK Tocris 1 μM 
FH535 Β-catenin Abcam 1 μM 
Staurosporine PKC Tocris 10 nM 
GF109203X PKC Tocris 5 μM 
PKCζi PKC Calbiochem 10 μM 
CID755673 PKD Tocris 11 μM 
PF562271 FAK Abcam 10 nM 
Bosutinib Src Shellek 
chemicals 
1 μM 
NSC23766 Rac1 Tocris 100 μM 
EHT1864 Rac1 Cambridge 
Biosciences 
100 nM 
ZCL278 Cdc42 Tocris 20 μM 
CCG 1432 RhoA Tocris 1 μM 
Y27632 ROCK Tocris 20 μM 
CPYPP DOCK1/2/5 Tocris 100 μM 
LY294002 Pi3K Tocris 10 μM 
AKTi AKT Abcam 20 μM 
CK666 Arp2/3 Tocris 80 μM 
H89 HCL PKA Tocris 10 nM 
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  Statistical data analysis 
Data analysis was performed using GraphPad Prism V6 software (La Jolla, CA). 
Unpaired t-test was used to analyse two-variables while One-way ANOVA with post-hoc 
Dunnett’s multiple comparison was performed on three or more variables. Kruskal-Wallis 
non-parametric test with post Dunn’s multiple comparison tests were applied for 
normalized values. 95% was considered a value for significance in all statistical tests 
performed with p-value indicating no significance p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** 
= p ≤ 0.001, and **** = p ≤ 0.0001. Data represents the mean ± standard errors of means 
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3 Chapter 3: Characterisation of cancer cell 
response to CXCL8 and CXCL10 
 Introduction 
Chemokines were first described as chemoattractant cytokines, which play a key role in 
guiding the movement of leukocytes under basal and inflammatory conditions [79]. 
CXCL8 was identified as a neutrophil-activating factor and is produced by a plethora of 
cell types including keratinocytes, fibroblasts, neurons, endothelial cells, epithelial cells, 
smooth muscle cells, hepatocytes, and melanocytes (as reviewed by [280]). CXCL8 
binding to the G-protein coupled receptors CXCR1 and CXCR2 expressed on these cells 
may participate in modulating various steps of cancer progression including growth, 
proliferation, and migration [408]. CXCL8 has been documented to stimulate angiogenic 
responses in endothelial cells, as well as increasing the growth, survival, and migration 
of both endothelial and cancer cells [143], [280], [414], [415]. Likewise, elevated levels 
of CXCL10 have been reported in a diverse range of human diseases such as infectious, 
inflammatory, autoimmune disorders, and cancer [237], [416], [417]. CXCL10 has a 
crucial role in the recruitment and homing of leukocytes to the inflamed area, but this 
recruitment can result in significant tissue damage  [201]. CXCL10, together with CXCL9 
and CXCL11, bind to CXCR3, which has been associated with malignant melanoma, 
ovarian carcinoma, multiple myeloma, B-cell lymphoma, and basal cell carcinoma (as 
reviewed by Liu et al. [237]). In this chapter, we investigated the expression of CXCL8 
and CXCL10 receptors on cancer cells, the effect of activating these receptors on 
intracellular calcium release, along with their effect on the migratory behaviour of 
different cancer types.  
Cell migration is crucial to many biological processes including, wound healing, 
embryogenic development, and immune defence. However, cell migration also 
significantly contributes to tumour progression. Therefore, the migratory capacity of a 
tumour cell is an important indicator of its potential to metastasize [418]. Three forms of 
locomotion can characterize cell migration: random, kinesis, and chemotaxis. Random 
motion happens in the absence of environmental stimuli. Kinesis, specifically 
chemokinesis, is a random motion that is influenced by a chemical stimulus. While 
chemotaxis is a directed movement of  cells towards a gradient of a stimulus [282]. Here 
we present different in vitro migration assays to study the migratory behaviour of various 
cancer cell types. They are based on two-dimensional (2D) methods including the wound 
healing assay, chemotaxis, Boyden chamber assay, Oris migration assay, and agarose 
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spot assay. However, these protocols have temporal limitations and do not allow the 
acquisition of migratory information in real-time. Here, we tracked individual cells using 
in vitro 2D time-lapse real-time cell imaging. The suitable cell type for each of these 
protocols is presented, and all the data acquired by these protocols is accompanied by 
an explanation on the troubleshooting and analysis process.  
Chapter Aims:  
Investigate the response of various cancer cell types to CXCL8 and CXCL10. 
Optimise migration assays for different cancer cell types to study the chemotactic effect 























 Characterising the response of cancer cells to CXCL8 
 
3.2.1.1 The response of THP-1 cells to CXCL8 
3.2.1.1.1 Expression of CXCR1 and CXCR2 receptors on THP-1 cells  
THP-1 cells are non-adherent, acute monocytic leukaemia cells that are a well-
established model for studying the behaviour of monocytes [419]. They share common 
features with  normal human monocytes, such as their morphology, expression of plasma 
membrane receptors and cytokines [420]. Using semi-quantitative analysis of receptor 
mRNA expression, THP-1 monocytes showed strong expression of CXCR2 mRNA but 
not CXCR1 [421]. These results by other research groups agree with our 
immunofluorescence observations whereby CXCR2 was detectable on THP-1 cells, but 
CXCR1 was not (Figure 17). Whilst CXCR1 expression was not visible in THP-1 cells, 
MDA-MB231 cells clearly express this receptor (Figure 25).  




Figure 17. THP-1 cells express CXCR2 but not CXCR1. Immunofluorescence 
staining of the THP-1 cell line using anti-CXCR1, or anti-CXCR2 and their 
corresponding secondary anti-mouse Alexa-488 conjugated antibodies (green). 
Control represents anti-mouse Alexa-488 alone. The nucleus was stained with DAPI 
(blue). Images are representative of the cell population of one experiment from three 
independent experiments, acquired at 63x objective using a Leica DMII fluorescence 
microscope and Leica imaging suite.  
 
3.2.1.1.2 THP-1 cells migrate towards CXCL8, and inhibiting CXCR1 and 
CXCR2 reduces the number of migrating cells  
Tumour progression is determined by the interaction of cancer cells with the host 
microenvironment. Several reports have demonstrated the impact of chemokines not 
only on the motility of endothelial cells, and thus angiogenesis, but also chemotaxis of 
cancer cells  [418]. Therefore, chemotaxis assay was used to identify the directed 
migration of THP-1 cells. Results showed that treating THP-1 cells with CXCL8 (5 nM) 
for five hrs resulted in an almost two-fold increase in the number of migrating cells when 
compared to un-treated basal cells (Figure 18).  
81 | P a g e  
 
 
Figure 18. CXCL8 increases the migration of THP-1 cells in a chemotaxis assay. 
The number of migrating THP-1 cells increased significantly after 5 hrs incubation in 
the presence of CXCL8 (5 nM) in a ChemoTx® System relative to the unstimulated 
cells. Data shown are the mean ± SEM of six independent experiments. (Unpaired t-
test, **** = p ≤ 0.0001). 
 
Reparixin is a low molecular weight inhibitor of human CXCL8 receptor activation 
[162]. It inhibits CXCL8-induced migration and calcium flux in human and rat neutrophils 
[422]. SCH527123 is a potent small molecule and allosteric antagonist of both CXCR1 
and CXCR2. It was applied for the treatment of inflammation arising from neutrophil 
infiltration [163]. This compound has also been shown to inhibit colon cancer metastasis, 
decrease tumour neovascularization, and induce tumour cell death in mouse models 
[423]. Additionally, Reparixin and SCH527123 have been used in clinical trials to inhibit 
the development of breast, colon, and colorectal cancer [424]–[426]. Moreover, 
SB225002, the first non-peptide antagonist of CXCR2 has also been identified [427]. 
This compound blocked CXCL8 binding to recombinant and native CXCR2, as well as 
inhibited CXCL8-induced chemotaxis of neutrophils in vitro and in vivo [427]. The 
concentrations of these antagonists chosen took into consideration the IC50 for each 
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To investigate the effect of CXCR1 and CXCR2 antagonists; Reparixin, 
SCH527123, and SB225002 on the migration of THP-1 cells. Cells were pre-treated with 
the antagonist for half an hour prior to loading onto the chemotaxis filter, while CXCL8 
(5 nM) was present in the bottom chamber. There was a significant increase in the 
number of migrating cells upon stimulation with CXCL8 (p ≤0.05) compared to untreated 
basal cells. All of the three antagonists were able to decrease the migration of THP-1 
cells, but only SCH527123 and SB225002 could significantly impact the number of cells 
migrating towards the CXCL8 gradient (Figure 19). 
 
  
Figure 19. CXCR1 and CXCR2 antagonists reduce the migration of THP-1 cells 
towards CXCL8 in a chemotaxis assay. The multiple comparison test conducted 
after 5 hrs incubation with CXCL8 (5 nM) and inhibitors showed that SCH527123 (20 
μM) or SB225002 (1 μM) significantly reduced the number of migrating CXCL8-
stimulated THP-1 cells. Reparixin (15 μM) also impacted the migration of cells but not 
significantly. Comparison was made against CXCL8. 1% DMSO was added to the 
basal cells as a vehicle control. Data shown are the mean ± SEM of at least 3 
independent experiments. (One-way ANOVA with a Dunnett’s multiple comparisons 
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3.2.1.1.3 CXCL8 promotes intracellular calcium responses in THP-1 cells  
Upon CXCL8 binding to CXCR1 or CXCR2, GPCR signalling pathways are stimulated 
which induces downstream events such as chemotaxis, intracellular calcium release, 
and/or receptor internalisation [130]. The downstream release of calcium has been used 
for many years as an indicator of chemokine receptor activation [386]. Figure 20 shows 
the release of intracellular calcium upon the addition of CXCL8 in a concentration-
dependent manner. The release of calcium increases with the elevation of the CXCL8 
concentration, but the curve does not plateau because the maximum is not reached. 
 
 
Figure 20. Intracellular calcium response of THP-1 cells following treatment with 
varying concentrations of CXCL8. Data is expressed as changes in fluorescence ratio 
(340 nm/380 nm) upon incubation with 4 µM Fura-2 for 30 min. The basal fluorescence, 
prior to the addition of CXCL8, is subtracted from the peak fluorescence following 
injection with CXCL8. Data represent mean ± SEM from four independent experiments. 
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3.2.1.1.4 CXCR1 and CXCR2 antagonists block intracellular calcium flux in 
CXCL8-treated THP-1 cells 
We next determined the effect of blocking CXCL8 receptors on the intracellular calcium 
responses. We observed that inhibition with Reparixin (15 μM) could reduce the release 
of intracellular calcium upon activating the receptor with CXCL8 (200 nM; Figure 21a). 
Similarly, significant reductions in the ability of CXCL8 to stimulate intracellular calcium 
release were observed following inhibition with SCH527123 (20 μM; Figure 21b) and 
SB225002 (1 μM; Figure 21c). 
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Figure 21. CXCR1 and CXCR2 antagonists reduce intracellular calcium release in 
CXCL8-stimulated THP-1 cells. Pre-treatment for 30 mins with a) Reparixin (15 μM), 
b) SCH527123 (20 μM), and c) SB225002 (1 μM) significantly reduce the release of 
calcium when activated with CXCL8 (200 nM). Intracellular calcium measurement 
traces are taken from a representative experiment. 1% DMSO was added to CXCL8. 
Data represents the mean ± SEM of nine independent experiments. (Unpaired t-test ** 
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3.2.1.1.5 Toxicity of CXCR1 and CXCR2 antagonists towards THP-1 cells 
An MTS assay was performed to test the cell toxicity of CXCR1 and CXCR2 antagonists 
on THP-1 cells. Treatment of THP-1 cells with increasing concentrations of SCH527123 
and SB225002 resulted in a cytotoxic effect, while Reparixin up to 30 μM was not 
cytotoxic (Figure 22). The concentrations used in our experiments demonstrated no 
cytotoxicity because the IC50 and concentrations used in previous studies were taken into 
consideration [428], [429]. In this study, Reparixin concentrations up to 30 μM were 
tolerated, SCH527123 became toxic at 30 μM, and SB225002 demonstrated toxicity at 
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Figure 22. Toxicity of CXCR1 and CXCR2 antagonists towards THP-1 cells. The 
absorbance following incubation of THP-1 for 24 hrs with a) Reparixin, b) SCH527123, 
and c) SB225002 and treatment with MTS reagent for 2 hrs. 1% DMSO was added to 
the basal as a vehicle control. Data is representative of the mean ± SEM of three 
independent experiments (One-way ANOVA with a Dunnett’s multiple comparisons 
test as post-test, n.s.= no significance p>0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 
0.001, **** = p ≤ 0.0001). 
88 | P a g e  
 
3.2.1.2 The response of Jurkat cells to CXCL8 
3.2.1.2.1 Jurkat cells do not migrate towards CXCL8  
Jurkat cells are immortalized T lymphocytes that were obtained from the peripheral blood 
of a one-year-old boy with acute T cell leukaemia. They have been widely used as they 
express multiple chemokine receptors, and they are prone to viral entry [430]–[432]. As 
for THP-1 cells, we investigated the effect of CXCL8 on the migration of Jurkat cells. Our 
lab have already reported that CXCL12 induces the migration of Jurkat cells [388], [433]–
[435], so CXCL12 was used as a positive control. Indeed, Jurkat cells migrate 
significantly more in response to CXCL12, but no chemotactic activity was observed in 
the presence of CXCL8 (both 5 nM; Figure 23). To our knowledge, the activation of 
Jurkat cells by CXCL8 or native expression of the CXCL8 receptor have not been 
reported. However, they have been used as a model system for transfection with CXCL8 
receptors [436], [437]. 
 
Figure 23. Jurkat cells do not migrate towards CXCL8 in a chemotaxis assay. 
After 5 hrs incubation, CXCL8 treatment (5 nM) did not induce migration in Jurkat cells, 
but cells migrated towards CXCL12 (5 nM). Data shown are the mean ± SEM of three 
independent experiments. (One-way ANOVA with a Dunnett’s multiple comparisons 
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3.2.1.2.2 Weak intracellular calcium release in response to CXCL8 in Jurkat 
cells 
The induction of intracellular calcium signalling was used to determine chemokine 
receptor activation. Injecting CXCL8 in a concentration-dependent manner gave 
fluctuating results, generally with very low responses from the cells (Figure 24a). It was 
difficult to determine a realistic EC50 considering there was hardly any calcium release. 
Neither the lowest (10 nM) or highest (300 nM) concentrations of CXCL8 could elicit 
significant intracellular calcium responses (Figure 24b). No further experiments with 
Jurkat cells were performed, as they responded very poorly to CXCL8, suggesting their 
lack of CXCL8 receptors expression. 
 
Figure 24. CXCL8 does not induce intracellular calcium release in Jurkat cells. 
a) Intracellular calcium responses upon CXCL8 injection. Data is expressed as 
changes in fluorescence ratio (340nm/380nm) where the basal fluorescence, prior to 
the injection of CXCL8, is subtracted from peak fluorescence following injection of 
CXCL8. b) Lowest and highest concentrations of CXCL8 showing no significant 
release of calcium (Unpaired t-test, n.s.=no significance). Data represent mean ± SEM 
from six independent experiments. (Non-linear regression dose-concentration 
response curve assuming a Hill coefficient of 1). 
90 | P a g e  
 
3.2.1.3 The response of MDA-MB231 to CXCL8 
3.2.1.3.1 Expression of CXCR1 and CXCR2 receptors on MDA-MB231 cells 
The cellular model MDA-MB231 is extensively used for studying breast cancer 
metastasis [438]. To estimate the biological effects of CXCL8 on MDA-MB231 cancer 
cells, it was important to check for receptor expression. MDA-MB231 stained positive for 
both CXCR1 and CXCR2 after staining with anti-CXCR1 (also known IL-8RA) mAB and 
anti-CXCR2 (also known IL-8RB) mAB, respectively (Figure 25). This comes in 
agreement with studies by other groups whereby high levels of CXCR1 expression were 
measured by flow cytometry and RT-PCR showing expression of CXCR2 in MDA-MB231 
cells [243], [439]. 
 
Figure 25. MDA-MB231 cells express CXCR1 and CXCR2. Immunofluorescence 
staining of MDA-MB231 cells using anti-CXCR1, anti-CXCR2 and their corresponding 
secondary Alexa-488 conjugated antibodies (green). Control was anti-mouse Alexa-488 
alone. The nucleus was stained with DAPI (blue). Cells were fixed and images are 
representative of the cell population of one experiment out of three independent repeats, 
acquired at 63x objective using a Leica DMII fluorescence microscope and Leica imaging 
suite. 
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3.2.1.3.2 MDA-MB231 cells migrate towards CXCL8 in a Boyden chamber 
migration assay 
Since MDA-MB231 cells showed expression of both CXCR1 and CXCR2, a Boyden 
chamber migration assay was performed to determine the migratory capacity of the cells 
in response to CXCL8. MDA-MB231 cells are a highly aggressive, invasive, and poorly 
differentiated triple-negative breast cancer cell line [440]. They obtain their invasiveness 
from their ability to degrade the extracellular matrix. A Boyden chamber migration assay 
is a widely used technique that creates a chemoattractant concentration gradient. In the 
upper chamber, cells were cultured in serum free media (to prevent cytokines and growth 
factors tampering with the stimulus effect). CXCL8 (10 nM) was added to the bottom 
chamber, separated through surface tension, which hinders the chemokine from readily 
dispersing into the cell chamber. Indeed, there was a significant increase in the number 
of MDA-MB231 cells migrating towards CXCL8 relative to the control (Figure 26). 
  
Figure 26. CXCL8 induces migration of MDA-MB231 cells in a Boyden chamber 
transwell assay. Cells were incubated with or without CXCL8 (10 nM) on a transwell 
insert to maintain a chemokine gradient for 24 hrs, they were then stained with calcein 
for 45 mins and fluorescence was measured at 530nm/ 410nm. All data shown are the 
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3.2.1.3.3 Agarose spot assays are not suitable for measuring the migration 
of MDA-MB231 cells 
Our results obtained with the Boyden chamber migration assay, which relies on a semi-
permeable membrane to generate a concentration gradient, showed that MDA-MB231 
cells migrate towards CXCL8. To confirm these results, an agarose spot assay was 
performed to increase the reliability. In this assay, the chemokine is contained in the 
middle of the well in a bubble formed of 0.5% agarose. Theoretically, cells seeded 
outside of this spot should travel towards the chemokine contained in the soft agarose. 
The protocol used for this experiment was inspired by work performed by Vinadar et al. 
[441] and Ahmed et al. [442]. They found that cells significantly migrated towards 
CXCL12 compared to the control. However, the reproducibility of this assay was 
challenging, and no meaningful results were generated with MDA-MB231 cells in 
response to CXCL8 (10 nM) or CXCL12 (10 nM). There were several different 
observations noted from repeating the experiments. i) A colony of cells would penetrate 
into the agarose spot (Figure 27a), ii) the agarose spot kept dislodging and moving from 
its intended position (Figure 27b). Although different conditions were attempted to 
maintain the agarose spot in one place, for example, switching between plastic and glass 
bottom plates, altering cooling and heating temperatures, or slightly changing the 
concentration of the agarose; the penetration of cells under the agarose spot was not 
successful. Figure 27c, d represents the expected number of migrating cells (in a well-
contained agarose spot) to a chemokine-gradient. However, in order to generate 
randomized, unbiased data, the whole spot should be imaged. As mentioned before, 
some clusters of cells tended to migrate towards one position more than the other. 
Ahmed et al. [442] imaged the agarose spot of PC3 cells migration at different angles, 
however, we think that also imaging the spot circumference in full at a lower microscope 
objective would give a better representation of the migration patterns of the cells. Overall, 
this approach did not seem reproducible for measuring chemokine-induced chemotaxis 
and there are numerous challenges associated with the analysis process. 
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Figure 27. Agarose spot assays did not provide consistent data for MDA-MB231 
cells. a) A colony of cells migrating under the agarose spot. The dash lines indicate the 
spot border. b) Agarose spot sliding as indicated with the position of the two arrows. c, 
d) Different angles of the agarose spot represents different sets of migrating cells. Data 
are representative of four different experiments. Cells images are representative of the 
cell population acquired at 10x objective using a Leica DMII inverted microscope and 
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3.2.1.3.4 The migration speed of MDA-MB231 cells increases when activated 
with CXCL8  
After testing CXCR1 and CXCR2 expression and the ability of CXCL8 to induce migration 
in MDA-MB231 cells, a time-lapse migration assay was performed to study the speed of 
the migrating cells. Following treatment of the cells with CXCL8 (10 nM), the speed of 
migration increased by almost two-fold. The basal speed of cells was 24.4 ± 5.8 μm/hr, 




Figure 28. MDA-MB231 cells migrate faster in the presence of CXCL8. a) MDA-
MB231 cells activated by CXCL8 (10 nM) demonstrated a significant increase in the 
migration speed upon analysing 10 cells from each experiment. Data representative 
of the mean ± SEM of four independent experiments (unpaired t-test, ** = p ≤ 0.01) b) 
Endpoint images from individual cell tracking using Fiji/ImageJ after 10 hrs, i) Basal, 
ii) CXCL8 (10 nM). Images are a representation of the cell population and were taken 
at 10x objective with Zeiss Axiovert 200M microscope and processed using AxioVision 
Rel 4.8 software. 
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MDA-MB231 cells treated with Reparixin (10 µM), SCH527123 (10 μM) or 
SB225002 (1 μM), followed by activation with CXCL8 (10 nM) were significantly slowed 
down (32.2 ± 11.5 μm/hr, 29.5 ± 5.2 μm/hr and 15.4 ± 7.1 μm/hr, respectively), 
demonstrating full inhibition of the CXCL8 effect (Figure 29). Fu et al. [443] found that 
Reparixin (40 or 60 μM/L) or SCH527123 (40 or 60 μM/L) did not inhibit cell viability, 
colony formation, or wound healing closure as significantly as the potent inhibition 
achieved by combining either of them with bazedoxifene (targeting IL-6). 
  
Figure 29. The migration speed of MDA-MB231 cells is reduced in the presence of 
CXCR1 and CXCR2 antagonists. Reparixin (10 μM), SCH527123 (10 μM), and 
SB225002 (1 μM) significantly reduce the migration of MDA-MB231 towards CXCL8 (10 
nM) over 10 hrs. Comparison was made against CXCL8. 1% DMSO was added to the 
basal cells as a vehicle control. Data are representative of three independent 
experiments (One-way ANOVA with a Dunnett’s multiple comparisons test as post-test, 
* = p ≤ 0.05, ** = p ≤ 0.01). 
 
Another experiment was performed to investigate the migration speed of MDA-
MB231 cells over a period of 30 hrs. This experiment was performed on a different more 
basic microscope (Celestron 44126-CGL Micro 360). On average, cells migrated up to 
60 μm/hr (Figure 30a). The significant effect of CXCL8 on the enhanced migration of 
cells compared to control cells can be clearly observed from the images obtained after 






























































Figure 30. MDA-MB231 cells migrate faster in the presence of CXCL8 over 30 
hrs. a) MDA-MB231 cells migrate faster in the presence of CXCL8 (10 nM). b) Arrows 
pointing at cell tracks that were randomly picked and analysed of the i) basal sample 
(image taken after 20 hrs), ii) followed by the addition of CXCL8 (10 nM) to the same 
well and imaged over 30 hrs. Data are representative of three independent 
experiments. Images are a representation of the cell population and were taken at 10x 
objective using a Celestron 44126-CGL Micro 360 and Celestron HD digital 
microscope imager, processed by Debut professionals-NCH software, decompressed 
videos with Camtasia studio 8.0, tracking and analysis with Fiji/ImageJ. (Unpaired t-
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3.2.1.3.5 CXCL8 induces proliferation in MDA-MB231 cells 
CXCL8 and its receptors CXCR1 and CXCR2 are expressed by various cancer cell types 
and activate cancer cell proliferation and migration in an autocrine fashion (reviewed by 
[131]). Results obtained by the time-lapse migration assay indicated that treating cells 
with CXCL8 (10 nM) increased MDA-MB231 cell migration. Further analysis was 
performed on the videos generated by this experiment. Taking two screenshots of the 
cells at 0 hr-time point and 10 hrs-time-point, the number of cells were counted using 
Fiji/ImageJ. Analysis showed that cells treated with exogenous CXCL8 displayed 
enhanced proliferation compared to the control cells Figure 31a. The experiment was 
repeated three times and this increase was observed in all experiments. A number of 
studies have shown that several cell lines react in the same way when stimulated with 
CXCL8, including breast, lung, melanoma, and epithelial cells [142], [146], [325], [444]. 
However, we cannot specifically conclude that CXCL8 induce the proliferation in MDA-
MB231 from this mere observation. That is because the screenshot was taken from a 
discrete location in the well, therefore cells could have migrated away from the field of 
view. Yet, we could still observe that within this limited area, cells exhibited more 













Figure 31. A significant increase in the proliferation of MDA-MB231 cells was 
observed in the presence of CXCL8. a) The number of cells were elevated 
significantly in the presence of CXCL8 (10 nM). b) Images from 0 hr and 10 hrs-
timepoints obtained from the time-lapse migration assay with the red crosses indicating 
the number of cells in each frame analysed using Fiji/ImageJ. Data representative of 
three independent experiments (Unpaired t-test, * = p ≤ 0.05). Images are a 
representation of the cell population and were taken at 10x objective with a Zeiss 
Axiovert 200M microscope and processed using AxioVision Rel 4.8 software. 
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3.2.1.3.6 Toxicity of CXCR1 and CXCR2 antagonists towards MDA-MB231 
cells 
An MTS assay was performed to test the cellular toxicity of the CXCR1 and CXCR2 
antagonists on MDA-MB231 cells. A study conducted by Brandolini et al. [445] found that 
treating cells with 1 µM - 3 mM of Reparixin for 72 hrs resulted in a reduction of cell 
viability in a concentration-dependent manner, up to 60% of the control. 
In our hands, Reparixin at concentrations of 5 to 30 μM, SCH527123 at 20 μM to 
50 μM, and SB225002 at 1, 5 and 10 μM showed no toxicity after 24 hrs (Figure 32).  
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Figure 32. Toxicity of CXCR1 and CXCR2 antagonists towards MDA-MB231 cells. 
Toxicity of MDA-MB231 cells after treatment with a) Reparixin, b) SCH527123, and c) 
SB225002 for 24 hrs and MTS reagent for 2 hrs. Data are representative of the mean 
± SEM of three independent experiments (One-way ANOVA with a Dunnett’s multiple 
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3.2.1.4 The response of MCF-7 cells to CXCL8 
3.2.1.4.1 Expression of CXCR1 and CXCR2 receptors on MCF-7 cells 
MCF-7 cells are another mammary cell model used to study the expression of chemokine 
receptors. Xu et al. [446] reported that MCF-7 cells express CXCR2 at low levels. 
Conversely, Müller et al. [447] showed that CXCR2 was upregulated in MCF-7 cells 
through flow cytometric analyses and quantitative RT-PCR. Our findings show that MCF-
7 cells expressed both CXCR1 and CXCR2 in an immunofluorescence assay (Figure 
33). 
 
Figure 33. MCF-7 cells express CXCR1 and CXCR2. Immunofluorescence staining of 
the MCF-7 cells using anti-CXCR1, anti-CXCR2 and their corresponding secondary 
Alexa-488 conjugated antibodies (green). Control was anti-mouse Alexa-488 alone. The 
nucleus was stained with DAPI (blue). Cells were fixed, and images are representative 
of the cell population of one experiment out of three independent experiments, acquired 
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3.2.1.4.2 CXCL8 promotes MCF-7 wound closure 
A wound healing assay is a well-known, simple, cheap, and useful technique for the 
analysis of cell migration in vitro in two dimensions. The assay steps are initiated by 
creating a scratch in an adhered monolayer of cells, then capturing images of the wound 
closure with different treatments at different time-points to monitor the scratch closure. 
After observing the expression of CXCR1 and CXCR2 on MCF-7 cells, a wound healing 
assay was performed to assess the migration potential of the cells in the presence of 
CXCL8 (10 nM). Indeed, after 24 hrs incubation with CXCL8, MCF-7 cells migrated 
significantly more towards closing the scratch compared to controls. The wound width 
ratio was 0.85 for CXCL8 whilst it was 0.95 for the control (Figure 34). Here, 0 denotes 
















Figure 34. CXCL8-treated MCF-7 cells display an enhanced migration in a wound 
healing assay. a) CXCL8 (10 nM) promotes MCF-7 wound closure after 24 hrs. A value 
of 1 denotes no migration, whilst 0 denotes complete migration. b) Image representing 
CXCL8 (10 nM) wound closure in the cells after 24 hrs. MCF-7 cells treated with CXCL8 
had a wound width ratio of 0.85 compared to 0.95 for the basal. Results represent the 
mean ± SEM of eight independent experiments. All images were taken at 10x objective 
using a Leica DMII inverted microscope and Leica imaging suite. (Unpaired t-test, ** = 
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Furthermore, the wound healing assays were used to assess the inhibitory 
capacity of CXCR1 and CXCR2 small molecule antagonists; Reparixin (500 nM), 
SCH527123 (500 nM) and SB225002 (250 nM). CXCL8-activated cells migrated 
significantly more than the untreated basal cells (p ≤ 0.05). Whilst Reparixin and 
SCH527123 did not significantly affect the migration of cells, SB225002 seemed to block 
the binding of CXCL8 to CXCR1 and CXCR2, therefore less migration was noted upon 
activation with CXCL8 (10 nM) (Figure 35). 
 
 
Figure 35. CXCR1 and CXCR2 antagonist SB225002 blocks the migration of MCF-
7 cells in the presence of CXCL8. Pre-treatment of MCF-7 cells with SB225002 (250 
nM) significantly reduced the migration of MCF-7 cells, while SCH527123 (500 nM) and 
Reparixin (500 nM) only slightly reduced the migration after activation with 10 nM 
CXCL8. A value of 1 denotes no migration, whilst 0 denotes complete migration. 
Comparison was made against CXCL8. 1% DMSO was added to the basal cells as a 
vehicle control. Results represent the mean ± SEM of three independent experiments 
(Two-way ANOVA, Tukey’s multiple comparisons test, n.s.= no significance, p >0.05, * 
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3.2.1.4.3 CXCL8 induces intracellular calcium release in a concentration-
dependent manner in MCF-7 cells 
The release of intracellular calcium was identified as an indicator of chemokines 
activating their cognate receptors [387]. Indeed, as for MCF-7 cells, CXCL8 could induce 
intracellular calcium release in a concentration-dependent manner (Figure 36). 
 
Figure 36. Intracellular calcium response of MCF-7 cells following treatment with 
varying concentrations of CXCL8. Data is expressed as changes in the 
fluorescence ratio (340nm/380nm) where the basal fluorescence, prior to the addition 
of CXCL8, is subtracted from peak fluorescence following addition of CXCL8. Data 
represents the mean ± SEM from three independent experiments. Non-linear 
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3.2.1.4.4 CXCR1 and CXCR2 antagonists inhibit intracellular calcium release 
in MCF-7 cells 
Since CXCL8 induced release of intracellular calcium in MCF-7 cells, we blocked the 
receptors associated with CXCL8 signalling. Reparixin (500 nM), SCH527123 (500 nM), 
and SB225002 (250 nM) inhibited the release of intracellular calcium by CXCL8 (200nM; 
Figure 37a). Individual traces of calcium release were plotted to present the inhibitory 
effect of the antagonists used (Figure 37b).  
 
 
Figure 37. CXCR1 and CXCR2 antagonists reduce intracellular calcium release in 
CXCL8-activated MCF-7 cells. a) Reparixin (500 nM), SCH527123 (500 nM), and 
SB225002 (250 nM) significantly reduce the release of intracellular calcium of MCF-7 
cells upon activation with 200 nM CXCL8. b) Calcium measurement traces 
(representative of one experiment) when activated with CXCL8 (200 nM). 1% DMSO 
was added to the basal cells as a vehicle control. Data represents the mean ± SEM of at 
least four independent experiments. (One-way ANOVA with a Dunnett’s multiple 
comparisons test as post-test * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001). Data are 
expressed as the relative ratio of fluorescence emitted at 510 nm after sequential 
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3.2.1.4.5 Toxicity of CXCR1 and CXCR2 antagonists towards MCF-7 cells  
To investigate whether the inhibitory effect of the antagonists on intracellular calcium 
release in MCF-7 cells was due to cytotoxicity, an MTS cytotoxicity assay was performed. 
Treatment of MCF-7 cells with increasing concentrations of Reparixin, SCH527123 and 
SB225002 for 24 hrs showed no cytotoxicity to the cells. Although there were high 
standard errors, possibly due to the experiment being repeated only twice, the 
concentrations tested by other groups [196], [448] were already higher than the 
concentrations used in our experiments. Therefore, we can be sure that there was no 
cytotoxic effect of the antagonists at the concentrations used in our experiments with 
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Figure 38. Toxicity of CXCR1 and CXCR2 antagonists towards MCF-7 cells. Toxicity 
of MCF-7 cells following treatment with a) Reparixin, b) SCH527123, and c) SB225002 
for 24 hrs and MTS reagent for 2 hrs. 1% DMSO was added to the basal as a vehicle 
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3.2.1.5 The response of PC3 cells to CXCL8 
3.2.1.5.1 Expression of CXCR1 and CXCR2 receptors on PC3 cells 
PC3 cells have been used for many years and represent the aggressive form of prostate 
cancer [449]. CXCR1 and CXCR2 RNA transcripts were detected in PC3 cells using RT-
PCR [450], [451]. We confirmed these findings via immunofluorescence and 
demonstrated that both CXCR1 and CXCR2 were expressed on PC3 cells (Figure 39). 
 
Figure 39. PC3 cells express CXCR1 and CXCR2. Immunofluorescence staining of 
PC3 cells using anti-CXCR1, anti-CXCR2 and their corresponding secondary Alexa-488 
conjugated antibodies (green). Control was anti-mouse Alexa-488 alone. The nucleus 
was stained with DAPI (blue). Cells were fixed, and images are representative of the cell 
populations from one independent experiment out of a triplicate, acquired at 63x 
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3.2.1.5.2 CXCL8 induced the migration of PC3 cells in an Oris migration 
assay 
To study the potential of PC3 cells to migrate towards CXCL8, an Oris migration assay 
was conducted. This assay is regarded to provide a more reproducible, accurate and 
precise results [412]. Cells were seeded in a well with a polymeric insert in the middle of 
the well to prevent cells penetrating the inner detection zone. Once cells attached and 
formed a monolayer, the chemokine was added overnight. A mask was also inserted into 
the bottom of the well to detect only the hole created by the gel insert. Following this, 
calcein (4 µM) was added to stain the cells and only cells that penetrated the middle 
detection zone were quantified. Significant numbers of cells migrated towards the 
analytical zone when stimulated with CXCL8, as detected via fluorescent endpoints on 
a microplate reader (Figure 40). 
 
Figure 40. PC3 cells migrate more in the presence of CXCL8 in an Oris migration 
assay. a) Analysis of untreated (basal) and CXCL8 (10 nM) treated cells overnight. b) 
The detection area generated in the middle of the Oris well shows increased migration 
of cells in the CXCL8-treated sample relative to the basal. Data represent mean ± SEM 
from six independent experiments, (Unpaired t-test, ** = p ≤ 0.01). Images are 
representative of the cell populations, acquired at 10x objective using a Leica DMII 
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3.2.1.5.3 The migration speed of PC3 cells increases when activated with 
CXCL8  
To determine the speed that PC3 cells migrated in the presence of CXCL8, a time-lapse 
migration assay was performed. It was previously reported that the presence of CXCR2 
on PC3 cells mediates cellular adhesion, migration on laminin, and direct invasion 
through a reconstructed basement membrane [450]. Upon treating the cells with CXCL8 
(10 nM), a significant increase in the speed of cell migration was detected, with an 
average speed of 31.6 ± 3.5 μm/hr for the basal and 55.1 ± 4.4 μm/hr for CXCL8-treated 
cells (Figure 41).  
 
 
Figure 41. PC3 cells migrate faster in the presence of CXCL8. a) PC3 cells 
stimulated with CXCL8 (10 nM) displayed increased migratory speed upon analysing 
10 cells per experiment. Data representative of the mean ± SEM of eight independent 
experiments (unpaired t-test, *** = p ≤ 0.001). b) Endpoint images from individual cell 
tracking using Fiji/ImageJ after 10 hrs, i) Basal, ii) CXCL8. Images are a representation 
of the cell population and were taken at 10x objective with a Zeiss Axiovert 200M 
microscope and processed using AxioVision Rel 4.8 software. 
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CXCR1 and CXCR2 antagonists, Reparixin (10 μM), SCH527123 (10 μM) and 
SB225002 (1 μM) were administered to block ligand-receptor binding. There was a 
significant difference between the untreated basal cell and CXCL8-activated cells (p ≤ 
0.01). The three compounds could significantly reduce the migration speed of PC3 cells 
in the presence of CXCL8. Average speeds of 30.1 ± 1.5 μm/hr, 22.1 ± 12.8 μm/hr, and 
16.9 ± 4.1 μm/hr were reported following treatment with Reparixin, SCH527123, or 
SB225002, respectively (Figure 42). 
 
  
Figure 42. The migration speed of PC3 cells is reduced in the presence of CXCR1 
and CXCR2 antagonists. Reparixin (10 μM), SCH527123 (10 μM), and SB225002 (1 
μM) reduce the migration speed of PC3 cells activated with CXCL8 (10 nM). 1% DMSO 
was added to the basal cells as a vehicle control. Data are representative of three 
independent experiments (One-way ANOVA with a Dunnett’s multiple comparisons test 
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3.2.1.5.4 CXCL8 does increase the proliferation of PC3 cells, although not 
significantly 
Seaton et al. [452] showed that the proliferation of PC3 cells rate were abrogated when 
CXCL8 expression was blocked. We utilised the same approach to measure proliferation 
as above (section 3.2.1.3.5). We observed that there was no significant increase in the 
number of PC3 cells, however the standard error was high (p = 0.064), showing more 

























Figure 43. An increase in the proliferation rate of PC3 cells was observed in the 
presence of CXCL8. a) Almost double the number of cells were counted following 
CXCL8 (10 nM) stimulation. b) Images from 0 hr and 24 hrs-timepoints obtained from 
the time-lapse migration assay with the red crosses indicating the number of cells in 
each frame analysed using Fiji/ImageJ. Data are representative from three 
independent experiments (Unpaired t-test, n.s.= no significance p>0.05). Images are 
a representation of the cell population and were taken at 10x objective with a Zeiss 
Axiovert 200M microscope and processed using AxioVision Rel 4.8 software. 
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3.2.1.5.5 Toxicity of CXCR1 and CXCR2 antagonists towards PC3 cells  
An MTS assay was performed to test the viability of PC3 cells towards the CXCR1 and 
CXCR2 antagonists. The concentrations chosen for the study were based on the IC50 of 
the compounds along with the concentrations used in published studies. Here, we 
observed that Reparixin, SCH527123, and SB225002 at 10 μM and 20 μM showed no 
toxicity (Figure 44).  
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Figure 44. Toxicity of CXCR1 and CXCR2 antagonists towards PC3 cells. Toxicity 
of PC3 cells following incubation with a) Reparixin, b) SCH527123, and c) SB225002 for 
24 hrs and treated with MTS reagent for 2 hrs. Data are representative of the mean ± 
SEM of three independent experiments (One-way ANOVA with a Dunnett’s multiple 
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 Characterising the response of cancer cell to CXCL10 
 
3.2.2.1 The response of THP-1 cells to CXCL10 
3.2.2.1.1 Expression of CXCR3 receptors on THP-1 cells  
Several studies showed that CXCL10 is a chemoattractant for circulating monocytes, 
leading to the accumulation of macrophages in the tissues [453], [454]. CXCL10 must 
bind to its receptor CXCR3 to elicit biological responses. Therefore, we first investigated 
the expression of CXCR3 on THP-1 cells via immunofluorescence. Indeed, cells stained 




Figure 45. THP-1 cells express CXCR3. Immunofluorescence staining of the THP-1 
cell line using anti-CXCR3, and its corresponding secondary Alexa-488 conjugated 
antibodies (green). Control was anti-mouse Alexa-488 alone. The nucleus was stained 
with DAPI (blue). Cells were fixed, and images are representative of the cell population 
of one experiment out of three independent repeats, acquired at 63x objective using a 
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3.2.2.1.2 THP-1 cells migrate towards CXCL10 using a chemotaxis assay 
Following the results showing that CXCR3 is expressed by THP-1 monocytic cells, the 
response of cells to CXCL10 (1 nM) was measured using a chemotaxis assay (Figure 
46). Petrovic-Djerovic and colleagues [455] already confirmed that recombinant human 
CXCL10 could stimulate chemotaxis in THP-1 cells. Our results supported their 
observations and CXCL10 could significantly enhance chemotaxis of THP-1 cells.   
 
 
Figure 46. CXCL10 increases the migration of THP-1 cells in a chemotaxis assay. 
Cells were incubated with or without CXCL10 (1 nM) for 5 hrs. Data shown are the mean 
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3.2.2.1.3 CXCL10 stimulates intracellular calcium response in THP-1 cells  
To investigate receptor activation upon application of CXCL10, calcium flux assays were 
performed. CXCL10 was shown to induce intracellular calcium release in a 
concentration-dependent manner (Figure 47). 
 
 
Figure 47. Intracellular calcium response of THP-1 cells following treatment with 
varying concentrations of CXCL10. Data is expressed as changes in fluorescence 
ratio (340 nm/380 nm) upon incubation with 4 µM Fura-2 for 30 min. The basal 
fluorescence, prior to the addition of CXCL10, is subtracted from peak fluorescence 
following injection of CXCL10. Data represent mean ± SEM from five independent 
experiments. (Non-linear regression dose-concentration response curve assuming a Hill 
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3.2.2.2 The response of MDA-MB231 cells to CXCL10 
3.2.2.2.1 Expression of the CXCR3 receptor on MDA-MB231 cells 
CXCR3 on MDA-MB231 cells was already highlighted to be highly expressed by flow 
cytometer [243]. Again, our immunofluorescence data confirms these previous 
observations (Figure 48). 
 
 
Figure 48. MDA-MB231 cells express CXCR3. Immunofluorescence staining of the 
MDA-MB231 cell line using anti-CXCR3, and its corresponding secondary Alexa-488 
conjugated antibodies (green). Control was anti-mouse Alexa-488 alone. The nucleus 
was stained with DAPI (blue). Cells were fixed and images are representative of the cell 
population of one experiment out of three independent repeats, acquired at 63x objective 
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3.2.2.2.2 MDA-MB231 cells migrate faster with CXCL10 in a time-lapse 
migration assay 
Cell migration is a process required for wound healing, immune system function and 
cancer invasion [456]. It is a complex process that starts with cell polarization and 
extension of protrusions in the direction of migration [25]. Conventional methods like the 
Boyden chamber are often used to study chemotaxis in vitro. However, this method takes 
into account the endpoint of an assay and does not allow individual cell monitoring in 
real time. Although we have already shown that MDA-MB231 cells migrate towards 
CXCL8 (10 nM) with Boyden chamber assay, this method was not reproducible with 
other treatments. Therefore, random migration by applying a stimulus (chemokinesis) to 
the wells of adhered cells was conducted and the speed of migrating cells was analysed. 
The migration speed of MDA-MB231 cells significantly increased upon the application of 
CXCL10 (18.9 ± 6.3 μm/hr and 31.2 ± 5.2 μm/hr for the basal and CXCL10-stimulated 



















Figure 49. MDA-MB231 cells migrate faster in the presence of CXCL10. a) MDA-
MB231 cells stimulated with CXCL10 (10 nM) show a significant increase in the speed 
of cell migration (average speed of 10 cells in each experiment). b) endpoint images 
from individual cell tracking using Fiji/ImageJ after 10 hrs, i) Basal, ii) CXCL10 (10 nM). 
Data shows representative cell tracks from individual cell tracks from three independent 
experiments (Unpaired t-test, ** = p ≤ 0.01). Images are representative of the cell 
population and were taken at 10x objective with a Zeiss Axiovert 200M microscope and 
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3.2.2.2.3 The Oris migration assay is not reproducible with MDA-MB231 
cells 
The Oris migration assay could be considered as a robust alternative method to the 
wound healing assay. It allows the formation of an accurate cell free area for the free 
migration of cells without the presence of dead cells following the formation of a wound. 
Upon testing the wound healing assay with MDA-MB231 cells, no migration towards 
closing the wound was observed and results were too inconsistent to make conclusions. 
MDA-MB231 cells in the Oris migration assay showed similar patterns of cell migration. 
Cells seemed to be migrating to the edges, rather than moving towards the centre of the 
Oris detection area. Therefore, when staining the migrating cells, many of them migrated 
to the sides of the wells, and not towards the detection area as shown from the images 
taken with light and fluorescence microscopy (Figure 50). Subsequently, it was decided 
that this assay was not adequate for measuring MDA-MB231 cell migration. 
 
 
Figure 50. Oris migration assay is not a suitable system to study MDA-MB231 cell 
migration. MDA-MB231 cells appear to migrate to the edges rather than to the middle 
of the detection area. This made Oris migration assay an un-suitable system for 
quantifying migration. a) Shows a bright-field image of the well after stimulation with 
CXCL10 (10 nM) over 24 hrs; arrows indicate where the cells are residing away from the 
centre of the detection area demonstrated by the dash line. b) Calcein-stained image of 
the same location captured with fluorescence microscopy. Images were taken at 10x 







124 | P a g e  
 
3.2.2.3 The response of PC3 cells to CXCL10 
3.2.2.3.1 Expression of the CXCR3 receptor on PC3 cells  
CXCR3 binding ligands has been acknowledged to block the migration of adherent cells 
such as fibroblasts and endothelial cells, despite being chemotactic for leukocytes [205], 
[457], [458]. CXCR3 mRNA was already reported by Wu et al., [226] to be expressed in 
PC3 cells. Here, immunofluorescence staining confirmed that CXCR3 was expressed on 
PC3 cells (Figure 51). 
 
 
Figure 51. PC3 cells express CXCR3. Immunofluorescence staining of the PC3 cell 
line using anti-CXCR3, and its corresponding secondary Alexa-488 conjugated 
antibodies (green). Control was anti-mouse Alexa-488 alone. The nucleus was stained 
with DAPI (blue). Cells were fixed, and images are representative of the cell population 
from one experiment out of three independent repeats, acquired at 63x objective using 
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3.2.2.3.2 PC3 cells migrate faster with CXCL10 in a time-lapse migration 
assay 
Cells were incubated with CXCL10 (10 nM) and a time-lapse migration assay was 
performed to assess the effect of this chemokine on the speed of migration. The speed 
of untreated cells was 18.9 ± 2.7 μm/hr which increased to 50.4 ± 8.7 μm/hr following the 




Figure 52. PC3 cells migrate faster in the presence of CXCL10. a) PC3 cells 
stimulated with CXCL10 (10 nM) displayed a significant increase in the speed of 
migration (average speed of 10 cells in each experiment). b) Endpoint images from 
individual cell tracking using Fiji/ImageJ after 10 hrs, i) Basal, ii) CXCL10 (10 nM). 
Data shows representative cell tracks from individual cell tracks from three 
independent experiments (Unpaired t-test, **** = p ≤ 0.0001). Images are 
representative of the cell population and were taken at 10x objective with a Zeiss 
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 Discussion 
Chemokines and chemokine receptors are acknowledged to provide navigational cues 
for leukocytes or cancer cells, induce migration and metastasis, promote entry into the 
circulation, and enhance invasion into specific tissues [78]. Various cancer cell types 
have been found to have elevated expression of both chemokines and their receptors, 
resulting in dysregulated chemokine signalling [78]. CXCL8 was first characterized as a 
leukocyte chemoattractant, however, further studies have shown its pleiotropic role in 
tumour progression. For example, CXCL8 has a demonstrable role in recruiting 
neutrophils to the tumour microenvironment, inducing angiogenesis, regulating the 
progression and aggressiveness of cancer cells, and protecting the cancer stem cell 
population from cancer therapy [459]. Aberrant expression of CXCL8 and its cognate 
receptors therefore contribute to the invasive phenotype observed in breast, ovarian, 
pancreatic, thyroid and other cancers (as reviewed by [131] and [459]). 
CXCR1 and CXCR2 are GPCRs that share roughly 76% sequence homology 
[460], and are directly involved in the physiological and pathological signalling of CXCL8. 
CXCR1 has high affinity and specificity for CXCL8, and CXCR2 can bind to chemokines 
CXCL1-3 and CXCL5-8, with higher affinity to CXCL8 [461], [462]. The expression of 
CXCR1 and CXCR2 on different cancer cell types and the effect of CXCL8 binding on 
the migration speed and chemotaxis of these cell types was investigated in this chapter. 
The transient intracellular calcium release upon chemokine binding was also 
investigated to assess receptor activation on these cells. When GPCRs are activated, 
the intracellular calcium in chemokine-stimulated cells can rise rapidly. The low basal 
intracellular calcium levels and the rapid rise of the cytosolic calcium allows the use of 
the fluorescent dye Fura-2 to measure transient changes in cytosolic calcium 
concentrations [463]. Receptor activation promotes PLC which cleaves PIP2 to IP3 and 
DAG. DAG is membrane bound, while IP3 is released into the cytosol where it opens IP3 
channels present on intracellular calcium stores [464].  
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Several cancer cell types were used to screen the effects of CXCL8, including 
the human monocytic leukaemia THP-1, acute T-cell leukaemia Jurkat, breast MDA-
MB231 and MCF-7, and prostate PC3 cancer cell lines (Table 5). Jurkat cells stimulated 
with CXCL8 showed no increases in migration (Figure 23), however, they migrated 
towards CXCL12. This effect of CXCL12 on Jurkat cells was previously confirmed by 
Mills et al. [388]. Intracellular calcium release was used as a tool to inspect CXCR1 and 
CXCR2 activation upon CXCL8 administration. Indeed, Jurkat cells responded poorly 
when stimulated with varying concentrations of CXCL8, with the EC50 being difficult to 
determine. To our knowledge, CXCL8 and its receptor axis had not been investigated 
previously in Jurkat cells. We assumed that Jurkat cells do not express CXCL8 receptors, 
as indicated by the chemotaxis and calcium flux experiments, or that CXCL8 is unable 
to induce chemotactic activity in this cell type. Indeed, GPCRs can mediate many other 
functions such as cell survival or apoptosis, cell proliferation, and gene transcription. 
However, these functions are dependent on the cell type, receptor, and stimulus [465], 
[466]. So, even if there was activation of the receptor in the cells, it is does not necessarily 
mean that induction of intracellular signalling would only lead to chemotaxis.  
 
Table 5. Summary of the response of different cancer cell types to CXCL8 or CXCL10 
along with chemokine receptor expression. N/A: not applicable 
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THP-1 cells on the other hand, showed elevated expression level of CXCR2 
which agrees with a previous study [421]. Since intracellular calcium changes and 
chemotaxis are mediated by CXCL8 receptors, these cellular responses can be utilized 
to assess receptor usage. Migrating cell numbers were significantly increased in the 
presence of exogenous CXCL8. Furthermore, blocking CXCR1 and/or CXCR2 with the 
antagonists SCH527123 or SB225002 reduced the number of migrating cells 
significantly. Reparixin also decreased the number of cells migrating, although not 
significantly, and this could be because it has a lower inhibitory effect towards CXCR2 
than CXCR1 [467]; as THP-1s did not express CXCR1. 
The metastatic potential of breast cancer cell lines is highly correlated with 
ectopic expression of CXCL8. Studies have found that CXCL8 production is elevated in 
metastatic breast cells compared to their less metastatic counterparts [167]. Miller et al. 
[468] found that CXCR1 and CXCR2 were expressed in all breast cancer cells while only 
50% of the benign breast cells expressed either of the receptors. Using RT-PCR, Freund 
et al. [439] reported that CXCR1 expression level was very low. However, several other 
studies have shown the expression of CXCR1 is actually much higher than that first 
reported in MDA-MB231 cells [243], [424], [445]. Another study reported CXCR2 levels 
are low in MCF-7 but high in MDA-MB231 cells [446]. MCF-7 and MDA-MB231 cells 
were tested for receptor expression as well as their migratory behaviour. Although there 
is controversy around the expression of CXCL8 receptors on MCF-7 cells [439], [446], 
[447], our findings showed that both MCF-7 and MDA-MB231 expressed both CXCR1 
and CXCR2  (Figure 25 and Figure 33). This controversy could be due to the oestrogen 
receptor dependency of the cells [469]. The oestrogen receptor is a contributing factor 
to the invasiveness of the breast cancer cell lines, for example, MDA-MB231 cells are 
oestrogen receptor negative and constitutively express elevated levels of CXCL8 which 
is suggested to be associated with its invasive and metastatic features [439], [470]. 
Conversely, MCF-7 cells are oestrogen receptor positive and were reported not to 
express CXCL8 using RT-PCR, ELISA, and Northern blot, thus have a low invasion 
potential profile [470].  
As there is not enough data from the current literature to conclude the effects of 
CXCL8 on the motility of breast cancer cells, we examined the migratory behaviour of 
both MCF-7 and MDA-MB231 cell lines in response to exogenous CXCL8. Using wound 
healing migration assays, MCF-7 cells migrated more in the presence of CXCL8, and 
the CXCR1 and CXCR2 antagonist, SB225002, significantly blocked this migration over 
24 hrs (Figure 35).  CXCL8 also induced calcium flux in MCF-7 cells in a concentration-
dependent manner, giving an EC50 of 364 nM. Moreover, Reparixin and SB225002 
significantly blocked the release of calcium. MDA-MB231 cells reacted similarly to 
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CXCL8, and increased migration was observed in a Boyden chamber migration assay. 
In addition, faster cell migration in response to CXCL8 was observed using a time-lapse 
migration assay. The migration speed was significantly reduced when CXCR1/2 was 
inhibited by SCH527123 or SB225002. Comparing the migratory response of both cell 
types, we found that the migration speed of MCF-7 cells was too low to be analysed via 
a time-lapse migration assay or in a Boyden chamber. In fact, Larco et al. [470] looked 
at the morphological changes of both cell types and reported that MDA-MB231 
(oestrogen-independent) displayed a more mesenchymal cellular shape. Whereas MCF-
7 (oestrogen-dependent), with lower CXCL8 production, exhibited an epithelioid shape, 
forming more cell-to-cell interactions associated with a non-migratory response. 
Therefore, we observed that both MCF-7 and MDA-MB231 cells respond to CXCL8, 
however, the response varied between the cell lines, presumably because of their 
invasiveness which is associated with their oestrogen-receptor dependency.  
CXCL8 was also shown to significantly enhance proliferation of MDA-MB231 
cells. However, the approach we used to analyse the results here was merely based on 
observation. Screenshots of MDA-MB231 cells in the time-lapse migration assay were 
taken before and after the addition of CXCL8. More cells appeared in the picture frame 
in the presence of CXCL8 in the three experiments undertaken. Xu et al. [446] have 
suggested that high expression of CXCR2 in MDA-MB231 cells promoted their 
proliferation and tumorigenesis activity. However, in another study that linked CXCL8 to 
the invasion properties of MDA-MB231 cells, they did not see the proliferation rate being 
affected [439]. Subsequently, our preliminary analysis showed more MDA-MB231 cells 
proliferating in response to CXCL8, nonetheless, the role of this chemokine on mitogenic 
activity appears to be more complex and requires further investigation.  
Increased CXCL8 levels is a contributing factor for poorer overall survival in men 
with metastatic prostate cancer [471]. We observed CXCR1 and CXCR2 expression on 
PC3 cells and found that they express both receptors. This is in agreement with previous 
reports that detected CXCR1 and CXCR2 RNA transcripts in PC3 cells using RT-PCR 
[450] [451]. PC3 cells migrated significantly faster in the presence of CXCL8 in an Oris 
migration assay, and their migration speed was doubled using time-lapse migration 
assay. Reparixin, SCH527123, or SB225002 drastically reduced the speed of cells. To 
further elucidate the mechanism of how CXCL8 stimulates migration, it is worth 
investigating the specific CXCL8 receptor involved in this process. For example, Reiland 
et al. [450] found that CXCL8 mediated its adhesive and migration effects through 
CXCR2. While Murphy et al. [331] attributed the increased mitogenic activity to both 
CXCR1 and CXCR2. Another study by Araki and colleagues [472] reported that CXCL8 
expression was androgen dependent, whereby CXCL8 is highly expressed in androgen-
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independent cells like PC3 and poorly expressed in androgen-responsive cells like 
LNCaP. They also found that CXCL8-transfected LNCaP along with PC3 cells, have 
increased chemotactic motility and invasion rates in the presence of CXCL8. 
Furthermore, CXCL8 could be associated with an enhanced mitogenic activity in several 
cell types [473]. We observed an increased proliferation rate in PC3 cells in the presence 
of CXCL8 relative to the basal sample (Figure 43). In agreement with this observation it 
has been reported that CXCL8 can stimulate PC3 proliferation via ERK-MAPK signalling 
or AKT phosphorylation [474], [331]. Additionally, blocking CXCR2 with SB225002 could 
reduce the number of proliferating cells [331]. Furthermore, silencing CXCL8 signalling 
using CXCL8 siRNA reduced proliferation and inhibited invasiveness [475]. Altogether, 
our data along with others highlight CXCL8 as a crucial chemokine involved in enhancing 
the metastasis and proliferation of prostate cancer PC3 cells. Yet, further investigation 
of the specific CXCL8 receptors involved or the dependency on androgen could give a 
better vision for developing more targeted treatments. 
CXCR1 and CXCR2 are proven targets for small molecular antagonists, and thus 
considered as useful anticancer therapies. Reparixin is a non-competitive allosteric 
inhibitor of CXCR1 and, to a lesser extent, of CXCR2 [162]. It was reported to reduce 
metastasis of breast cancer and cancer stem cells in human and xenografts in mice, 
alone or with chemotherapy [424]. A recent study showed that Reparixin appeared safe, 
and cancer stem cells could be reduced in several patients, implying a role for CXCR1 
[476]. Reparixin functions by locking CXCL8 receptors in an inactive conformation, 
therefore blocking receptor signalling [477]. This antagonist was found to induce its 
inhibitory effects at different concentrations based on the cell type. Experiments were 
initiated with low doses of the antagonist Reparixin calculated on the basis of the IC50. 
Starting with MCF-7 cells, we found a significant decrease in intracellular calcium release 
with 500 nM Reparixin. Bertini et al. [162] found that polymorphonuclear (PMN) cells 
responded to Reparixin with a significant reduction in cell migration and calcium release 
observed with concentrations of 1 nM to 1 µM in the presence of CXCL8 (3, 10 or 30 
nM). They suggested that the IC50 for CXCR1 was 1 nM while CXCR2 had a higher IC50 
of around 100 nM in PMN cells, making Reparixin a more potent antagonist to CXCR1 
than CXCR2. However, our results showed that MDA-MB231 and PC3 cells required 
higher concentrations of the antagonists to generate an inhibitory effect. At a 
concentration of 10 µM, Reparixin reduced the speed of migrating MDA-MB231 cells. In 
a relevant study, Reparixin induced a concentration-dependent inhibitory effect (1 µM - 
1 mM) on cell viability, mammosphere size, focal adhesion kinase, and β-catenin levels 
[445]. Another study used 40 or 60 µM of Reparixin or SCH527123 on MDA-MB231 cells 
and found that there was an inhibitory effect on cell viability and a modest decrease to 
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cell migration or colony formation [443]. Furthermore, THP-1 cells also required slightly 
higher concentrations of the receptor’s antagonists, suggesting that the cellular context 
may influence the susceptibility to Reparixin. The variability in the inhibitory 
concentrations required to cause an effect is possibly due to the heterogeneity of cancer 
cell types and cell batches used in different laboratories. 
SCH527123 is an allosteric antagonist that binds to CXCR1 and CXCR2; while it 
has moderate affinity for CXCR1, it is CXCR2-selective [163]. SCH527123 has shown 
potential therapeutic value in inflammatory diseases, as well as inhibited recombinant 
cells (CXCR1 and CXCR2) and neutrophil chemotaxis [163]. Another study found that 
SCH527123 blocked melanoma cancer proliferation and colorectal cancer liver 
metastasis by reducing the growth and angiogenesis, and promoting apoptosis of 
malignant cells [424], [478]. We found that THP-1 chemotaxis and calcium flux were 
significantly inhibited by SCH527123. Additionally, MCF-7 cells intracellular calcium 
release was drastically reduced. Moreover, MDA-MB231 and PC3 cell motility was 
slowed down in SCH527123-treated cells in the presence of CXCL8.  
SB225002 is another potent, specific CXCR2 receptor antagonist. In vivo studies 
of the antagonist showed that it could inhibit proliferation of prostate cancer cells [429]. 
This is in agreement with the reduced migration speed of PC3 and MDA-MB231 cells we 
observed whilst using SB225002. Moreover, intracellular calcium flux and migration were 
also significantly reduced in THP-1 and MCF-7 cells following inhibition. Different articles 
reported that SB225002 induces cell death in ovarian cancer cells, as well as cell arrest 
in acute lymphoblastic leukemic cells [479], [480]. Our data showed no cytotoxicity with 
any of the antagonist concentrations used, therefore, the inhibitory response they 
induced on the cells was due to the interference with the ligand-receptor interaction and 
not cytotoxicity.  
It is worth noting that the previous migration assays reported were applied to all 
cell lines, however, not all the cell lines reacted in the same way due to differences in 
the migration patterns. For example, the wound healing assay is widely used, and a 
cheap method to detect cell migration. Trying this method with MCF-7 cells did not 
produce reliable enough data to confirm the effects of CXCL8 and its receptors 
antagonists. MCF-7 are made of epithelial cell types that form cellular sheets. During 
tumour progression these epithelial cells can take on a mesenchymal morphology by 
displaying enhanced migratory capacity and less adhesion [481]. The wound healing 
assays were applicable for this cell type due to the cells being grown in sheets. However, 
this method was time consuming and gave varying results with different cell batches. 
This assay proved not to be reproducible with more invasive cell lines like PC3 and MDA-
MB231 cells. Moreover, we were intrigued to try the agarose spot migration assay which 
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was already reported [442] as a method that forms a chemokine concentration gradient 
and therefore a potential determinant of the directionality of cell migration. Yet, this 
method was unreproducible, primarily due to the agarose spots sliding in the wells, even 
with changing the well types from plastic to glass (Figure 27). Time-lapse migration 
assays were an ideal technique for quantifying the migration speed of cells in real-time; 
sparse seeding of MDA-MB231 and PC3 cells allowed them to migrate freely, but MCF-
7 moved too slow to analyse, even in the presence of a stimulus. Furthermore, Boyden 
transwell chambers are widely used [482] to measure the chemotactic behaviour to a 
specific stimulus. However, although some data was generated with MDA-MB231 cells 
responding to CXCL8, the reproducibility of this method declined giving variable and 
inconsistent results when attempted with different compounds. No data was generated 
with PC3 and MCF-7 cells using this method.  
The results obtained with CXCL8 prompted us to investigate and compare the 
effects of CXCL10 in the previously used cell lines. CXCR3 can bind to CXCL9, CXCL10, 
and CXCL11 and has received much attention due to its role in regulating immune cell 
migration, differentiation, and activation. Many cells like natural killer and natural killer T 
cells, dendritic cells, CD4+, CD8+ T cells, and regulatory T cells express CXCR3 [483], 
[484]. It was reported that tumour cells can hijack the CXCR3/ligand signalling axis to 
migrate from the primary tumour and to metastasize to niches with elevated levels of 
CXCR3 ligands, such as the lymph node or lungs [240], [249], [250], [253]. Moreover, 
overexpression of CXCL9 and CXCL10 was found to induce higher numbers of tumour-
infiltrating lymphocytes and enhanced survival rates in multiple cancer types like in 
breast, ovarian, colon, lung and other cancers (as reviewed by [485]). Other studies have 
reported that CXCR3 expression by cancer cells is correlated with poorer prognosis in 
these cancers by recruiting tumour-promoting regulatory T cells [486], therefore the 
overall effect of CXCR3 overexpression by tumour cells should be further investigated.  
CXCR3 is a GPCR that is identified to have three different isoforms. CXCR3-A 
and CXCR3-B bind to CXCL9, CXCL10, CXCL11, CXCL4 and CXCL4L1, with varying 
affinity. CXCR3-A activates several signals involved in functions such as chemotaxis, 
invasion, proliferation, and cell survival [487]. Whereas, CXCR3-B does not induce 
chemotaxis, instead it is responsible for anti-angiogenic and anti-proliferative responses 
[205]. The third isoform is CXCR3-Alt, which was found to have affinity to CXCL11 but 
not CXCR9 or CXCL10, initiates moderate chemotaxis and calcium flux responses [227], 
[487].  
The expression of CXCR3 in different cancer cell types along with the migratory 
behaviour in the presence of CXCL10 is discussed here. Immunofluorescence assays 
demonstrated the expression of CXCR3 by THP-1 cells. Chemotaxis assays showed 
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enhanced migration of THP-1 cells towards CXCL10. This agrees with a study reporting 
THP-1 chemotaxis was increased by CXCL10 but not CXCL11 [455]. CXCR3 activation 
in THP-1 cells was identified by calcium flux. Indeed, CXCL10 induced calcium release 
in a concentration-dependent manner giving an estimate EC50 of 416 nM. CXCL10 was 
already reported to induce calcium flux and chemotaxis [217]. Furthermore, 
immunofluorescence analysis also revealed CXCR3 receptor expression on breast 
MDA-MB231 cells. The high expression of CXCR3 by these cells was already reported 
by flow cytometer measurements [243]. Time-lapse migration assays demonstrated an 
increase of the speed of cell migration in the presence of CXCL10. This corresponds to 
a study showing an increased motility rate associated with CXCR3 [244]. Moreover, 
prostate cancer PC3 cells also showed expression of CXCR3. However, the robustness 
of the CXCL10/CXCR3 axis is challenged by the variant isoforms of CXCR3. As 
mentioned before, CXCR3-A and CXCR3-B appear to have contradictive downstream 
signalling effects. We could hypothesise that the previous cell lines have potentiated their 
migratory effect through CXCR3-A, which was already reported to have induced cell 
migration; and possess lower levels of CXCR3-B, having a lower inhibition effect on 
migration. Nonetheless, further experiments looking into the dominant expression levels 
of both receptors as well as ruling out the main receptor involved in the migration process 
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 Conclusion 
This chapter explored the expression of CXCL8 and CXCL10-receptors on different 
cancer cell lines along with their roles in controlling migratory behaviour. This resulted in 
several conclusions: 
1. MCF-7, MDA-MB231, and PC3 cells express CXCR1 and CXCR2. THP-1 cells 
do not express CXCR1 but express CXCR2. 
2. CXCL8 induces intracellular calcium signalling in a concentration-dependent 
manner in THP-1 and MCF-7 cells.  
3. THP-1, MCF-7, MDA-MB231, and PC3 cells migrate more in the presence of 
CXCL8 either directly or randomly based on the migration assay used. 
4. MDA-MB231 cells have higher proliferation rate in the presence of CXCL8. PC3 
cells too showed a similar trend but it was not significant.  
5. Small molecular antagonists for CXCR1 and CXCR2 - Reparixin, SCH527123, 
and SB225002 reduce CXCL8 signalling by reducing calcium release, wound 
healing, and/or migration speed. 
6. THP-1, MDA-MB231, and PC3 cells express CXCR3. 
7. Significant number of THP-1 cells migrate towards CXCL10, as well as increasing 
intracellular calcium in a concentration-dependent manner was reported in the 
presence of CXCL10. 
8. MDA-MB231 cells migrate faster in the presence of CXCL10 and PC3 cells with 
CXCL10 and CXCL11.  
9. We tested several migration assays such as agarose spot assay, Oris migration 
assay, wound healing assay, Boyden chamber, time-lapse migration assay, and 
highlighted the most reproducible system for each cell line.
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4 Chapter 4: Intracellular signalling 
pathways involved in the migration of 
CXCL8-activated cancer cells  
 Introduction 
Protein phosphorylation regulates several aspects of cellular functions, including cell 
migration and actin reorganisation [262]. This process involves transferring 
phosphoryl groups onto target proteins to alter their activity. The reverse of this action 
is carried out by phosphatases, which remove phosphoryl groups from target proteins 
[323]. Once the target protein is phosphorylated, a series of signalling-transduction 
pathways are induced, allowing intracellular and extracellular signals to be 
transduced through the cell to the nucleus. The abnormal behaviour of kinases due 
to the loss of inhibitory regulators or mutations could lead to diseases that are 
associated with uncontrolled survival and/or proliferation of cells, such as in cancer  
[488], [489]. Several strategies have been established that are aimed at targeting 
protein kinases, such as the development of small molecule inhibitors and antibodies. 
These approaches work by a) targeting the ATP-binding site of the catalytic site of 
the kinase, b) recognising the inactive conformation of the kinase c) binding outside 
the ATP-binding site to an allosteric site, or d) irreversibly forming covalent bonds to 
the kinase active site [490].  
Targeting signalling molecules involved in chemokines-driven cancer cell 
migration could lead to more precise cancer therapeutic advancements. Chemokines 
are involved in cell migration by activating intracellular signalling cascades that lead 
to cytoskeletal rearrangement and cell polarization [77]. The process of cell migration 
begins with cell polarization, characterised by the formation of lamellipodia, filipodia, 
and stress fibres. These three structures are vital to drive the several stages of actin-
based endothelial cell motility [491]. Several signal transduction molecules are 
involved in the regulation of migration. The Rho GTP-binding family, Rho, Rac, and 
Cdc42 control the formation of focal adhesion, lamellipodia, and filipodia, respectively 
[25]. In addition, Ras, MAPK, FAK, Pi3K, and PLC and their effects on intracellular 
calcium have been implicated in the activation of cell migration [282]. Collectively, 
further investigation should be carried out to clarify how these signalling molecules 
convert the recognition of chemokines via their receptors into physical action.  
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Chapter aim: 
Investigate the main signalling pathways involved in CXCL8-induced cell migration 
and cell morphology changes in MDA-MB231 and PC3 cells.  
 It is worth noting that the time-lapse migration assay conducted throughout 
this chapter involved all the set of inhibitors run together for each cell line at the same 
time. However, data was presented separately by categorizing inhibitors according to 
























 Pi3K and AKT signalling pathway  
4.2.1.1 Pi3K/AKT signalling is important for cells migration 
In the previous chapter, we investigated the migratory behaviour of MDA-MB231 cells 
after being stimulated with 10 nM CXCL8. The migration speed of the cells almost 
doubled within the 10 hrs time-lapse imaging assay performed, relative to the basal 
untreated cells. Growing evidence has highlighted that Pi3K acts as the major 
downstream intracellular signalling molecule of CXCL8. Here, it is implicated in the 
regulation of a diverse array of cellular functions such as cell survival, actin 
reorganisation, and chemotaxis [336], [492]. LY294002, is a well-established potent 
pharmacological inhibitor of Pi3K and its use has advanced our knowledge on the 
importance of this signalling pathway [290]–[292]. A time-lapse migration experiment 
was conducted to compare the speed of cells treated with CXCL8 in the presence or 
absence of LY294002 (10 µM). We observed a significant decrease in the speed of 
cells with the inhibitor. Untreated basal cells had a speed of 21.07 ± 7.5 µm/hr and 
addition of 10 nM CXCL8 increased this speed to 48.3 ± 4.4 µm/hr (p ≤ 0.0001). 
Furthermore, cells incubated with 10 µM LY294002 and activated with CXCL8 
displayed a speed comparable to untreated cells of 26.1 ± 3.3 µm/hr (Figure 53).  
AKT (or PKB) is a serine/threonine kinase and a critical downstream 
component of the receptor tyrosine kinase-Pi3K complex [493]. Interest in AKT has 
emerged because of its role in regulating cell survival, growth, angiogenesis, and 
migration [282], [283]. Migration of MDA-MB231 cells has been demonstrated to be 
dependent on AKT proteins [494]. Indeed, MDA-MB231 cells incubated with the AKT 
inhibitor (AKTi) at a concentration of 20 µM drastically slowed the motility of CXCL8-
treated cells down to a speed of 18.9 ± 3.3 µm/hr (Figure 53). This data agrees with 
a study showing that both LY294002 and AKTi  can slow the motility of EGF-treated 
MDA-MB231 cells [495]. This same study found no effect of Pi3K and AKT inhibitors 
on the migration of MDA-MB231 without stimulation. 
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Figure 53. CXCL8-activated MDA-MB231 cells migrate slower in the presence 
of Pi3K or AKT inhibitors. Cells were incubated with the Pi3K inhibitor: LY294002 
(10 µM) or AKT inhibitor: AKTi (20 µM) and activated with CXCL8 (10 nM). 
Significant reduction in the speed of migrating cells with both inhibitors was 
observed when compared to CXCL8. 1% DMSO was added to the basal cells as a 
vehicle control. Data are representative of the mean ± SEM of four independent 
experiments (One-way ANOVA with a Dunnett’s multiple comparisons test as post-
test, **** = p ≤ 0.0001). 
 
Prostate PC3 cells seem to be affected by Pi3K/AKT inhibition in a similar 
fashion to MDA-MB231 cells. Indeed, the basal speed of cells after 10 hrs was 25.7 
± 7.9 µm/hr, and the addition of CXCL8 (10 nM) increased this speed to 59.0 ± 21.4 
µm/hr (p ≤ 0.0001). LY294002 treatment could reduce this speed to 22.1 ± 11.1 µm/hr. 
While treatment with AKTi almost completely inhibited the migration of cells (speed 
of 3.4 ± 1.1 µm/hr; Figure 54). Notably, although cells treated with LY294002 alone 
without chemokine stimulation is not presented in this study, another group have 
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Figure 54. CXCL8-activated PC3 cells migrate slower in the presence of Pi3K or 
AKT inhibitors. Cells were incubated with the Pi3K inhibitor LY294002 (10 µM) or 
AKT inhibitor AKTi (20 µM) and activated with CXCL8 (10 nM). Both inhibitors 
reduced the speed of migrating cells when compared to CXCL8. Ten cells were 
analysed from each experiment using Fiji/ImageJ after 10 hrs. 1% DMSO was added 
to the basal cells as a vehicle control. Data are representative of the mean ± SEM of 
four independent experiments (One-way ANOVA with a Dunnett’s multiple 
comparisons test as post-test, * = p ≤ 0.05, ** = p ≤ 0.01). 
 
Furthermore, chemotaxis assays were performed on THP-1 cells to assess 
the importance of Pi3K on their migration. We found that LY294002 (10 µM) 
significantly decreased the number of migrating cells towards CXCL8 (Figure 55). A 
similar effect has been demonstrated by another group, showing that the migration of 
neutrophils stimulated with CXCL8 was abrogated with LY294002 [497]. Notably, our 
group have already confirmed that LY294002-treated THP-1 cells without chemokine 
activation show no migration, as well as no adverse effects towards actin filament 
structures as observed using an Alexa488-phalloidin actin stain [498]. 
However, injecting CXCL8 (200 nM) on to LY294002 pre-treated cells, did not 
inhibit the release of intracellular calcium (Figure 56).  
Taken together, the data suggests that the Pi3K/AKT pathway is essential for 
the CXCL8-stimulated migration of MDA-MB231, THP-1, and PC3 cells, but not for 
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Figure 55. Pi3K inhibitor LY294002 decreases the migration of CXCL8-
stimulated THP-1 cells in a chemotaxis assay. Significant reduction in the 
number of LY294002 (10 µM) treated cells towards CXCL8 (5 nM) compared to the 
migration of untreated cells after 5 hrs of incubation. 1% DMSO was added to the 
basal cells as a vehicle control. Data shown are the mean ± SEM of five 
independent experiments. (One-way ANOVA with a Dunnett’s multiple 
comparisons test as post-test, *= p≤ 0.05). 
 
Figure 56. Pi3K inhibitor LY294002 does not inhibit intracellular calcium 
release in CXCL8-stimulated THP-1 cells. Basal, or LY294002 (10 μM) pre-
treated cells shows no significant difference after stimulation with 200 nM CXCL8. 
1% DMSO was added to the basal cells as a vehicle control. Data represents the 
mean ± SEM of five independent experiments. (Unpaired t-test, n.s. = no 
significance p > 0.05). Data are expressed as the relative ratio of fluorescence 
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4.2.1.2 Pi3K/AKT inhibitors induce changes to the cellular 
morphology 
Pi3K has been identified as crucial for cell motility and establishment of cell polarity 
[499]. Clinical studies have demonstrated that cancer patients reporting elevated 
levels of AKT expression have more invasive and metastatic phenotypes which are 
correlated with poor prognosis [500]. These findings, along with our data, emphasize 
the role of AKT in cell migration in different tumour cells. In eukaryotic cells, the 
integrity and dynamic reorganisation of the cells actin cytoskeleton are vital for 
maintaining the cell morphology and generation of the forces required for migration 
[501]. LY294002, works like many other protein kinase inhibitors, by competing with 
ATP for binding to the Pi3K active site [290], [502]. Nonetheless, the molecular 
mechanisms associated with cell migration that are modulated by Pi3K/AKT are not 
fully known. We present here two sets of data: endpoint images of the time-lapse 
migration assay- the cells in these images were outlined to analyse the morphology. 
To do so, we looked at the aspect ratio; which is defined as the ratio of long axis 
(width) to short axis (length) [503], the circularity (where 0 denotes full circle and 1 
denotes elongated polygon), and the cell area. We also show images of cells stained 
with Alexa488-phalloidin to observe any cytoskeletal changes after incubation with 
the inhibitors for 10 hrs.  
The morphology of MDA-MB231 cells incubated with LY294002 or AKTi and 
stimulated with CXCL8 (10 nM) for 10 hrs were significantly compromised. Indeed, 
LY294002 (10 µM) treatment induced an elongation of the cells. This was possibly 
due to the inhibition of cytoskeletal fibre formation that is required for the development 
of protrusive endings necessary for cell migration. Also, inhibiting AKT resulted in the 
disruption of the cytoskeleton, noted visually and characterized by cells elongating 
excessively and forming sticky clusters in their bodies (indicated by red arrows in 
Figure 57). Moreover, light microscopy with 10x objective showed that cells adopted 
a distinct shape following treatment with LY294002 or AKTi and activation with 
CXCL8 (Figure 58). Upon identification of the cellular morphology, LY294002-treated 
cells showed a significant distribution in the aspect ratio. On the other hand, AKTi 
treatment caused a more disruptive phenotype with substantial changes to the aspect 
ratio, circularity, and area of the cells (Figure 59). Former studies have argued that 
AKT stimulation at the leading edge contributes to cell polarity, cytoskeletal 
reorganisation, and cellular body contraction, resulting in the cell moving in a certain 
direction [281]. Thus, we see a direct correlation between the hindered migration of 
cells and deformation of the cytoskeleton in MDA-MB231 cells. 
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Figure 57. Phalloidin actin staining of CXCL8-stimulated MDA-MB231 cells in 
the presence of Pi3K or AKT inhibitors. Actin cytoskeleton changes in cells pre-
treated with LY294002 (10 µM), or AKTi (20 µM) and activated with CXCL8 (10 
nM). 1% DMSO was added to cells as a vehicle control. Few cells elongated in the 
presence of LY294002 as indicated by the red arrows, and elongation with 
aggregations appeared with AKTi-treated cells. Cells were fixed and stained with 
Alexa-488 phalloidin actin green stain. Cell images are representative of three 
independent repeats and were acquired at 63x magnification using a Leica DMII 
inverted microscope and Leica imaging suite. 
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Figure 58. Illustrative images demonstrating morphological changes of MDA-
MB231 cells stimulated with CXCL8 in the presence or absence of Pi3K or 
AKT inhibitor. Cells were activated with CXCL8 (10 nM) alone or activated 
following pre-treatment with LY294002 (10 µM), or AKTi (20 µM). 1% DMSO was 
added to the vehicle control. Cells were outlined using Fiji/ImageJ and 
measurements of 70 cells per image, per experiment were analysed. Experiments 
were repeated at least three times. Images are representative of the cell population 
and were taken at 10x objective with a Zeiss Axiovert 200M microscope and 
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Figure 59. Analysis of the cellular morphology of MDA-MB231 cells stimulated 
with CXCL8 in the presence or absence of Pi3K or AKT inhibitors. Cells were 
incubated with LY294002 (10 µM) or AKTi (20 µM) prior to activation with CXCL8 (10 
nM). Comparisons were made against the CXCL8 control. 1% DMSO was added to 
the basal cells as a vehicle control. Cells were outlined and measurements of a) 
area, b) aspect ratio, and c) circularity were analysed for an average of 70 cells per 
image per experiment. Experiments were repeated three times (One-way ANOVA 
with a Dunnett’s multiple comparisons test as post-test, n.s.= no significance p >0.05, 
* = p ≤ 0.05, **** = p ≤ 0.0001). 
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Furthermore, the morphology of PC3 cells were assessed under the same 
conditions but seemed to react slightly differently to MDA-MB231 cells. Phalloidin 
actin staining of PC3 cells identified small build-ups inside the cells in the presence 
of the AKT inhibitor (Figure 60) upon which the cells seemed lose their motility. Light 
microscopy analysis showed that CXCL8 activation of AKTi-treated cells induced the 
formation of small cluster inside the cells (Figure 61), although there was no 
significant effect on the area, aspect ratio, or circularity (Figure 62). On the other 
hand, CXCL8 activation of LY294002-treated cells appeared smaller with less 
assembly of stress fibres. Therefore, although cells reacted differently to Pi3K/AKT 
inhibitors, there was no doubt that this pathway was essential for maintaining the 
cytoskeleton and inducing cell migration. 
 
Figure 60. Phalloidin actin staining of CXCL8-stimulated PC3 cells in the 
presence or absence of Pi3K or AKT inhibitors. Actin cytoskeleton changes in 
cells pre-treated with LY294002 (10 µM), or AKTi (20 µM) and activated with 
CXCL8 (10 nM). The red arrows indicate the small cluster accumulations inside the 
cells. 1% DMSO was added to cells as the vehicle control. Cells were fixed and 
stained with Alexa-488 phalloidin actin green stain. Cells images are representative 
of the population of one experiment out of three repeats, acquired at 63X 
magnification using a Leica DMII inverted microscope and Leica imaging suite. 
146 | P a g e  
 
 
Figure 61. Illustrative images demonstrating morphological changes of PC3 
cells stimulated with CXCL8 in the presence or absence of Pi3K or AKT 
inhibitor. Cells were activated with CXCL8 (10 nM) alone or following pre-
treatment with LY294002 (10 µM), or AKTi (20 µM). 1% DMSO was added to the 
vehicle control. Cells were outlined using Fiji/ImageJ and measurements of 70 cells 
per image per experiment were analysed. Experiments were repeated at least three 
time. Images are a representation of the cell population and were taken at 10x 
objective with Zeiss Axiovert 200M microscope and processed using AxioVision 
Rel 4.8 software. 
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Figure 62. Analysis of cellular morphology of PC3 cells stimulated with 
CXCL8 in the presence or absence of Pi3K or AKT inhibitors. Cells were 
incubated with LY294002 (10 µM) or AKTi (20 µM) and activated with CXCL8 (10 
nM). Comparisons were made against the CXCL8 control. 1% DMSO was added 
to the basal cells as a vehicle control. Cells were outlined and measurements of a) 
area, b) aspect ratio, and c) circularity were analysed for an average of 70 cells per 
image per experiment. Experiments were repeated three times (One-way ANOVA 
with a Dunnett’s multiple comparisons test as post-test, n.s.= no significance p> 
0.05). 
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4.2.1.3 MTS cytotoxic assay to quantify the cytotoxicity of Pi3K and 
AKT inhibitors 
To identify the viability of MDA-MB231 and PC3 cells following 24 hrs incubation with 
LY294002 (10 µM) and AKTi (20 µM), an MTS assay was conducted. The absorbance 
was measured at 492 nm and cellular cytotoxicity was compared against basal 
cytotoxicity. The concentrations of the inhibitors used did not show any cytotoxicity 
towards MDA-MB231 or PC3 cells (Figure 63). The concentrations we used for the 
inhibitors had been used previously in other studies [294], [496]. 
 
Figure 63. Toxicity of Pi3K and AKT inhibitors towards MDA-MB231 and PC3 
cells. The absorbance following incubation with LY294002 (10 µM) or AKTi (20 µM) 
for 24 hrs, followed by treatment with MTS reagent for 2 hrs in a) MDA-MB231 cells, 
or b) PC3 cells. 1% DMSO was added to the basal cells as a vehicle control. Data 
are representative of the mean ± SEM of three independent experiments (Kruskal-
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 The Ras/Raf/MEK/ERK, p38 MAPK, and β-catenin pathway  
4.2.2.1 Ras/Raf/MEK/ERK, p38 MAPK are important for cells 
migration but not β-catenin 
CXCL8 signalling modulates the activity of MAPK signalling pathways that comprise 
several serine/threonine kinases [143]. The best characterized pathway of these 
kinases is the Raf/Ras/MEK/ERK pathway. Pi3K has been identified as a mediator 
which couples CXCL8 to MAPK signalling in neutrophils [309]. CXCL8 induces rapid 
and transient phosphorylation of ERK1/2 and Pi3K in neutrophils [323]. The role of 
ERK1/2 in the migration of CXCL8-activated neutrophils is poorly understood [282], 
[309], [324]. Moreover, constitutive ERK1/2 stimulation by extracellular signals is 
suggested to have a dual effect on cancer cells; either enhancing or inhibiting cancer 
progression depending on the context and strength of stimulation [304]. Former 
studies suggested that ERK inhibition in lung cancer stimulates glycogen synthase 
kinase 3β, possibly leading to β-catenin degradation, which causes inhibition of 
cancer progression and migration [330]. Furthermore, p38 MAPK is part of the MAPK 
pathway that is identified as a regulator of inflammatory and stress responses [504]. 
Little is known about the role p38 MAPK plays in cell migration in response to CXCL8.  
The involvement of Ras/Raf/MEK/ERK, p38 MAPK or β-catenin activation on 
the migration of MDA-MB231 cells was investigated by analysing the migratory speed 
of cells pre-treated with pathway inhibitors and stimulated with CXCL8. Basal cells 
had a speed of 21.07 ± 7.5 µm/hr, while addition of CXCL8 (10 nM) increased the 
speed to 48.3 ± 4.4 µm/hr over 10 hrs (p ≤ 0.0001). Treating cells with the Raf 
inhibitor, L779450 (100 nM), after the addition of CXCL8 (10 nM) had a slight effect 
on the cells (38.3 ± 4.4 µm/hr). However, using another Raf inhibitor, ZM336372 (1 
µM), the speed of cells significantly decreased to 25.5 ± 11.1 µm/hr. Moreover, MEK 
inhibitors SL327 (1 µM) and PD98059 (25 µM) both decreased the speed of cells to 
32.9 ± 1.7 µm/hr, and 25.1 ± 2.6 µm/hr, respectively. The p38 MAPK inhibitor, 
SB203580 (1 µM), also reduced the speed of cells to 31.2 ± 9.9 µm/hr. Finally, the β-
catenin inhibitor FH535 (1 µM) did not have any major effects on cell motility (40.2 ± 
2.0 µm/hr; Figure 64). 
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Figure 64. The effect of Raf/MEK/ERK, p38 MAPK, or β-catenin inhibition on 
the migration speed of CXCL8-activated MDA-MB231 cells. Cells were pre-
treated with β-catenin inhibitor: FH535 (1 µM); Raf inhibitors: L779450 (100 nM), or 
ZM336372 (1 µM); MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM); or p38 
MAPK inhibitor: SB203580 (1 µM) and activated with CXCL8 (10 nM). Comparisons 
were made against CXCL8. 1% DMSO was added to the basal cells as a vehicle 
control. Data are representative of the mean ± SEM of four independent 
experiments (One-way ANOVA with a Dunnett’s multiple comparisons test as post-
test, n.s. = no significance p>0.05, * = p ≤0.05, ** = p ≤ 0.01, and **** = p ≤ 0.0001). 
 
 PC3 cells were also affected by inhibition of Ras/Raf/MEK/ERK, p38 MAPK, 
and β-catenin signalling. Cells were treated with the compounds then activated with 
CXCL8. The speed of basal cells was 25.7 ± 7.9 µm/hr and addition of CXCL8 (10 
nM) increased the speed to 59.0 ± 21.4 µm/hr (p ≤ 0.0001). Unlike MDA-MB231 cells, 
L779450 (100 nM) significantly decreased the speed of PC3 cells to 37.2 ± 15.9 
µm/hr. In addition, ZM336372 (1 µM), also reduced the speed to 27.2 ± 6.9 µm/hr. 
Likewise, both MEK inhibitors, SL327 (1 µM) and PD98059 (25 µM) attenuated the 
speed of cells significantly to 30.3 ± 2.8 μm/hr and 25.8 ± 5.0 µm/hr, respectively. p38 
MAPK inhibitor SB203580 (1 µM) decreased the speed to 31.3 ± 5.8 µm/hr. Only β-
catenin inhibitor, FH535 (1 µM) did not have a considerable effect on the speed (47.0 
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Figure 65. The effect of Raf/MEK/ERK, p38 MAPK, or β-catenin inhibition on 
the migration speed of CXCL8-activated PC3 cells. Cells were incubated with 
β-catenin inhibitor: FH535 (1 µM); Raf inhibitors: L779450 (100 nM), or ZM336372 
(1 µM); MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM); or p38 MAPK inhibitor: 
SB203580 (1 µM) and activated with CXCL8 (10 nM). Comparisons were made 
against CXCL8. 1% DMSO was added to the basal cells as a vehicle control. Data 
are representative of the mean ± SEM of four independent experiments (One-way 
ANOVA with a Dunnett’s multiple comparisons test as post-test, n.s. = no 
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4.2.2.2 Ras/Raf/MEK/ERK, p38 MAPK, or β-catenin inhibition did not 
induce a substantial morphological change in the cells  
We aimed to observe and analyse the cytoskeletal rearrangements induced following 
Ras/Raf/MEK/ERK, p38 MAPK, and β-catenin inhibition and activation of cells with 
CXCL8, after 10 hrs incubation.  
Visual assessment of phalloidin actin staining of MDA-MB231 cells with the 
different inhibitors: L779450, ZM336372, SL327, PD98059, SB203580, indicated that 
cells had increased in area compared to the controls, whereas FH535-treated cells 
looked slightly smaller (Figure 66). Cells treated with SB203580 seemed to have 
more microspikes formed at their edges. Additionally, few cells appeared elongated 
following ZM336372 treatment. However, when images were taken via light 
microscopy (Figure 67) and cells were outlined for morphology analysis, only 
PD98059-treated cells showed a minor increase to the aspect ratio, but overall no 
other significant differences appeared with any of the compounds used (Figure 68). 
PC3 cells stained with phalloidin actin stain after being incubated with the 
previous set of inhibitors showed no substantial changes to the cellular morphology 
after 10 hrs (Figure 69). Notably, FH535-treated cells appeared slightly smaller 
compared to the control sample, this was similar to the observations noted with MDA-
MB231 cells. Images taken via light microscopy (Figure 70) also did not show any 
crucial changes to the shape of the cells. This was confirmed following image analysis 
(Figure 71). 
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Figure 66. Phalloidin actin staining of CXCL8-stimulated MDA-MB231 cells in the presence or absence of Raf/MEK/ERK, p38 
MAPK, and β-catenin inhibitors. Actin cytoskeleton changes to the cells pre-treated with β-catenin inhibitor: FH535 (1 µM); Raf 
inhibitors: L779450 (100 nM), or ZM336372 (1 µM), MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM), or p38 MAPK inhibitor: 
SB203580 (1 µM) and activated with CXCL8. 1% DMSO was added as a vehicle control. Cells were fixed and stained with Alexa-488 
phalloidin actin green stain. Cells images are representative of the population of cells from one experiment out of three repeats, 
acquired at 63X magnification using a Leica DMII inverted microscope and Leica imaging suite.   
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Figure 67. Illustrative images demonstrating morphological changes of MDA-MB231 cells treated with CXCL8 in the 
presence or absence of Raf/MEK/ERK, p38 MAPK, and β-catenin inhibitors. Cells were treated with the β-catenin inhibitor: 
FH535 (1 µM); Raf inhibitors: L779450 (100 nM), or ZM336372 (1 µM), MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM); or p38 
MAPK inhibitor: SB203580 (1 µM) and activated with CXCL8 (10 nM). 1% DMSO was added as a vehicle control. Cells were drawn 
around using Fiji/ImageJ and measurements of 70 cells per image per experiment were analysed. Experiments were repeated at 
least three times. Images are representative of the cell population and were taken at 10x objective with a Zeiss Axiovert 200M 
microscope and processed using AxioVision Rel 4.8 software. 
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Figure 68. Analysis of the cellular morphology of MDA-MB231 cells following 
treatment with CXCL8 in the presence or absence of Raf/MEK/ERK, p38 
MAPK, or β-catenin inhibitors. Cells were treated with β-catenin inhibitor: FH535 
(1 µM); Raf inhibitors: L779450 (100 nM), or ZM336372 (1 µM), MEK inhibitors: 
SL327 (1 µM), or PD98059 (25 µM), or p38 MAPK inhibitor: SB203580 (1 µM) and 
activated with CXCL8 (10 nM). Comparisons were made against CXCL8. 1% 
DMSO was added to the basal cells as a vehicle control. Cells were outlined and 
measurements of a) area, b) aspect ratio, and c) circularity were analysed for an 
average of 70 cells per image per experiment. Experiments were repeated three 
times (One-way ANOVA with a Dunnett’s multiple comparisons test as post-test, 
n.s.= no significance, p > 0.05). 
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Figure 69. Phalloidin actin staining of CXCL8-stimulated PC3 cells with Raf/MEK/ERK, p38 MAPK, and β-catenin inhibitors. 
Actin cytoskeleton changes in cells pre-treated with β-catenin inhibitor: FH535 (1 µM); or Raf inhibitors: L779450 (100 nM), or 
ZM336372 (1 µM); or MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM); or p38 MAPK inhibitor: SB203580 (1 µM) and activated 
with CXCL8 (10 nM). 1% DMSO was added to the cells as a vehicle control. Cells were fixed and stained with Alexa-488 Phalloidin 
actin green stain. Cells images are representative of the population of one experiment out of three repeats acquired at 63X 
magnification using a Leica DMII inverted microscope and Leica imaging suite.  
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Figure 70. Illustrative images demonstrating morphological changes of PC3 cells treated with CXCL8 in the presence or 
absence of Raf/MEK/ERK, p38 MAPK and β-catenin inhibitors. Cells were treated with β-catenin inhibitor: FH535 (1 µM); Raf 
inhibitors: L779450 (100 nM), or ZM336372 (1 µM), MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM), or p38 MAPK inhibitor: 
SB203580 (1 µM) and activated with CXCL8 (10 nM). 1% DMSO was added as a vehicle control. Cells were outlined using Fiji/ImageJ 
and measurements of 70 cells per image per experiment were analysed. 1% DMSO was added to the basal cells and CXCL8-treated 
cells. Experiments were repeated at least three times. Images are representative of the cell population and were taken at 10x objective 
with a Zeiss Axiovert 200M microscope and processed using AxioVision Rel 4.8 software. 
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Figure 71. Cellular morphology analysis of PC3 cells treated with CXCL8 in the 
presence or absence of Raf/MEK/ERK, p38 MAPK, and β-catenin inhibitors. Cells 
were treated with β-catenin inhibitor: FH535 (1 µM); Raf inhibitors: L779450 (100 nM), 
or ZM336372 (1 µM); MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM); or p38 MAPK 
inhibitor: SB203580 (1 µM) and activated with CXCL8 (10 nM). Comparisons were made 
against CXCL8. 1% DMSO was added to the basal cells as a vehicle control. Cells were 
outlined and measurements of a) area, b) aspect ratio, and c) circularity were analysed 
for an average of 70 cells per image per experiment. Experiments were repeated three 
times (One-way ANOVA with a Dunnett’s multiple comparisons test as post-test, n.s.= 
no significance). 
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4.2.2.3 MTS cytotoxicity assay to quantify the cytotoxicity of 
Raf/MEK/ERK or β-catenin inhibitors 
Treatment of MDA-MB231 and PC3 cells for 24 hrs with Raf inhibitors: L779450 (100 
nM), or ZM336372 (1 µM), MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM), p38 
MAPK inhibitor: SB203580 (1 µM), or β-catenin inhibitor: FH535 (1 µM) showed no 
cytotoxicity (Figure 72). These concentrations were already tested in other studies 
[388], [505]. 
 
Figure 72. Toxicity of Raf/MEK/ERK, p38 MAPK, and β-catenin inhibitors 
towards MDA-MB231 and PC3 cells. The absorbance following incubation with β-
catenin inhibitor: FH535 (1 µM); Raf inhibitors: L779450 (100 nM), or ZM336372 (1 
µM); MEK inhibitors: SL327 (1 µM), or PD98059 (25 µM); or p38 MAPK inhibitor: 
SB203580 (1 µM) for 24 hrs and treatment with MTS reagent for 2 hrs in a) MDA-
MB231 cells, or b) PC3 cells. 1% DMSO was added to the basal cells as a vehicle 
control. Data are representative of the mean ± SEM of three independent experiments 
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 The Rho GTPases and DOCK1/2/5 signalling pathways 
4.2.3.1 Rho GTPases and DOCK1/2/5 are important for cells migration 
Amongst other signalling pathways which have been highlighted as being involved in 
CXCL8-stimulated migration are the Rho GTPases. This superfamily belongs to Ras 
and among its well-characterized molecules are Rho, Rac and Cdc42. Rho GTPases 
regulate cellular processes by working as a switch based on their GDP or GTP-
bounding form. GTP hydrolytic activity is associated with Rho GTPases stimulation 
which is reported to be involved in the cytoskeleton rearrangement, migration, 
proliferation, transformation and differentiation [338]. For example, it was shown that 
the inhibition of RhoA and ROCK (Rho-activated kinase) inhibition block THP-1 cell 
migration towards CCL3 [506]. Here, we look at the correlation between CXCL8 
activation and the migration speed of cells incubated with a range of small molecule 
inhibitors targeting Rho GTPases or DOCK1/2/5. 
Time-lapse migration assay of MDA-MB231 cells showed an important role of 
the Rho GTPases in regulating the migration speed of the cells. The speed of basal 
cells is 21.07 ± 7.5 µm/hr, while addition of CXCL8 (10 nM) activated the cells to 
migrate faster with a speed of 48.3 ± 4.4 µm/hr after 10 hrs. Cells were further treated 
with different inhibitors and activated with CXCL8. Treating cells with the Rac1 
inhibitor, NSC23766 (100 µM), did not affect the migration speed; 42.6 ± 6.1 µm/hr, 
however, the other Rac1 inhibitor used, EHT1864 (100 nM), significantly decreased 
the speed to 32.2 ± 3.6 µm/hr. In addition, inhibition of ROCK by Y27632 (20 µM) 
drastically reduced the speed of migrating cells to 26.9 ± 3.4 µm/hr. This is consistent 
with previous result showing around a 50% decrease in Y27632-treated MDA-MB231 
cell migration [507]. CPYPP, a DOCK 1/2/5 inhibitor, had a similar effect giving a 
speed of 26.3 ± 10.0 µm/hr. CCG 1423 (1 µM) is a small-molecule inhibitor of RhoA, 
this inhibitor did not affect the speed of MDA-MB231 cells giving a speed of 41.4 ± 
9.1 µm/hr. Finally, Cdc42 inhibitor, ZCL278 (20 µM) did not cause a significant 
reduction to the migration of the cells, however, the standard error bar associated 
with this observation was high19.6 ± 12.1 µm/hr (Figure 73), therefore requires 
further investigation. In summary, EHT1864, Y26732 and CPYPP inhibit the migration 
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Figure 73. The effect of Rac/Rho/Cdc42 or DOCK1/2/5 inhibitors to the 
migration speed of CXCL8-activated MDA-MB231 cells. Cells were pre-treated 
with Rac1 inhibitors: NSC23766 (100 µM), or EHT1864 (100 nM), or Rho/ROCK 
inhibitors: CCG 1423 (1 µM), or Y27632 (20 µM), or Cdc42 inhibitor: ZCL278 (20 
µM), or DOCK1/2/5 inhibitor: CPYPP (100 µM) and activated with CXCL8 (10 nM). 
Comparison was made against CXCL8. 1% DMSO was added to the basal cells as 
a vehicle control. Data are representative of the analysis of 10 cells in each 
experiment using Fiji/ImageJ, with the mean ± SEM of four independent 
experiments (One-way ANOVA with a Dunnett’s multiple comparisons test as post-
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The same set of inhibitors and conditions were applied to PC3 cells and this 
cell line showed some similarities to MDA-MB231 cells with some variations. The 
speed of basal cells was 25.7 ± 7.9 µm/hr, activation with CXCL8 (10 nM) increased 
the speed to 59.0 ± 21.4 µm/hr. Cell were then treated with the inhibitors and then 
activated with CXCL8. Treatment with Rac1 inhibitor NSC23766 (100 µM) modestly 
reduced the speed to 40.4 ± 7.4 µm/hr, but not significantly. The other Rac1 inhibitor 
used, EHT1864 (100 nM), substantially reduced the speed to 24.5 ± 13.1 µm/hr. 
Unlike MDA-MB231 cells, the inhibitory effect of ROCK inhibitor, Y27632 (20 µM), on 
the migration speed of PC3 cells was not greatly affected; 39.9 ± 7.1 µm/hr. 
Additionally, CPYPP (100 µM), DOCK1/2/5 inhibitor, affected PC3 cells in a similar 
fashion as MDA-MB231, with the speed drastically decreasing to 21.8 ± 12.5 µm/hr. 
Moreover, the RhoA inhibitor, CCG 1423 (1 µM), did not affect the speed significantly; 
41.9 ± 12.9 µm/hr. Eventually, although Cdc42 inhibitor, ZCL278 (20 µM), did not 
affect the speed of MDA-MB231 considerably, it had a significant inhibitory effect on 
PC3 cells giving a speed of 27.6 ± 13.7 µm/hr (Figure 74). In all, the migration speed 
of PC3 cells was mainly affected by EHT1864, ZCL278, and CPYPP but not with 
NSC23766, CCG 1423, or Y27632. 
Taken together, the small molecule inhibitors of Rho GTPases or DOCK1/2/5 
showed slightly variable effects on the migration speed between the two cell lines, 
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Figure 74. The effect of Rac/Rho/Cdc42 or DOCK1/2/5 inhibitors to the migration 
speed of CXCL8-activated PC3 cells. Cells were pre-treated with Rac1 inhibitors: 
NSC23766 (100 µM), or EHT1864 (100 nM), or Rho/ROCK inhibitors: CCG 1423 (1 
µM), or Y27632 (20 µM), or Cdc42 inhibitor: ZCL278 (20 µM), or DOCK1/2/5 inhibitor: 
CPYPP (100 µM) and activated with CXCL8 (10 nM). Comparison was made against 
CXCL8. 1% DMSO was added to the basal cells as a vehicle control. Data are 
representative of the analysis of 10 cells in each experiment using Fiji/ImageJ, with 
the mean ± SEM of four independent experiments (One-way ANOVA with a Dunnett’s 
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4.2.3.2 ROCK inhibition affects the cellular morphology 
Re-arrangement of the cytoskeleton contribute significantly to cell migration and 
chemotaxis, and Rho GTPases (Rac, Rho and Cdc42) play a vital role in these 
processes [340]. Indeed, actin filament reorganisation is a process that involve actin 
polymerising and depolymerizing factors. Rho modulate stress fibres and focal 
adhesion formation via stimulating downstream signals mDia, ROCKI and ROCKII 
[508]; Rac is involved in the formation of lamellipodia; and Cdc42 is required for the 
cell polarity and filopodia formation, guiding the direction of migration [341]. The 
absence of Rho can cause an inhibition to the cell tail detachment through reduced 
actin-myosin contraction [347]. Activation of chemokine receptors involves actin 
stress fibres and membrane ruffling [509]–[511]. We saw before that some of the 
Rac/Rho/Cdc42 and DOCK1/2/5 signals were important for the migration of cells 
upon stimulation with CXCL8, therefore, we investigated if the inhibitory effect of 
blocking these signals was associated with changes to the cellular morphology. 
 For visual observation, images were obtained with phalloidin actin staining of 
MDA-MB231 cells upon their activation with CXCL8. NSC23766 is a Rac1 inhibitor 
that has been useful to address the role of Rac in cellular responses and to reverse 
tumour cell phenotypes correlated with Rac deregulation [512]. This inhibitor did not 
cause a significant difference to the speed of migration, but with the actin stain, cells 
seemed to have formed small clusters in the form of accumulation of punctate actin 
at their sides (Figure 75). Cells treated with ZCL278 (Cdc42 inhibitor) exhibited 
similar formation of small actin lumps. CCG 1432 (RhoA inhibitor) gave few cells 
some elongated appearance. Additionally, cells treated with Rac1 inhibitor, EHT1864, 
looked more compact with no obvious formation of lamellipodia or filopodia necessary 
for cell migration compared with the control samples. CPYPP (DOCK 1/2/5) showed 
no substantial changes to the cells. Moreover,  Y27632 is an orthosteric ROCK 
inhibitor that compete with ATP binding on the catalytic domain of ROCK, leading to 
interference with actin stress fibre formation [509]. Cells treated with Y27632 
demonstrated a tangled actin meshwork, complete abolishment to the cell junctions, 
and elongation of the leading/tail endings of the cells. These observations along with 
the reduced migration speed agrees with previous studies [507], [513].  
Having taken images of the cells using light microscope at 10x objective, none 
of the Rho GTPases or DOCK1/2/5 inhibitors caused a substantial change to the 
morphology of the cells except for Y27632 (Figure 76). Although CCG 1432 and 
NSC23766 caused some elongation to the cells, analysis of the images did not detect 
these changes in the cell shape (Figure 77).
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Figure 75. Phalloidin actin staining of CXCL8-activated MDA-MB231 cells in the presence or absence of Rac/Rho/Cdc42 
and DOCK1/2/5 inhibitors. Actin cytoskeleton changes to the cells pre-treated with Rac1 inhibitors: NSC23766 (100 µM), EHT1864 
(100 nM), Rho/ROCK inhibitors: CCG 1423 (1 µM), Y27632 (20 µM), or Cdc42 inhibitor: ZCL278 (20 µM), DOCK1/2/5 inhibitor: 
CPYPP (100 µM) and activated with CXCL8 (10 nM). The red arrows point out accumulation of punctate actin or cells elongation. 
1% DMSO was added as a vehicle control. Cells were fixed and stained with Alexa-488 Phalloidin actin green stain. Cells images 
are representative of the population of cells from one experiment out of three repeats, acquired at 63x magnification using a Leica 
DMII inverted microscope and Leica imaging suite. 
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Figure 76. Illustrative images demonstrating morphological changes of MDA-MB231 cells treated with CXCL8 in the 
presence or absence of Rac/Rho/Cdc42 or DOCK1/2/5 inhibitors. Cells were treated with Rac1 inhibitors: NSC23766 (100 µM), 
or EHT1864 (100 nM), or Rho/ROCK inhibitors: CCG 1423 (1 µM), or Y27632 (20 µM), or Cdc42 inhibitor: ZCL278 (20 µM), or 
DOCK1/2/5 inhibitor: CPYPP (100 µM) and activated with CXCL8 (10 nM). 1% DMSO was added to the vehicle control. Cells were 
drawn around using Fiji/ImageJ and measurements of 70 cells per image per experiment were analysed. Experiments were repeated 
at least three times. Images are representative of the cell population and were taken at 10x objective with Zeiss Axiovert 200M 
microscope and processed using AxioVision Rel 4.8 software. 
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Figure 77. Analysis of the cellular morphology of MDA-MB231 cells following 
treatment with CXCL8 in the presence or absence of Rac/Rho/Cdc42 or 
DOCK1/2/5 inhibitors. Cells were treated with Rac1 inhibitors: NSC23766 (100 
µM), EHT1864 (100 nM), Rho/ROCK inhibitors: CCG 1423 (1 µM), Y27632 (20 
µM), Cdc42 inhibitor: ZCL278 (20 µM), or DOCK1/2/5 inhibitor: CPYPP (100 µM) 
and activated with CXCL8 (10 nM). 1% DMSO was added to the basal cells as a 
vehicle control. Comparisons were made against the positive control of cells 
incubated with CXCL8. Cells were drawn around and measurements of a) area, b) 
aspect ratio, and c) circularity were analysed for an average of 70 cells per image 
per experiment. Experiments were repeated three times (One-way ANOVA with a 
Dunnett’s multiple comparisons test as post-test, n.s.= no significance p>0.05, *** 
= p ≤0.001 **** = p ≤0.0001). 
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The effect of Rho GTPases and DOCK 1/2/5 on the cellular morphology of 
PC3 cells is presented. Phalloidin actin stain with 10 nM CXCL8 stimulated 
membrane ruffling and lamellipodia formation as pointed out with the white arrows in 
Figure 78. When PC3 cells were treated with Rac1 inhibitor, NSC23766, even more 
bleb-like membrane ruffles were noticed (white arrows) as well as formation of 
microspikes (red arrows). Moreover, few cells with CCG 1423 (Rho inhibitor) 
treatment had a more pointed leading edge with actin reorganising at the leading edge 
and cells assuming a polarized morphology (pointed with red arrow heads). Cdc42 
inhibitor, ZCL278, showed few membrane ruffling. More protrusive ends and 
membrane ruffling appeared with Rac1 inhibitor EHT1864. ROCK inhibitor, Y27632, 
impacted the morphology of the cells where they assumed an extensive thin 
elongation to their bodies, and cells were interlaced with no barriers. Indeed, Zhang 
et al. [514] found similar findings with Y27632, but with imaging at 400x magnification 
using confocal microscopy, they also noticed a considerable reduction in stress fibres 
formation identified by the decreased intensity of actin meshwork and compacted 
cellular morphology. ROCK has been demonstrated to phosphorylate the regulatory 
myosin light chain, which promotes its binding to F-actin [515]. Furthermore, DOCK 
1/2/5 inhibitor, CPYPP gave the cells a widely spread with bigger cell area shape 
comparing with the control samples. 
Images obtained with a light microscope using lower objective (10x) showed 
changes of the cells overall without specifically detecting actin reorganisation. Just 
like the previous observation, PC3 cells treated with Y27632 over 10 hrs 
demonstrated substantial elongation of the cells (Figure 79). The alternation of cell 
shape was analysed and resulted in a significant change to the cell area, aspect ratio 
and circularity (Figure 80). The other inhibitors tested showed no significance 
towards CXCL8-activated cells.  
In summary, Rho/Rac/Cdc42 or DOCK1/2/5 inhibitors presented distinct 
effects on the speed of migration of MDA-MB231 and PC3 cells stimulated with 
CXCL8, while ROCK inhibitor, Y27632, significantly affected the morphology of both 
cell lines.  
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Figure 78. Phalloidin actin staining of CXCL8-activated PC3 cells in the presence or absence of Rac/Rho/Cdc42 or DOCK1/2/5 
inhibitors. Actin cytoskeleton changes to pre-treated cells with Rac1 inhibitors: NSC23766 (100 µM), or EHT1864 (100 nM), or 
Rho/ROCK inhibitors: CCG 1423 (1 µM), or Y27632 (20 µM), or Cdc42 inhibitor: ZCL278 (20 µM), or DOCK1/2/5 inhibitor: CPYPP 
(100 µM) and activated with CXCL8 (10 nM). The red arrows indicate membrane microspikes formation or apical-basal polarity as well 
as elongating cells, while the white arrows show membrane ruffling. 1% DMSO was added to cells as the vehicle control. Cells were 
fixed and stained with Alexa-488 Phalloidin actin green stain. Cells images are representative of the population of one experiment out 
of three repeats, acquired at 63x magnification using a Leica DMII inverted microscope and Leica imaging suite. 
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Figure 79. Illustrative images demonstrating morphological changes of CXCL8-stimulated PC3 cells in the presence or 
absence of Rac/Rho/Cdc42 or DOCK1/2/5 inhibitors. Cells were activated with CXCL8 (10 nM) alone or following pre-treatment 
with Rac1 inhibitors: NSC23766 (100 µM), or EHT1864 (100 nM), or Rho/ROCK inhibitors: CCG 1423 (1 µM), or Y27632 (20 µM), or 
Cdc42 inhibitor: ZCL278 (20 µM), or DOCK1/2/5 inhibitor: CPYPP (100 µM). 1% DMSO was added to the vehicle control. Cells were 
outlined using Fiji/ImageJ and measurements of 70 cells per image per experiment were analysed. Experiments were repeated at 
least three time. Images are a representation of the cell population and were taken at 10x objective with Zeiss Axiovert 200M 
microscope and processed using AxioVision Rel 4.8 software. 
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Figure 80. Analysis of cellular morphology of CXCL8-stimulated PC3 cells 
in the presence or absence of Rac/Rho/Cdc42 and DOCK1/2/5 inhibitors. 
Cells were treated with Rac1 inhibitors: NSC23766 (100 µM), or EHT1864 (100 
nM), or Rho/ROCK inhibitors: CCG 1423 (1 µM), or Y27632 (20 µM), or Cdc42 
inhibitor: ZCL278 (20 µM), or DOCK1/2/5 inhibitor: CPYPP (100 µM) and 
activated with CXCL8 (10 nM). Comparisons were made against CXCL8. 1% 
DMSO was added to the basal cells as a vehicle control. Cells outlined around 
and measurements of a) area, b) aspect ratio, and c) circularity were analysed 
of an average of 70 cells per image per experiment. Experiments were repeated 
three times (One-way ANOVA with a Dunnett’s multiple comparisons test as post-
test, n.s.=no significance p>0.05, *** = p ≤0.001 **** = p ≤0.0001). 
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4.2.3.3 MTS cytotoxic assay to quantify the cytotoxicity of 
Rac/Rho/Cdc42 and DOCK1/2/5 
To identify the cells viability of MDA-MB231 and PC3 cells following 24 hrs incubation 
with Rho GTPases or DOCK1/2/5 inhibitors Rac1 inhibitors: NSC23766 (100 µM), or 
EHT1864 (100 nM), or Rho/ROCK inhibitors: CCG 1423 (1 µM), or Y27632 (20 µM), 
or Cdc42 inhibitor: ZCL278 (20 µM), or DOCK1/2/5 inhibitor: CPYPP (100 µM) an 
MTS assay was conducted. The concentrations used of the inhibitors did not show 
any cytotoxicity to MDA-MB231 cells (Figure 81). However, in PC3 cells Cdc42 
inhibitor, ZCL278, showed a significant toxicity to the cells at 20 μM. Therefore, the 
reduced effect on the migration speed presented in Figure 74 could possibly be due 
to the cytotoxicity of the inhibitor on the cells. Nonetheless, amid observation of cells 
migration in real-time using the time-lapse migration assay, we noticed that the cells 
slowed down but did not stop migrating or proliferating - no visible cytotoxicity 
demonstrated by floating or dying cells appeared. Indeed, Friesland et al. [362] used 
even a higher concentration reaching to 50 μM of ZCL278 on PC3 cells and found 
that the cell viability was not affected while cell motility was abolished. Another 
plausible explanation could be that the observation of the time-lapse migration assay 
was made over a period of 10 hrs, while for the MTS assay, the cells viability was 
detected after 24 hrs incubation period. Therefore, the inhibitor could have shown 
cytotoxicity over an extended period. It is worth performing another cell cytotoxicity 
assay for confirmation, such as Countess Automated Cell Counter (provided by 
Invitrogen) and combine it with a trypan blue dye staining assay, or LDH-cytotoxicity 
assay. 
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Figure 81. Toxicity of Rac/Rho/Cdc42 and DOCK1/2/5 inhibitors towards 
MDA-MB231 and PC3 cells. The absorbance following incubation with Rac1 
inhibitors: NSC23766 (100 µM), or EHT1864 (100 nM), or Rho/ROCK inhibitors: 
CCG 1423 (1 µM), or Y27632 (20 µM), or Cdc42 inhibitor: ZCL278 (20 µM), or 
DOCK1/2/5 inhibitor: CPYPP (100 µM), for 24 hrs and treatment with MTS reagent 
for 2 hrs in a) MDA-MB231 cells, or b) PC3 cells. 1% DMSO was added to the basal 
cells as a vehicle control. Data are representative of the mean ± SEM of three 
independent experiments (Kruskal-Wallis test, Dunn’s multiple comparisons test, 
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 The FAK and Src signalling pathway 
4.2.4.1 FAK and Src are important for cells migration 
Activation of CXCR1 and CXCR2 in response to CXCL8 stimulates members of Rho 
GTPases family and thus, promotes stimulation of protein kinases such as Src and 
FAK [143]. Induction of these protein kinases was previously reported to elevate cells 
proliferation and migration [368]. Indeed, activation of RBL cells with CXCL8 
promoted FAK phosphorylation and re-localization, which was correlated with 
increased cell spreading and migration [143], [375], [376]. 
FAK inhibitor: PF562271 (10 nM) and Src inhibitor: Bosutinib (1 µM) 
significantly reduced the speed of CXCL8-activated MDA-MB231 and PC3 cells. 
MDA-MB231 basal cells had a speed of 21.07 ± 7.5 µm/hr, while addition of CXCL8 
(10 nM) increased the speed to 48.3 ± 4.4 µm/hr. Cells treated with PF562271 had a 
speed of 29.9 ± 13.6 µm/hr, and Bosutinib almost completely abolished the migration; 
4.2 ± 2.1 µm/hr (Figure 82).  
  
Figure 82. The effect of FAK and Src inhibitors on the migration speed of 
CXCL8-activated MDA-MB231 cells. Cells were pre-treated with FAK inhibitor: 
PF562271 (10 nM) or Src inhibitor: Bosutinib (1 µM) and activated with CXCL8 (10 
nM). Comparisons were made against CXCL8. 1% DMSO was added to the basal 
cells as a vehicle control.  Data are representative of the analysis of 10 cells in each 
experiment using Fiji/ImageJ, with the mean ± SEM of four independent 
experiments (One-way ANOVA with a Dunnett’s multiple comparisons test as post-
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PC3 cells reacted in the same way; having a basal speed of 25.7 ± 7.9 µm/hr, 
addition of CXCL8 (10 nM) increased the speed to 59.0 ± 21.4 µm/hr, incubating with 
PF562271 had a speed of 34.8 ± 11.1 µm/hr, and incubating with Bosutinib drastically 
reduced the speed to 6.6 ± 1.4 µm/hr (Figure 83). 
  
Figure 83. The effect of FAK and Src inhibitors on the migration speed of 
CXCL8-activated PC3 cells. Cells were pre-treated with FAK inhibitor: PF562271 
(10 nM) or Src inhibitor: Bosutinib (1 µM) and activated with CXCL8 (10 nM). 
Comparisons were made against CXCL8. 1% DMSO was added to the basal cells 
as a vehicle control. Data are representative of the analysis of 10 cells in each 
experiment using Fiji/ImageJ, with the mean ± SEM of four independent 
experiments (One-way ANOVA with a Dunnett’s multiple comparisons test as post-
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4.2.4.2 Src inhibition affects the cellular morphology 
Cancer cells have the ability to grow in an anchorage-independent fashion and FAK 
is thought to be associated with this phenotype [516]. FAK localizes in focal adhesions 
plaques and function as a scaffolding and signalling protein for other adhesion 
molecules. The stimulation of Src-kinases and FAK are observed in cancer cells after 
induction with CXCL8 [367]. Indeed, CXCR1 and CXCR2 transfected HEK293 and 
RBL cells confirm that Src and FAK are upstream signalling cascades of CXCL8 
[375], [376]. Therefore, their activation was reported to be associated with cell 
proliferation, spreading, migration and invasion [368], [397].   
Since integrin signalling is mediated through FAK catalytic activity [517], we 
used PF562271 as a small molecule inhibitor of FAK which could lead to integrin 
signalling inhibition. Phalloidin actin stain of MDA-MB231 cells pre-treatment with 
PF562271 (10 nM) and activation with CXCL8 (10 nM) showed that cells have lost 
their intact structures and clustered around each other (red arrows Figure 84). It is 
thought that FAK stimulates actin and β-tubulin re-localization to promote spreading 
and migration that is directly associated with CXCL8-activated migratory response 
[376]. Indeed, Cohen-Hillel et al. [376] have suggested that induction with CXCL8 
controls actin and microtubule rearrangements associated with regulating FAK. This 
could explain the cellular morphological changes upon FAK inhibition which 
corresponds to the abrogation of cellular speed (as shown above). However, having 
bright-field microscopy images obtained after 10 hrs incubation with the inhibitor did 
not show a substantial effect on the cell area, aspect ratio and circularity of the cells 
(Figure 85). This was indicated with the analysis of these images by randomly 
selecting cells and drawing around them (Figure 86).  
On the other hand, Src inhibitor, Bosutinib (1 µM), showed a significant effect 
on the MDA-MB231 cellular morphology. Bosutinib is an FDA approved drug for 
chronic myeloid leukaemia [518]. With Bosutinib treatment, cells seemed to have lost 
their structure. They are stretched out with overlapping filaments of interlacing cells 
along with disorganised stress fibres appeared. Some cells showed accumulation of 
crosslinked networks of lamellipodia and filopodia at the leading/tailing edge (red 
arrows Figure 84). The changes in cell shape were also witnessed in the images 
obtained by light microscopy (Figure 85), along with a significant increase in the cell 
area presented from the images analysis (Figure 86). 
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Figure 84. Phalloidin actin staining of CXCL8-activated MDA-MB231 cells in 
the presence or absence of FAK and Src inhibitors. Cells were treated with FAK 
inhibitor: PF562271 (10 nM) or Src inhibitor: Bosutinib (1 µM) and activated with 
CXCL8 (10 nM). 1% DMSO was added as a vehicle control. Cells were fixed and 
stained with Alexa-488 Phalloidin actin green stain. Cells images are representative 
of the population of cells from one experiment out of three repeats, acquired at 63x 
magnification using a Leica DMII inverted microscope and a Leica imaging suite. 
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Figure 85. Illustrative images demonstrating morphological changes of 
CXCL8-stimulated MDA-MB231 cells in the presence or absence of FAK and 
Src inhibitors. Cells were pre-treated with the FAK inhibitor: PF562271 (10 nM) or 
Src inhibitor: Bosutinib (1 µM) and activated with CXCL8 (10 nM). 1% DMSO was 
added as a vehicle control. Cells were drawn around using Fiji/ImageJ and 
measurements of 70 cells per image per experiment were analysed. Experiments 
were repeated at least three times. Images are representative of the cell population 
and were taken at 10x objective with a Zeiss Axiovert 200M microscope and 
processed using AxioVision Rel 4.8 software. 
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Figure 86. Analysis of the cellular morphology of CXCL8-stimulated MDA-
MB231 cells in the presence or absence of FAK and Src inhibitors. Cells were 
treated with FAK inhibitor: PF562271 (10 nM) or Src inhibitor: Bosutinib (1 µM) and 
activated with CXCL8 (10 nM). Comparison was made against CXCL8. 1% DMSO 
was added to the basal cells as a vehicle control. Cells were drawn around and 
measurements of a) area, b) aspect ratio, and c) circularity were analysed for an 
average of 70 cells per image per experiment. Experiments were repeated three 
times (One-way ANOVA with a Dunnett’s multiple comparisons test as post-test, 
n.s.= no significance p>0.05, * = p ≤0.05). 
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Actin rearrangement was observed by staining PC3 cells with phalloidin 
showed no major effect with PF562271 (10 nM) treatment. However, Bosutinib has 
yet again induced changes to the cell morphology characterised by significant 
enlargement of the cells area going up to almost double the size comped to the control 
samples as shown in Figure 87. Furthermore, the effect of Bosutinib was obvious 
with images generated from light microscopy (Figure 88), where a significant impact 
on the cell area is presented in (Figure 89). 
 
 
Figure 87. Phalloidin actin staining of CXCL8-activated PC3 cells in presence 
or absence of FAK and Src inhibitors. Cells were treated with FAK inhibitor: 
PF562271 (10 nM) or Src inhibitor: Bosutinib (1 µM) and activated with CXCL8 (10 
nM). 1% DMSO was added to the cells as a vehicle control. Cells were fixed and 
stained with Alexa-488 Phalloidin actin green stain. Cells images are representative 
of the population of one experiment out of three repeats, acquired at 63x 
magnification using a Leica DMII inverted microscope and Leica imaging suite. 




Figure 88. Illustrative images demonstrating morphological changes of PC3 
cells in the presence or absence of FAK and Src inhibitors. Cells were treated 
with FAK inhibitor: PF562271 (10 nM) or Src inhibitor: Bosutinib (1 µM) and 
activated with CXCL8 (10 nM). 1% DMSO was added as a vehicle control. Cells 
were outlined using Fiji/ImageJ and measurements of 70 cells per image per 
experiment were analysed. Experiments were repeated at least three times. 
Images are representative of the cell population and were taken at 10x objective 
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Figure 89. Cellular morphology analysis of CXCL8-stimulated PC3 cells in the 
presence of FAK and Src inhibitors. Cells were pre-treated with FAK inhibitor: 
PF562271 (10 nM) or Src inhibitor: Bosutinib (1 µM) and activated with CXCL8 (10 
nM). Comparisons were made against CXCL8. 1% DMSO was added to the basal 
as a vehicle control. Cells were outlined and measurements of a) area, b) aspect 
ratio, and c) circularity were analysed for an average of 70 cells per image per 
experiment. None demonstrated any significance except for Bosutinib cell area. 
Experiments were repeated three times (One-way ANOVA with a Dunnett’s 
multiple comparisons test as post-test, n.s.= no significance p>0.05, ** = p ≤0.01). 
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4.2.4.3 MTS cytotoxic assay to quantify the cytotoxicity of FAK and 
Src inhibitors 
Strong evidence has suggested the presence of activated FAK [368] and Src [369] in 
CXCL8-activated cancer cells [139]. Using FAK inhibitor, PF62271, at a concentration 
of 10 nM, and Src inhibitor, Bosutinib, at a concentration of 1 µM, over a period of 24 
hrs has yielded in no cytotoxic effects on either MDA-MB231 or PC3 cells (Figure 90) 
using an MTS assay. Different studies have used a range of concentrations of 
Bosutinib starting from 25 nM to 250 nM [505] where no effect on the cell migration 
was reported, and 10 µM [388], [519] where this concentration inhibited cells 
migration. However, the latter concentration caused cell morphology changes 
associated with cytotoxicity on neuroblastoma cells and HeLa cells [520], [521]. 
Therefore, using 1 µM seemed ideal to have generated a response without being 
cytotoxic. 
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Figure 90. Toxicity of FAK and Src inhibitors towards MDA-MB231 and PC3 
cells. The absorbance of FAK inhibitor: PF562271 (10 nM) or Src inhibitor: Bosutinib 
(1 µM), incubated for 24 hrs and treatment with MTS reagent for 2 hrs in a) MDA-
MB231 cells, or b) PC3 cells. 1% DMSO was added to the basal cells as a vehicle 
control. Data are representative of the mean ± SEM of three independent experiments 
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 The PKA, Arp2/3, and PKD signalling pathways 
4.2.5.1  PKA, Arp2/3 or PKD have an important effect on cell 
migration 
Protein phosphorylation regulated by protein kinases has a vital role in cellular signal 
transduction [522]. H89, is a potent PKA small molecule inhibitor that has a wide 
spectrum effect on other protein kinases depending on the concentration used. 
CXCL8 was reported to activate vasodilator-stimulated phosphorylation (VASP) 
through PKA and PKC signalling, which is crucial for the chemotaxis and polarization 
of HL-60 cells. A study by Lee et al. [523] found that the inhibition of the Arp2/3 
complex abrogates PKA activity and tyrosine phosphorylation causing disturbance to 
actin polymerization. Additionally, protein kinase D (PKD) is identified as an upstream 
regulator of Arp2/3 and F-actin binding protein cortactin [524]. CID755673 is a PKD 
inhibitor that was identified for its tumour-enhancing role in prostate cancer cells [525].  
Treatment of MDA-MB231 cells with H89 (10 µM) in the presence of CXCL8 
(10 nM) was made over 10 hrs. Untreated MDA-MB231 basal cells had a speed of 
21.07 ± 7.5 µm/hr, and the activation with CXCL8 (10 nM) increased the speed to 
48.3 ± 4.4 µm/hr. Treatment with H89 (10 nM) generated a speed of 43.1 ± 4.0 µm/hr. 
However, Arp2/3 inhibitor CK666 (80 µM) significantly attenuated the speed to 19.5 
± 4.4 µm/hr. A total abrogation of cell migration was reported with CID755673 (11 µM) 
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Figure 91. CXCL8-activated MDA-MB231 cells migration speed in the presence 
or absence of PKA, Arp2/3, or PKD inhibitors. Cells were pre-treated with PKA 
inhibitor: H89 (10 nM), or Arp2/3 complex inhibitor: CK666 (80 µM), or PKD inhibitor: 
CID755673 (11 µM) and activated with CXCL8 (10 nM). Comparisons were made 
against CXCL8. 1% DMSO was added to the basal cells as a vehicle control. Data 
are representative of the analysis of 10 cells in each experiment using Fiji/ImageJ, 
with the mean ± SEM of four independent experiments (One-way ANOVA with a 
Dunnett’s multiple comparisons test as post-test, n.s.= no significance p>0.05, **** = 
p ≤ 0.0001). 
 
PC3 cells reacted differently to the PKA inhibitor H89 compared to MDA-
MB231 cells. The speed of PC3 basal cells was 25.7 ± 7.9 µm/hr, addition of CXCL8 
(10 nM) increased the speed to 59.0 ± 21.4 µm/hr. H89 treatment had reduced the 
speed to 30.6 ± 12.6 µm/hr. Additionally, Arp2/3 complex inhibitor CK666 (80 µM) had 
completely paralysed the cells; 4.4 ± 2.5 µm/hr. PKD inhibitor CID755673 (11 µM)  
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Figure 92. CXCL8-activated PC3 cells migration speed in the presence of 
PKA, Arp2/3, or PKD inhibitors. Cells were treated with the PKA inhibitor: H89 
(10 nM), or Arp2/3 complex inhibitor: CK666 (80 µM), or PKD inhibitor: CID755673 
(11 µM) and activated with CXCL8 (10 nM). Comparisons were made against 
CXCL8. 1% DMSO was added to the basal cells as a vehicle control. Data are 
representative of the analysis of 10 cells in each experiment using Fiji/ImageJ, with 
the mean ± SEM of four independent experiments (One-way ANOVA with a 
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4.2.5.2 PKD inhibition affects cellular morphology 
Since the Arp2/3 complex and PKD proved to be vital for the migration of PC3 and 
MDA-MB231 cells, and H89 for PC3 cells, we further inspected the cellular changes 
of the cells. Mills. [498] found that H89 treatment of THP-1 cells have caused a 
significant reduction of the migration of the cells towards CXCL12 using a chemotaxis 
assay as well as disrupted the directional F-actin responses of CHO.CCR5 and MCF-
7 cells to both CCL3 and CXCL12. 
For CXCL8-activated MDA-MB231 cells, Arp2/3 complex inhibitor, CK666, 
slightly decreased the appearance of spiked protrusions of actin assembly density 
at the leading edge with few lamellipodia extensions to some cells (Figure 93). In 
fact, Yang et el. [43] described the effect of CK666 (80 µM) to have disrupted actin 
veils with actin retraction. Another study has also found that CK666 leads to the 
disappearance of lamellipodia [526]. Moreover, PKA inhibitor H89 (10 nM) had no 
significant effect, although cells looked modestly bigger than the controls with 
elongation to few cells. Additionally, having incubated CID755673 (11 µM) with the 
cells have radically changed their shape; appearance of very long stretched cells 
growing over each other and overlapping filaments indicating that cells have lost 
their ability to retract or move forward.  
The effect of CID755673 was also evident using lower magnification (10x) 
with bright-field microscope, where the cells looked bigger in size with pointed 
leading edges (Figure 94). Quantification of the cellular morphology with the above 
inhibitors showed that CID755673 majorly affected the circularity and cell area while 








Figure 93. Phalloidin actin staining of CXCL8-activated MDA-MB231 cells in presence or absence of PKA, Arp2/3, or PKD inhibitors. 
Cells were treated with PKA inhibitor: H89 (10 nM), or Arp2/3 complex inhibitor: CK666 (80 µM), or PKD inhibitor: CID755673 (11 µM) and 
activated with CXCL8 (10 nM). 1% DMSO was added to the cells as a vehicle control. Cells were fixed and stained with Alexa-488 phalloidin 
actin green stain. Cells images are representative of three independent repeats and were acquired at 63x magnification using a Leica DMII 
inverted microscope and Leica imaging suite. 




Figure 94. Illustrative images demonstrating morphological changes of CXCL8-stimulated MDA-MB231 cells in the presence of PKA, 
Arp2/3, or PKD inhibitors. Cells were treated with PKA inhibitor: H89 (10 nM), or Arp2/3 complex inhibitor: CK666 (80 µM), or PKD inhibitor: 
CID755673 (11 µM) and activated with CXCL8 (10 nM). 1% DMSO was added to the vehicle control. Cells were drawn around using Fiji/ImageJ 
and measurements of 70 cells per image per experiment were analysed. Experiments were repeated at least three time. Images are a 
representation of the cell population and were taken at 10x objective with Zeiss Axiovert 200M microscope and processed using AxioVision Rel 
4.8 software. 
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Figure 95. Analysis of the cellular morphology of CXCL8-stimulated MDA-
MB231 cells in the presence or absence of PKA, Arp2/3, or PKD inhibitors. 
Cells were pre-treated with PKA inhibitor: H89 (10 nM), or Arp2/3 complex inhibitor: 
CK666 (80 µM), or PKD inhibitor: CID755673 (11 µM) and activated with CXCL8 
(10 nM). Comparisons were made against CXCL8. 1% DMSO was added to the 
basal cells as a vehicle control. Cells were outlined and measurements of a) area, 
b) aspect ratio, and c) circularity were analysed for an average of 70 cells per 
image per experiment. Experiments were repeated three times (One-way ANOVA 
with a Dunnett’s multiple comparisons test as post-test, n.s.= no significance 
p>0.05, * = p ≤0.05, **** = p ≤0.0001).  
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CXCL8-activated PC3 cells incubated with the same set of inhibitors 
demonstrated similar responses to MDA-MB231 cells.  Although H89 (PKA inhibitor)-
treated cells decreased the speed of migrating cells, using phalloidin actin stain to 
inspect actin rearrangement only showed a slight increase to the cells area with this 
inhibitor relative to the controls (Figure 96). CK666 (Arp2/3 inhibitor)-treated cells had 
more membrane ruffles (indicated by the white arrows), formed some microspikes 
tips (indicated with the red arrows) as well as caused actin clumping demonstrated 
by the little dots’ accumulation inside the cells. Moreover, CID755673 (PKD inhibitor)-
treated cells appeared bigger in size with extensive amount of visible microspikes of 
lamellipodia and filopodia forming antenna-like shapes almost surrounding all the cell 
with no particularly directed protrusions.  
Further observations of the cellular morphology using bright-field microscope 
presented again that with CID755673 treatment, cells looked bigger, although 
microspikes formations did not show with these images (Figure 97). The cellular area, 
aspect ratio and circularity where significantly different as presented with statistical 
analysis (Figure 98). This change of the cellular morphology with CID755673 was 
associated with reduction of the migration speed of PC3 cell. 
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Figure 96. Phalloidin actin staining of CXCL8-activated PC3 cells in the presence or absence of PKA, Arp2/3, or PKD inhibitors. Cells 
were treated with PKA inhibitor: H89 (10 nM), or Arp2/3 complex inhibitor: CK666 (80 µM), or PKD inhibitor: CID755673 (11 µM) and activated 
with CXCL8 (10 nM). White arrows point out membrane ruffling, and red arrows show actin clumping and microspikes. 1% DMSO was added 
to cells as the vehicle control. Cells were fixed and stained with Alexa-488 Phalloidin actin green stain. Images are representative of a population 
of one experiment out of three repeats, acquired at 63x magnification using a Leica DMII inverted microscope and Leica imaging suite. 
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Figure 97. Illustrative images demonstrating morphological changes of CXCL8-stimulated PC3 cells in the presence or absence of 
PKA, Arp2/3, or PKD inhibitors. Cells were treated with PKA inhibitor: H89 (10 nM), or Arp2/3 complex inhibitor: CK666 (80 µM), or PKD 
inhibitor: CID755673 (11 µM) and activated with CXCL8 (10 nM). 1% DMSO was added to the vehicle control. Cells were outlined using 
Fiji/ImageJ and measurements of 70 cells per image per experiment were analysed. Experiments were repeated at least three time. Images 
are a representation of the cell population and were taken at 10x objective with Zeiss Axiovert 200M microscope and processed using 
AxioVision Rel 4.8 software. 




Figure 98. Analysis of cellular morphology analysis of CXCL8-stimulated PC3 
cells in the presence or absence of PKA, Arp2/3, or PKD inhibitors. Cells were 
treated with PKA inhibitor: H89 (10 nM), or Arp2/3 complex inhibitor: CK666 (80 
µM), or PKD inhibitor: CID755673 (11 µM) and activated with CXCL8 (10 nM). 
Comparisons were made against CXCL8. 1% DMSO was added to the basal as a 
vehicle control. Cells were outlined and measurements of a) area, b) aspect ratio, 
and c) circularity were analysed of an average for 70 cells per image per 
experiment. Experiments were repeated three times (One-way ANOVA with a 
Dunnett’s multiple comparisons test as post-test, * = p ≤0.05, ** = p ≤0.01). 
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4.2.5.3 MTS cytotoxic assay to quantify the cytotoxicity of PKA, 
Arp2/3, and PKD inhibitors 
Since the inhibition of Arp2/3 inhibitor and PKD inhibitor has greatly reduced the 
speed of MDA-MB231 and PC3 cells. We wanted to see if this inhibition was due to 
a cytotoxic effect. Indeed, CK666 at 80 µM in PC3 cells and CID755673 at 11 µM in 
MDA-MB231 cells have showed cytotoxicity of the inhibitors in the MTS assay (Figure 
99). However, this assay was performed over 24 hrs, while the time-lapse migration 
assay was conducted over 10 hrs. From the observations of the treated cells in real 
time, we did not see any abnormal behaviour of the cells resembled by their death. 
Therefore, it is unlikely that the inhibitory response CK666 and CID755673 induce on 
the cells is due to toxicity. Nonetheless, it is preferable to test these inhibitors for the 
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Figure 99. Toxicity of PKA, Arp2/3, or PKD inhibitors towards MDA-MB231 
and PC3 cells. The absorbance of PKA inhibitor: H89 (10 nM), or Arp2/3 complex 
inhibitor: CK666 (80 µM), or PKD inhibitor: CID755673 (11 µM), incubated for 24 
hrs and treatment with MTS reagent for 2 hrs in a) MDA-MB231 cells, or b) PC3 
cells. 1% DMSO was added to the basal cells as a vehicle control. Data are 
representative of the mean ± SEM of three independent experiments (Kruskal-
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 Discussion 
Binding of chemokines to their respective receptors leads to the stimulation of various 
intracellular signalling cascades associated with several cellular responses such as, 
cell adhesion, proliferation, and migration [77]. Signalling pathways involved in 
CXCL8 activation have attracted a lot of attention due to their involvement in cancer, 
angiogenesis, survival, proliferation, and tumorigenesis [280]. One of the most widely 
studied signalling pathways is the Pi3K-associated pathway. This pathway has been 
proven to contribute significantly to the ability of cells to sense a chemokine gradient 
and migrate in response to chemokine receptor activation in multiple cell types [281]. 
Several studies have reported that Pi3K is crucial for cell polarization and chemotaxis 
induced by chemoattractant activation in a number of cell types, although different 
cells respond distinctly to the effect of Pi3K inhibitors [527], [528]. For example, our 
group showed that Pi3K activation was crucial for the migration of leukemic Jurkat 
cells in response to CXCL12, although MCF-7 cells did not respond in the same 
manner and did not migrate [388].  
AKT is believed to be a promising target for pharmacological intervention. CXCL8 
has been reported to elevate the expression of AKT in androgen-independent 
prostate cancer cell lines [452]. AKT stimulation phosphorylates several substrates, 
including cytoskeleton-regulating proteins and EMT-stimulating proteins that have 
different roles in the cell, particularly in the regulation of cell migration [281]. 
Moreover, activation of chemokine receptors on neutrophils result in F-actin 
polymerization and cytoskeletal contraction from PIP3 signalling [529]. This means 
that the assembly of actin is necessary for pseudopod extension, leading to the 
migration of neutrophil towards a chemokine gradient, which is dependent on AKT 
activity [529]. Indeed, another study identified that increased filopodia formation in 
breast BT549 cancer cells was AKT-dependent. Inhibition of AKT in these breast 
cancer cells using a specific AKT inhibitor, AKT/protein kinase 2 signalling inhibitor-2 
(API-2), resulted in the blockage of filopodia formation [493]. Furthermore, Pi3K/AKT 
inhibitors were tested on mesodermal cells and were found to inhibit membrane 
protrusive structures. These involved filopods and pseudopods, as well as 
disorganisation of the symmetric distribution of AKT at the leading edge, resulting in 
migration inhibition during vertebrate gastrulation [530]. Further evidence highlighted 
that Pi3K is involved in regulating the cytoskeletal changes during PDGF-induced 
lamellipodium formation [531]. The Pi3K inhibitor, wortmannin, was reported to inhibit 
membrane ruffling via the Rac-dependent pathway. This suggests that Pi3K might be 
199 | P a g e  
 
an upstream stimulator of Rac and Rho in CXCL8-activated cells, consequently 
affecting the cytoskeleton and cell migration [532]. 
Decreased cell migration could be a consequence of disruption of the dynamic 
remodelling of the cytoskeleton. This is characterised by defective actin 
polymerization and cell polarization in relation to inhibition of specific signals 
necessary for the cellular responses. We presented that Pi3K or AKT inhibition in 
MDA-MB231 cells disrupted the morphology of the cells and this coincided with a 
significant reduction in the speed of migrating cells. The disruption was characterised 
by excessively elongated cells, and in the case of AKT inhibition, the formation of 
aggregates in the cell body. The Pi3K inhibitor, LY294002, also resulted in stretched 
front and rear ends of MDA-MB231 cells. This was possibly due to the loss of the 
ability of the cell to form protrusive structures necessary for crawling and adhesion. 
This same effect on cell migration and morphology following Pi3K/AKT inhibition was 
noted in chicken embryo fibroblasts. The latter study inferred that the effects of 
Pi3K/AKT were transmitted through p70S6L1, which requires Rac and mediates actin 
filaments remodelling and cell migration [533]. A similar trend was observed in PC3 
cells pre-treated with Pi3K or AKT inhibitors and stimulated with CXCL8. The speed 
of migrating cells slowed down dramatically with the inhibitors. While the changes in 
cellular morphology were not statistically significant, visual observations of actin 
staining in AKTi-treated PC3 cells activated with CXCL8 demonstrated small 
accumulations inside the cells. Moreover, cells were completely immobile. LY294002-
treated PC3 cells looked slightly smaller in area, but this was not significant. These 
contradictory outcomes regarding the effects on cellular morphology were previously 
reported. Indeed, AKT mediated the remodelling of actin filaments and endothelial 
cell migration in response to VEGF [534], but not in PDGF-induced NIH3T3 cells 
[535]. We suggest that MDA-MB231 cells could utilize the Pi3K/AKT-Rho GTPase 
pathway to induce actin reorganization, leading to cellular migration. However, 
Pi3K/AKT signalling was found to be crucial for PC3 cell migration, but not actin 
reorganisation. This proposes that a Rho-GTPase-independent pathway was 
involved. 
Furthermore, THP-1 cells incubated with LY294002 showed a significant 
reduction in migration towards CXCL8 in a chemotaxis assay; which, as mentioned 
before, could be due to the substantial role of Pi3K in regulating the cellular polarity 
associated with directed cell migration [527], [528]. On the other hand, THP-1 cells 
did not show any dependence on Pi3K activity for intracellular calcium signalling when 
activated with CXCL8. This implies that cell migration can occur independently of 
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calcium release [387]. Nonetheless, using LY294002 in CX3CL1-induced CHO cells 
could abrogate intracellular calcium signalling [536] suggesting that the role of Pi3K 
in the induction of calcium flux is chemokine and cell line specific. Taken together, 
the increased migratory effect of CXCL8 activation in MDA-MB231, PC3, and THP-1 
cells was abolished with Pi3K or AKT inhibitors. This loss of migration was 
accompanied by disruption of the actin cytoskeleton with some variabilities between 
the two adherent cell lines, and no effect on intracellular calcium release in THP-1 
cells.  
 The Ras/Raf/MEK/ERK signalling cascade has an important role in tumour 
proliferation, survival, migration, invasion, and angiogenesis [537], [538]. ERK 
signalling is historically associated with cell proliferation, however, further studies 
have correlated its deregulation to be associated with different tumour phenotypes 
[304]. ERK is stimulated upon phosphorylation of MEK which itself is stimulated by 
Raf phosphorylation. Stimulation of the receptor tyrosine kinase triggers GTP loading 
of Ras GTPase, which in turn recruits Raf kinase to the plasma membrane for 
activation. Indeed, there is strong evidence validating the involvement of Raf and 
MEK in tumour growth and progression [539], [540]. We found that inhibiting Raf with 
ZM336372, which is a C-Raf selective inhibitor, could significantly reduce the 
migration speed of both MDA-MB231 and PC3 cells. This is in agreement with a study 
that found the same inhibitory effect in mesenchymal stromal cells [541]. Conversely, 
the other Raf inhibitor used, L779450, which is selective to B-Raf, did not significantly 
inhibit the migration of MDA-MB231 cells, while the effect on migration speed in PC3 
cells was substantial. This suggested that B-Raf was not important for CXCL8-
induced migration of MDA-MB231 cells, but essential for migration of PC3 cells. C-
Raf was important for both. The impact of these inhibitors on the migration speed was 
not associated with major changes to the cellular morphology of either cell lines.  
It has been suggested that MEK could be a suitable target for therapeutic 
intervention in cancer [323]. Our group have previously reported that MEK inhibitors: 
SL327 and PD98059 block the migration of CXCL12-stimulated Jurkat cells [388]. 
Here, we see the same effect with CXCL8-stimulated MDA-MB231 and PC3 cells. 
Cells migrate considerably slower in the presence of SL327 or PD98059. However, 
there are many contradictive studies concerning the effect of MEK inhibition on cancer 
proliferation and migration. For example, the MEK inhibitor, PD98059, works by 
preventing MEK phosphorylation by upstream activators, therefore, preventing the 
stimulation of ERK1/2 in the downstream signalling pathway. This inhibitor was found 
to supress the proliferation of MCF-7, MDA-MB231, and HCC1937 cells [542]–[544]. 
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Nonetheless, according to Zhao et al. [544], PD98059 enhanced the migration of 
MCF-7 and MDA-MB231 cells by promoting β-catenin nuclear translocation. Other 
studies have also shown that PD98059 had no effect on CXCL8-activated neutrophil 
chemotaxis [309], [497]. While Xythalis et al. [324] reported the opposite, whereby 
PD98059 supressed CXCL8-activated neutrophil chemotaxis. Moreover, Bian et al. 
[545] found that PD98059 did not affect cytokine expression mediated by the 
MAPK/ERK signalling pathway. PD98059 exerted no effect on cytoskeleton 
rearrangement leading to cytokine production. This study added that SB203580 
promoted cytoskeletal reorganisation in LPS-stimulated macrophages, leading to cell 
migration. Our results agreed that PD98059 did not affect cytoskeletal reorganization; 
however, we also see that SB203580 did not alter the cellular morphology associated 
with the reduced cell migration. Additionally, unlike the study reporting reduced 
migration with FH535 in CXCL12-induced Jurkat cells [388], here we did not see any 
effect of this β-catenin inhibitor on either MDA-MB231 or PC3 cell lines. Altogether, 
these distinctive effects are possibly due to the differences in the cell type tested and 
the stimulus used. Overall, we found that perturbations in the Ras/Raf/MEK/ERK and 
p38 MAPK pathways, but not β-catenin pathways, had a profound impact on the 
migration of both MDA-MB231 and PC3 cells without causing substantial changes to 
the cellular morphology.  
 Cell migration relies on actin cytoskeleton rearrangement and cellular 
responses that are regulated by Rho family GTPases which cause the formation of 
lamellipodia and actin polymerisation [546]. The abnormal activity of Rho GTPases 
has been associated with cancer and other human pathologies [547], [548]. 
Participation of Rho GTPases and their downstream effectors in chemokine-elicited 
motility is poorly understood. In this chapter, we examined the role of different Rho 
GTPases: Rac, Rho, ROCK, Cdc42, and DOCK1/2/5 in cell migration speed and 
cellular morphology. Rac1 inhibitor: EHT1864, ROCK inhibitor: Y27632, as well as 
DOCK1/2/5 inhibitor: CPYPP were important for the migration of MDA-MB231 cells. 
Moreover, along with EHT1864 and CPYPP, the Cdc42 inhibitor: ZCL278 reduced 
the migration speed of PC3 cells. Indeed, our group have already published that Rac1 
is important for the migration of CXCL12-stimulated MCF-7, THP-1, and Jurkat cells, 
while it is not necessary for CCL3 signalling [435]. This highlights the variability of 
cellular responses in each cell line to different chemokines.  
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Inhibition of Rho, Rac, and Cdc42 was reported previously to reduce the 
speed of cells as well as cause abnormal cellular morphological changes; 
characterised by elongation, rounding, loss of lamellipodia, and appearance of thick 
membrane extensions [549]. PC3 cells activated with CXCL8 presented some 
membrane ruffling, which is a character of a migratory cell forming a network of freshly 
formed polymerized actin filaments. This formation of membrane ruffles has been 
identified to be due to the activation of Rac [550]. When PC3 cells were treated with 
the Rac1 inhibitor NSC23766, there was an increase in bleb-like membrane ruffles, 
as well as formation of microspikes. MDA-MB231 cells on the other hand, showed a 
different response to NSC23766. These cells displayed less membrane ruffling, along 
with mild extension to both ends of the cells. This could be due to the loss of formation 
of sheet-like lamellipodia associated with Rac function. Gao et al. [551] have tested 
the effect of NSC23766 on PDGF-stimulated Swiss 3T3 fibroblast cells and found that 
this inhibitor reduced lamellipodia formation and membrane ruffling. While Hernández 
et al. [552] found that there was no crucial difference to the morphology of MDA-
MB435 cells treated with NSC23766, although this inhibitor did cause a significant 
reduction in cell migration. Moreover, the other Rac1 inhibitor used, EHT1864, 
appeared to be more potent [553]. This inhibitor resulted in slowing the migration of 
both PC3 and MDA-MB231 cells, yet no significant differences to their cellular 
morphology was noted. In this study, EHT1864 treatment of CXCL8-activated MDA-
MB231 cells resulted in the cells displaying a tangled actin meshwork, with elongation 
to both endings of the cells, as visualised with phalloidin staining. EHT1864 also 
caused a significant reduction in the speed of cell migration, while NSC23766 did not. 
No considerable changes to the cell shape in either cell line was noted, although, 
MDA-MB231 cells displayed interesting pattern changes in cellular morphology, 
which should be further investigated. In summary, the Rac1 inhibitor NSC23766 did 
not affect the migration speed of MDA-MB231 cells, whilst EHT1864 had a significant 
effect in reducing the speed. 
 Moreover, the ROCK inhibitor Y26732 completely degraded the integrity of 
MDA-MB231 cells. The cells presented extensive elongation to both ends, with 
frequently branching cell processes, and formation of tangled networks of interlaced 
actin filaments, also described as “deadhesion and retraction” [554], [456]. The 
formation of lamellipodia at the leading edge seemed to be driving the cells forward, 
however, the tail would stretch with the cytoplasm without moving ahead. Hence, the 
migration speed of MDA-MB231 cells was significantly reduced. A study confirmed 
the inhibitory effect of Y27632 on cell motility and deconstruction of the actin 
203 | P a g e  
 
cytoskeleton in MDA-MB231 and MCF-7 cells [507]. This effect was suggested to be 
due to ROCK regulating c-Myc, a transcription factor associated with breast cancer 
progression and metastasis [555]. PC3 cells treated with Y27632 also demonstrated 
considerable changes to their shape. Avril et al. [556] characterised Y27632-treated 
PC3 cells as having long extensions with stubborn detachment at the tailing end. 
However, the effect on cellular morphology was not as dramatic as what we see with 
MDA-MB231 cells, which could explain why Y27632 did not affect the migration speed 
of PC3 cells. Moreover, the Rho inhibitor CCG 1423, did not affect either the cellular 
morphology or the migration speed of either cell lines. In fact, little is known about the 
potency of this inhibitor. Evelyn et al. [557] associated the Rho inhibitory effect of 
CCG 1423 with functional blocking of transcription of the serum response factor 
(SRF). All in all, the cellular morphology of MDA-MB231 and PC3 cells was facilitated 
by ROCK, but the effect of this pathway on cell migration varied between the cell 
types; being crucial for MDA-MB231 cells but not PC3 cells. 
  DOCK2 binds to Rac and mediates the GTP-GDP exchange reaction. 
Inhibition of DOCK2 is thought to be an attractive target for inflammatory-related 
pathologies [356]. CPYPP interact with the DHR-2 domain of DOCK1/2/5, to inhibit 
the activity of guanine nucleotide exchange, leading to Rac stimulation [558]. 
DOCK1/2/5 was identified as a major regulator of Rac in neutrophils, therefore, 
blocking it could inhibit chemotactic migration of neutrophils [355]. Results from the 
Mueller group showed that CPYPP blocked CXCL12-stimulated Jurkat cell migration 
in a chemotaxis assay, but not migration of THP-1 cells [505]. Here, we presented 
that DOCK1/2/5 was essential for CXCL8-driven MDA-MB231 and PC3 cell 
migration. Although this effect was not associated with changes to the cellular 
morphology. Therefore, we proposed that DOCK1/2/5 was not directly involved in the 
rearrangement of the actin cytoskeleton.  
FAK and Src activation are recognized to play a vital role in cell migration 
[367], [134], [559]. Evidence came from studies that showed that CXCL8 could 
stimulate the migration of LNCaP cells [367] and bone marrow endothelial cells [134] 
through the activation of FAK and Src. Prostate cancer biopsy tissue showed the 
expression of CXCL8 was associated with elevated levels of FAK and Src [134]. The 
FAK inhibitor, PF562271, was reported to inhibit proliferation and colony formation in 
osteosarcoma cell lines. This was associated with a drastic reduction in 
osteosarcoma tumour volume, weight, and angiogenesis in vivo [560]. Indeed, 
Cohen-Hillel et al. [376] argued that CXCL8-induced cytoskeletal reorganisation by 
FAK activation and cytoskeleton contraction is necessary for the force and polarity-
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dependent process of cell motility. It was not surprising that our results supported the 
importance of FAK and Src in cell migration. PF562271 could inhibit the migration 
speed of both CXCL8-activated MDA-MB231 and PC3 cells. This agreed with data 
showing that PF562271 could block the migration of pancreatic ductal 
adenocarcinoma cells, cancer-associated fibroblasts, and macrophages [559]. 
Moreover, using an siRNA approach, Mills et al. [388] showed that Src knockdown 
could abolish CXCL12-stimulated Jurkat and MCF-7 migration. Indeed, our findings 
showed that the Src inhibitor, Bosutinib, abrogated the migration of CXCL8-stimulated 
MDA-MB231 and PC3 cells. Therefore, both FAK and Src play an important role in 
MDA-MB231 and PC3 cell migration following CXCL8 activation. 
Src kinase regulates several cellular processes including maintenance of the 
actin cytoskeleton, cell morphology, and motility through its substrate cortactin [561]. 
Actin cytoskeleton rearrangement downstream of Src contributes to growth factor and 
integrin signalling, for instance, cellular Src facilitates EGF-activated cellular motility, 
morphology, and stress fibre reorganisation [377]. We presented that the Src inhibitor, 
Bosutinib, had a significant effect on the cell morphology. CXCL8-stimulated MDA-
MB231 cells seemed to have lost their structure, appearing elongated, clustered, and 
with disorganised stress fibres. This was accompanied by visible accumulation of 
crosslinked networks of lamellipodia and filopodia and the leading/tailing edges. PC3 
cells were also affected by Bosutinib and almost doubled in size. The FAK inhibitor, 
PF562271, had no substantial effect on either of the cell morphology. All in all, since 
FAK and Src-kinase are activated in CXCL8-stimulated cancer cells [139], we 
confirmed the crucial effects of both kinases on cell motility and Src-induced 
cytoskeletal regulation.  
Protein Kinase A (PKA) is among the most widely studied kinases because of 
its association with a vast array of signal-transduction pathways; regulating 
proliferation, differentiation, cell cycle regulation, and/or metabolism [562]. H89, is a 
potent PKA small molecule inhibitor that was found to have a broad effect on other 
protein kinases, such as S6K1, MSK1, PKA, ROCKII, PKBα, and MAPKAP-K1b, 
depending on the concentration used [563]. H89 was reported to block ROCK activity 
significantly at 10 µM [564], [565]. Its inhibitory effect on the two substrates of ROCK, 
MYPT1 and MLC2, was similar to the inhibitory effect induced by Y27632 [566]. In 
fact, PKA on its own has been reported to block the actions of ROCK. Subsequently, 
PKA and H89 could have the same effect on ROCK, leading to misinterpreted 
conclusions [567], [568]. We also found that H89 blocked the migration of PC3 cells, 
but not MDA-MB231 cells. Additionally, H89 had no effect on the actin cytoskeleton 
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in both cell lines. Taken together, PC3 cells use the PKA signalling pathway for 
migration, but MDA-MB231 cells do not. 
The Arp2/3 complex has been studied for its role in actin filament assembly. 
It emerged as a key regulator for nucleating actin filament forming networks at the 
leading edge of migrating cells [43], [569] (Figure 2). A study by Lee et al. [523] found 
that inhibition of the Arp2/3 complex abrogated PKA activity and tyrosine 
phosphorylation, causing disturbances to actin polymerization. We inhibited the 
Arp2/3 complex with a small molecule inhibitor, CK666, to investigate the effects on 
the migratory speed and morphology of cells after 10 hrs. At 80 µM, CK666 showed 
cytotoxicity to the cells after a 24 hrs incubation, but as explained earlier, observing 
time-lapse videos of cells treated with this inhibitor over the course of 10 hrs did not 
indicate that cells were dying. Indeed, CK666 was used by other groups at even 
higher concentrations of up to 200 µM and showed no cytotoxicity. This was evident 
by Ilatovskaya et al. [570] who reported that F-actin reorganization was associated 
with a reduction of cell migration in M-1 mouse kidney principle cells and no loss of 
cell viability following treatment with 200 µM CK666. Although, this study only tested 
the cytotoxicity of the inhibitor over 2 hrs. Another study reported that 100 µM CK666 
caused glioma cells to lose their lamellipodia and polarity, along with a reduction in 
their migration [526], similar to our results. The concentration used by this study 
showed no cytotoxicity over a period of 30 mins. We concluded that although both 
CXCL8-stimulated motility in MDA-MB231 and PC3 cells were drastically slower in 
the presence of CK666, the toxicity of this inhibitor should be further investigated.  
Protein Kinase D (PKD) is characterised as being an upstream regulator of 
Arp2/3 and the F-actin binding protein cortactin [524]. CID755673 is a PKD inhibitor 
that was described to have a tumour-enhancing role in prostate cancer cells [525]. A 
study confirmed that since PKD could act on PKC signalling, targeted inhibition with 
CID755673 could specifically block cellular responses without inducing any effects on 
upstream broad-spectrum PKCs [405]. CID755673 was reported to have an inhibitory 
effect on prostate cancer invasion, proliferation, and migration [389], [405], [525]. Our 
data agree with these studies where the migration speed of both MDA-MB231 and 
PC3 cells were attenuated with CID755673 after stimulation with CXCL8. Indeed, 
along with inhibition of migration, cellular morphology was considerably altered in both 
cell lines. Therefore, we could conclude that PKD was important for maintaining the 
cellular integrity and morphology of MDA-MB231 and PC3 cells stimulated with 
CXCL8, when migrating. 
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The previous discussion was based on the analysis that tried to find a 
correlation between morphological changes and migration. While we reported that 
some of the inhibitors have caused a significant reduction to the migration of cells 
with corresponding changes to the morphology, other inhibitors only affected the 
migration. The time-lapse experiments were designed in a way to fit in all the 19 
inhibitors plus the control samples in a 24 well plate. Therefore, cells were stimulated 
with the chemokine, then exposed to the inhibitors. Whilst this way was beneficial in 
visualizing the effect of inhibitors on chemokine-stimulated cells at the same time, the 
lack of data representing the effect of inhibitors on unstimulated cells is an obstacle 
to achieve more certain conclusions. This opens the discussion to an alternative way 
of interpreting the data. We suggest that any drug that significantly alters cell 
morphology to be excluded from the analysis. The reason is that CXCL8 did not affect 
cell morphology and causes migration. For example, LY294002 affects cell migration 
but not morphology while AKTi affects both migration and morphology. This leads the 
conversation into investigating the effect of the inhibitors further before drawing 
conclusions associated with the effect on migration. Therefore, in retrospect, a 
different way to analyse the data is by considering the morphology effect as an 
exclusion criterion when the drug has caused a drastic change to the cells. 
The discussion of this chapter extensively reviews the effect of the inhibitors 
in different settings. Consensus was not reached with many inhibitors in terms of their 
association with morphology and migration, and this could potentially be due to 
different factors like variations in cell types. Therefore, under ideal conditions, 
obtaining more information on the effect of these drugs on the cells without activation 
with the chemokine could give us a better understanding of their behaviour and thus 
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 Conclusion 
The main conclusions drawn from this chapter are presented in Table 6.  
Table 6. Summary of the signal transduction molecules involved in MDA-MB231 
and PC3 cell migration speed and cellular morphology. 
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5 Chapter 5: The role of PKC in CXCL8 and 
CXCL10 directed prostate, breast, and 
leukemic cancer cell migration 
 Introduction 
The protein kinase C (PKC) family of serine/threonine kinases share structural 
homology yet demonstrate significant functional diversity. Activation of PKC is one of 
the earliest events involved in regulating cellular responses such as survival, 
proliferation, differentiation, apoptosis, and migration [571]. The different PKC 
isoforms are ubiquitously expressed in tissues, for example, PKCα, βI/II, δ, ε and ζ 
are found on most major tissues, while the expression of PKCγ is limited to the central 
nervous system and spinal cord, PKCη is expressed on the skin, lung, spleen and 
brain, and PKCθ in the skeletal muscle, lung, spleen, skin and brain [572], [573]. 
Genetic targeting of specific PKC isoforms has pointed out the redundancy in the 
function of PKCs while presenting the unique isoform-specific protein, which can alter 
particular cellular responses [574], [575]. Indeed, PKC isoforms can exhibit similar 
expression patterns in different types of cancer while demonstrating varying roles 
depending on the context and the cancer type [576]. Studies have shown that PKC 
isoforms are directly associated with cancer cells migration through chemokine 
receptors. For instance, PKCα is crucial for CXCL12-activated MCF-7 and Jurkat cells 
migration [388]. PKCζ inhibition blocked the migration of PC3 cells towards CXCL12 
[389]. Furthermore, the important role of PKC in migration is highlighted by their ability 
to regulate the actin cytoskeleton by supressing stress fibres and forming membrane 
ruffles as part of the cells’ mechanism to move [386]. The complexities and reversals 
in PKC pharmacology make it challenging to determine the role of each isoform in 
cellular responses [577]. Therefore, further investigations into the roles of these 
isoforms in CXCL8 and CXCL10 migration in different cellular subsets was the main 
objective of this chapter. 
 
Chapter Aim: 
To determine the role of PKC in CXCL8 or CXCL10-stimulated cancer cells using 
small molecule inhibitors. Specifically, looking at the effect PKC has on cytoskeletal 
rearrangement and migration and effects on intracellular calcium release. 
 




 CXCL8 and CXCL10-activated chemotaxis in THP-1 cells is 
inhibited by PKCζi 
THP-1 cells were confirmed to express CXCR2 and CXCR3 but not CXCR1 (Figure 
17, Figure 45). The expression of CXCR2 but not CXCR1 in THP-1 cells was already 
confirmed in a study by Phillips et al. [421]. To determine the effect of PKC in CXCL8 
(5 nM) and CXCL10 (1 nM) directed THP-1 cell migration we used three inhibitors: 5 
µM GF109203X (inhibits cPKC (α and β1) and nPKC (δ and ε)), 10 nM staurosporine 
(inhibits cPKC (α and γ) and nPKC (η)), and 10 µM PKCζi were utilised in chemotaxis 
assays.  
Initially, there was a significant difference in the migration of the untreated 
basal sample and the CXCL8-activated sample with p ≤ 0.05, and with CXCL10 
activation, p ≤ 0.05 (Figure 100). Upon that, cells were treated with the PKC inhibitors 
then activated with CXCL8 (5 nM) or CXCL10 (1 nM). Treating cells with GF109203X 
or staurosporine did not cause any inhibitory effect on the THP-1 cells, however, 
PKCζi significantly reduced chemotaxis towards CXCL8 and CXCL10. An MTS assay 
determined that there was no cellular toxicity with these inhibitors (Figure 122).  
Therefore, atypical PKCζ is important for the migration of THP-1 cells towards 















Figure 100. PKCζi blocks CXCL8 and CXCL10-stimulated THP-1 cells 
chemotaxis. Multiple comparison test with PKC inhibitors demonstrates that 10 
µM PKCζi block the migration of THP-1 cells towards a) CXCL8 (5 nM), and b) 
CXCL10 (1 nM), while staurosporine (10 nM) and GF109203X (5 µM) in the 
presence of either chemokines do not affect the migration. The comparison of 
inhibitor-treated cells was made against the chemokine samples. 1% DMSO was 
added to basal cells as a vehicle control. Data shown are the mean ± SEM of at 
least three independent experiments. (One-way ANOVA with a Dunnett’s multiple 
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 PKC isoform activation is not important for CXCL8 induced 
migration in PC3 and MDA-MB231 cells 
To study the importance of PKC signalling pathway on the migration speed of MDA-
MB231 and PC3 cells activated by CXCL8, a time-lapse migration assay was 
conducted. Both cell lines express CXCR1 and CXCR2 receptors as determined 
previously by immunofluorescence assay (Figure 25, Figure 39).  
MDA-MB231 and PC3 cells were incubated with three PKC inhibitors; 5 µM 
GF109203X, or 10 nM staurosporine, or 10 µM PKCζi then stimulated with 10 nM 
CXCL8. Ten individual cells were tracked per treatment and an average speed was 
calculated.  
The basal speed of MDA-MB231 cells was 21.07 ± 7.1 µm/hr, whereas the 
addition of CXCL8 increased the speed to 42.6 ± 7.7 µm/hr (p ≤ 0.01) (Table 7). There 
were no crucial changes to cell speeds with the treatment of staurosporine (44.0 ± 
5.3 µm/hr), GF109203X (36.9 ± 4.8 µm/hr), or PKCζi (34.5 ± 7.6 µm/hr) (Figure 101). 
Furthermore, the basal speed of PC3 cells was 23.7 ± 5.4 µm/hr, and the 
addition of CXCL8 increased the speed to 58.2 ± 16.8 µm/hr (p ≤ 0.001). The 
treatment with staurosporine or GF109203X caused the average migratory speed to 
slightly drop, although not significantly, to 42.4 ± 12.1 µm/hr, and 43.4 ± 14.4 µm/hr, 
respectively. Finally, with the treatment with PKCζi, an average speed of 35.4 ± 10.4 
µm/hr was calculated. 
Therefore, out of the three inhibitors, PKCζi treatment led to a slight reduction 
in the migratory speeds of both CXCL8-activated MDA-MB231 and PC3 cells 
however, this reduction proved to not be significant. Figure 102 and Figure 103 
demonstrate the tracks of the cells with each treatment. The images used where from 
the last frame (endpoint) image obtained from the time-lapse migration assay. 
 
Table 7. The migration speed of PC3 and MDA-MB231 cells when activated with 
CXCL8 with or without PKC inhibitors. Data representative of the mean ± SD of four 













10 nM CXCL8 
(µm/hr) 
10 µM 





27.5 ± 7.1 42.6 ± 7.7 44.0 ± 5.3 36.9 ± 4.8 34.5 ± 7.6 
PC3 23.7 ± 5.4 58.2 ± 16.8 42.4 ± 12.1 43.4 ± 14.4 35.4 ± 10.4 
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Figure 101. PKC inhibitors are not important for CXCL8-activated MDA-
MB231 and PC3 cells migration. Pre-treatment with staurosporine (10 nM), 
GF109203X (5 µM), or PKCζi (10 µM) did not affect the migration speed within 
10 hrs using a time-lapse migration assay after activation with CXCL8 (10 nM) 
in a) MDA-MB231 cells, and b) PC3 cells. Comparisons were made against 
CXCL8. 1% DMSO was added to the basal cells as a vehicle control. Data shown 
are the mean ± SEM of at least five independent experiments. (One-way ANOVA 
with a Dunnett’s multiple comparisons test as post-test, n.s.= no significance, p 
> 0.05). 
 
213 | P a g e  
 
 
Figure 102. Endpoint images of time-lapse tracking of CXCL8-activated MDA-
MB231 cells with PKC inhibitors. Manual individual cell tracking using 
Fiji/ImageJ of 10 cells per experiment. a) Basal, b) CXCL8 (10 nM), c) 
staurosporine (10 nM) and CXCL8 (10 nM), d) GF109203X (5 µM) and CXCL8 (10 
nM), e) PKCζi (10 µM) and CXCL8 (10 nM). 1% DMSO was added to the basal 
cells as a vehicle control. Experiments were repeated five times. Images are 
representative of the cell population and were taken at 10x objective with a Zeiss 
Axiovert 200M microscope and processed using AxioVision Rel 4.8 software. 
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Figure 103. Endpoint images of time-lapse tracking of CXCL8-activated PC3 
cells with PKC inhibitors. Manual individual cell tracking using Fiji/ImageJ of 10 
cells per experiment. a) Basal, b) CXCL8 (10 nM), c) staurosporine (10 nM) and 
CXCL8 (10 nM), d) GF109203X (5 µM) and CXCL8 (10 nM), e) PKCζi (10 µM) and 
CXCL8 (10 nM). 1% DMSO was added to the basal cells as a vehicle control. 
Experiments were repeated five times. Images are representative of the cell 
population and were taken at 10x objective with a Zeiss Axiovert 200M microscope 
and processed using AxioVision Rel 4.8 software. 
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 CXCL10 relies on PKC signalling for migration of PC3 and MDA-
MB231 cells 
Although PKC inhibitors do not significantly change the migratory speed of PC3 and 
MDA-MB231 cells upon activation with CXCL8, in the presence of CXCL10 (10 nM) 
there were significant changes. PC3 and MDA-MB231 cells both express CXCR3 
receptor (Figure 48, Figure 51), which has also been confirmed by other reports 
[226], [578] respectively.  
MDA-MB231 cells with no treatment had a speed of 18.9 ± 6.3 µm/hr, whereas 
the addition of CXCL10 (10 nM) increased the speed to 31.2 ± 5.2 µm/hr (p ≤ 0.05) 
(Table 8). Cells were treated with PKC inhibitors and activated with CXCL10. PKCζi 
(10 µM) treatment caused a significant decrease in the migratory speed to 20.1 ± 3.2 
µm/hr. GF109203X treatment caused a further reduction to 17.6 ± 2.6 µm/hr. 
Staurosporine, however, did not cause a difference to the migratory speed; 29.8 ± 5.6 
µm/hr (Figure 104). 
CXCL10-activated PC3 cells were also affected by the additions of the three 
PKC inhibitors. Basal untreated cells had a speed of 18.9 ± 2.7 µm/hr, whereas with 
CXCL10 (10 nM) activation, cells migrated faster at a speed of 50.4 ± 3.4 µm/hr (p ≤ 
0.01). The speed of migration was reduced significantly with the staurosporine, 
GF109203X and PKCζi, giving a speed of 32.3 ± 5.8 µm/hr, 26.9 ± 9 µm/hr, and 16.6 
± 3.4 µm/hr, respectively. The cells track in Figure 105 and Figure 106 shows the 
differences in the migrating distance with some treatments relative to the controls. 
Moreover, MTS assay showed no cytotoxicity when PC3 cells and MDA-MB231 cells 
were incubated with the equivalent concentrations of PKC inhibitors (Figure 122).  
 Thus, PKCs involvement in cell migration is cell-type and chemokine specific. 
 
Table 8. The migration speed of PC3 and MDA-MB231 cells when activated with 
CXCL10 with and without PKC inhibitors. Data representative of the mean ± SD of 













10 nM CXCL10 
(µm/hr) 
10 µM  





18.9 ± 6.3 31.2 ± 5.2 29.8 ± 5.6 17.6 ± 2.6 20.1 ± 3.2 
PC3 18.9 ± 2.7 50.4 ± 8.7 32.3 ± 5.8 26.9 ± 8.0 16.6 ± 3.4 
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Figure 104. PKC inhibitors affect CXCL10-induced MDA-MB231 and PC3 cells 
migration speed. Pre-treatment with staurosporine (10 nM), GF109203X (5 µM), or 
PKCζi (10 µM) followed by activation with CXCL10 (10 nM) affected the migration of 
a) MDA-MB231 cells, and b) PC3 cells. Comparisons were made against CXCL10. 
1% DMSO was added to the basal cells as a vehicle control. Data are representative 
of the mean ± SEM of at least four independent experiments. (One-way ANOVA with 
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Figure 105. Endpoint images of time-lapse tracking of CXCL10-activated MDA-
MB231 cells with PKC inhibitors. Manual individual cell tracking using Fiji/ImageJ 
of 10 cells per experiment. a) Basal, b) CXCL10 (10 nM), c) staurosporine (10 nM) 
and CXCL10 (10 nM), d) GF109203X (5 µM) and CXCL10 (10 nM), e) PKCζi (10 µM) 
and CXCL10 (10 nM). 1% DMSO was added to the basal cells as a vehicle control. 
Experiments were repeated four times. Images are representative of the cell 
population and were taken at 10x objective with a Zeiss Axiovert 200M microscope 
and processed using AxioVision Rel 4.8 software. 
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Figure 106. Endpoint images of time-lapse tracking of CXCL10-activated PC3 
cells with PKC inhibitors. Manual individual cell tracking using Fiji/ImageJ of 10 
cells per experiment. a) Basal, b) CXCL10 (10 nM), c) staurosporine (10 nM) and 
CXCL10 (10 nM), d) GF109203X (5 µM) and CXCL10 (10 nM), e) PKCζi (10 µM) 
and CXCL10 (10 nM). 1% DMSO was added to the basal cells as a vehicle control. 
Experiments were repeated four times. Images are representative of the cell 
population and were taken at 10x objective with a Zeiss Axiovert 200M microscope 
and processed using AxioVision Rel 4.8 software. 
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 PKC inhibitors reduce the migration of CXCL10-activated PC3 
cells, but not of CXCL8 activated cells 
An Oris migration assay was performed to confirm the role of PKC isoforms in PC3 
cells. Briefly, cells were left to adhere around a gel stopper followed by the removal 
of the gel stopper where the cells would respond to the stimulus by migrating towards 
the detection zone.  
PC3 cells were treated with the three PKC inhibitors; 10 nM staurosporine, or 
5 µM GF109203X, or 10 µM PKCζi then stimulated with 10 nM CXCL8 or 10 nM 
CXCL10. Upon staining the cells with calcein (4 µM), the fluorescence of the cells 
which migrated towards the detection zone was measured.  
Untreated PC3 cells did not show a significant difference to cells activated 
with either CXCL8 or CXCL10. However, an increase is still noticed with the activation 
with both chemokines (Figure 107). We carried on treating the cells with PKC 
inhibitors. Upon activation with CXCL8 there was a modest reduction of migration with 
staurosporine, or GF109203X, or PKCζi, however, the reduction was not significant.  
Furthermore, treating the cells with the same set of inhibitors but instead, 
activating with CXCL10 showed that both staurosporine and PKCζi reduced the 
migration to almost the level of the basal sample (Figure 107b). On the other hand, 
GF109203X significantly decreased the migration to even lower levels relative to the 
untreated basal sample. 
These results agree with the previous time-lapse migration assay data 
showing that PKC inhibitors did not cause a substantial change to the migration speed 
of CXCL8-activated PC3 cells but caused a noticeable reduction in CXCL10-activated 
cells. This data, however, is not conclusive mainly because there was a lack of 
significance between the untreated and chemokine-activated samples. This lack of 
significance is likely related to cells behaviour observed during these experiments 
where PC3 cells tend to cluster around the sides of the wells instead of migrating 
towards the detection zone in the middle of the well, hence the large error bars 
present. 
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Figure 107. The effect of PKC inhibitors on PC3 cells migration with CXCL8 
or CXCL10 using an Oris migration assay. Pre-treatment of PC3 cells with 
staurosporine (10 nM), GF109203X (5 µM), or PKCζi (10 µM) then stimulated with 
a) CXCL8 (10 nM), or b) CXCL10 (10 nM). The comparisons of the inhibitor-treated 
cells were made against the chemokine samples. 1% DMSO was added to the 
basal cells as a vehicle control. Data representative of the mean ± SEM of at least 
three independent experiments. (One-way ANOVA with a Dunnett’s multiple 





221 | P a g e  
 
 The PKC inhibitor staurosporine influences the cellular 
morphology of PC3 and MDA-MB231 cells 
To determine the change of cellular morphology after 10 hrs incubation with PKC 
inhibitors with or without CXCL8 (10 nM) or CXCL10 (10 nM), manual drawing around 
the cells was conducted and analysed. The characterisation of the cellular 
morphology changes was resembled by the alternation to the cell area, the circularity, 
and aspect ratio.  
The results below are laid out to show the changes in cell shape, followed by 
the analysis plotted in a graph. The images were obtained from the previous time-
lapse migration assay where the last frame indicating the end point of 10 hrs images 
was obtained and analysed. MDA-MB231 cells were treated with the three PKC 
inhibitors; 10 nM staurosporine, or 5 µM GF109203X, or 10 µM PKCζi then stimulated 
with 10 nM CXCL8. Visual observation of the cells with different treatments showed 
that staurosporine-treated cells demonstrated the most distinct shape change relative 
to the control and inhibitor samples (Figure 108). Cells were extensively elongated 
and thinned out. Some cells stretched out with GF109203X and PKCζi but not as 
dramatic. Notably, in the CXCL8-activated cells sample, there were slightly more 
elongated cells compared to the inactivated basal cells. The analysis in Figure 109 
confirm that staurosporine out of the other inhibitors or control samples was the one 
to induce a significant decrease in the circularity (where the y-axis reflects that moving 
closer to 0 generates a prolonged shape while 1 denotes full circle). There was also 
an increase in the aspect ratio (indication of the ratio of long axis (width) to the short 
axis (length)). There were not any remarkable changes with the other treatments. 
Furthermore, PC3 cells were treated in the same conditions and same set of 
inhibitors. Again, staurosporine has generated a notable effect on the cells. This effect 
was characterized by cells looking almost 1.5 times bigger than the other treatment 
(Figure 110). The data analysis showed that staurosporine affected the area, 
circularity, and aspect ratio significantly, whereas GF109203X and PKCζi did not 
(Figure 111). 
 




Figure 108. Illustrative images demonstrating morphological changes of 
CXCL8-activated MDA-MB231 cells with or without PKC inhibitors. a) Basal, b) 
CXCL8 (10 nM), c) staurosporine (10 nM) and CXCL8 (10 nM), d) GF109203X (5 
µM) and CXCL8 (10 nM), e) PKCζi (10 µM) and CXCL8 (10 nM). 1% DMSO was 
added to the basal cells as a vehicle control. Cells were outlined using Fiji/ImageJ 
and measurements of 70 cells per image per experiment were analysed and 
repeated three independent times. Images are representative of the cell population 
and were taken at 10x objective with a Zeiss Axiovert 200M microscope and 
processed using AxioVision Rel 4.8 software. 
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Figure 109. Cellular morphology analysis of MDA-MB231 cells treated with 
CXCL8 in the presence or absence of PKC inhibitors. Upon cells activation with 
CXCL8 (10 nM), pre-treatment with staurosporine (10 nM) yielded a significant effect 
on cells circularity and aspect ratio, whereas the treatment with GF109203X (5 µM), 
or PKCζi (10 µM) did not have any crucial effects. The comparisons were made 
against the CXCL8 sample. 1% DMSO was added to the basal cells as a vehicle 
control. Cells were outlined and measurements of a) area, b) circularity, and c) 
aspect ratio were an analysed for an average of 70 cells per image per experiment 
and repeated three independent times. (One-way ANOVA with a Dunnett’s multiple 
comparisons test as post-test, n.s.= no significance, *** = p ≤ 0.001, **** = p ≤ 
0.0001).  
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Figure 110. Illustrative images demonstrating morphological changes of 
CXCL8-activated PC3 cells with or without PKC inhibitors. a) Basal, b) CXCL8 
(10 nM), c) staurosporine (10 nM) and CXCL8 (10 nM), d) GF109203X (5 µM) and 
CXCL8 (10 nM), e) PKCζi (10 µM) and CXCL8 (10 nM). 1% DMSO was added to 
the basal cells as a vehicle control. Cells were outlined using Fiji/ImageJ and 
measurements of 70 cells per image per experiment were analysed and repeated 
three independent times. Images are representative of the cell population and were 
taken at 10x objective with a Zeiss Axiovert 200M microscope and processed using 
AxioVision Rel 4.8 software.  
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Figure 111. Cellular morphology analysis of PC3 cells treated with CXCL8 in 
the presence or absence of PKC inhibitors. Upon cells activation with CXCL8 
(10 nM), pre-treatment with staurosporine (10 nM) yielded a significant effect on 
cells area, circularity, and aspect ratio, whereas the treatment with GF109203X (5 
µM), or PKCζi (10 µM) did not have any crucial effects. 1% DMSO was added to 
the basal cells as a vehicle control. Cells were outlined and measurements of a) 
area, b) circularity, and c) aspect ratio were analysed for an average of 70 cells per 
image per experiment and repeated three independent times. Comparisons were 
made against CXCL8. (One-way ANOVA with a Dunnett’s multiple comparisons 
test as post-test, * = p ≤ 0.05, ** = p ≤ 0.01). 
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The cellular morphology changes upon treating MDA-MB231 with PKC 
inhibitors followed by activation with CXCL10 (10 nM) is reported. Visual assessment 
of the cells shows again that 10 nM staurosporine treatment allowed the cells to 
assume a long shape, although the size of the cells did not seem to be different. 
GF109203X (5 µM) and PKCζi (10 µM) looked relatively similar to the control samples 
(Figure 112). Statistical analysis was generated by zooming into the images to ease 
the process of manually drawing around the cells considering the small size of the 
cells. These analyses verify the significant effect generated on the cellular circularity 
and aspect ratio with staurosporine treatment with no notable effect by the other two 
inhibitors (Figure 113).   
Moreover, treatment of PC3 cells with the previous PKC inhibitors followed by 
the activation with CXCL10 (10 nM) revealed slightly different outcomes. Here, 
GF109203X (5 µM) and staurosporine (10 µM) images show that cells look slightly 
smaller in size, and more circular (Figure 114). Data analysis reveal that the aspect 
ratio is significantly different with both GF109203X and staurosporine treatment, with 
no effect generated by PKCζi (10 µM) (Figure 115). 
 




Figure 112. Illustrative images demonstrating morphological changes of 
CXCL10-activated MDA-MB231 cells with or without PKC inhibitors. a) Basal, 
b) CXCL10 (10 nM), c) staurosporine (10 nM) and CXCL10 (10 nM), d) GF109203X 
(5 µM) and CXCL10 (10 nM), e) PKCζi (10 µM) and CXCL10 (10 nM). 1% DMSO 
was added to the basal cells as a vehicle control. Cells were outlined using 
Fiji/ImageJ and measurements of 70 cells per image per experiment were analysed 
and repeated three independent times. Images are representative of the cell 
population and were taken at 10x objective with a Zeiss Axiovert 200M microscope 
and processed using AxioVision Rel 4.8 software.  
 
228 | P a g e  
 
 
Figure 113. Cellular morphology analysis of MDA-MB231 cells treated with 
CXCL10 in the presence or absence of PKC inhibitors. Upon cells activation 
with CXCL10 (10 nM), pre-treatment with staurosporine (10 nM) yielded a 
significant change of the cells’ circularity and aspect ratio, whereas the treatment 
with GF109203X (5 µM), or PKCζi (10 µM) did not have any crucial effects. 1% 
DMSO was added to the basal cells as a vehicle control. Cells were outlined and 
measurements of a) area, b) circularity, and c) aspect ratio were analysed of an 
average of 70 cells per image per experiment and repeated three independent 
times. Comparisons were made against CXCL10. (One-way ANOVA with a 
Dunnett’s multiple comparisons test as post-test, * = p ≤ 0.05, ** = p ≤ 0.01).  
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Figure 114. Illustrative images demonstrating morphological changes of 
CXCL10-activated PC3 cells in the presence or absence of PKC inhibitors. a) 
Basal, b) CXCL10 (10 nM), c) staurosporine (10 nM) and CXCL10 (10 nM), d) 
GF109203X (5 µM) and CXCL10 (10 nM), e) PKCζi (10 µM) and CXCL10 (10 nM). 
Cells were outlined using Fiji/ImageJ. 1% DMSO was added to the basal cells as a 
vehicle control. Cells were outlined using Fiji/ImageJ and measurements of 70 cells 
per image per experiment were analysed and repeated three independent times. 
Images are representative of the cell population and were taken at 10x objective 
with a Zeiss Axiovert 200M microscope and processed using AxioVision Rel 4.8 
software. 
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Figure 115. Cellular morphology analysis of PC3 cells treated with CXCL10 in 
the presence or absence of PKC inhibitors. Upon cells activation with CXCL10 
(10 nM), pre-treatment with staurosporine (10 nM) and GF109203X (5 µM) yielded 
a significant effect on cells aspect ratio, whereas the treatment PKCζi (10 µM) did 
not have any crucial effects. 1% DMSO was added to the cells as a vehicle control. 
Cells were outlined and measurements of a) area, b) circularity, and c) aspect ratio 
were analysed of an average of 70 cells per image per experiment and were 
repeated at least three times. Comparisons were made against CXCL10. (One-way 
ANOVA with a Dunnett’s multiple comparisons test as post-test, n.s.= no 
significance p > 0.05, * = p ≤ 0.05). 
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 Staurosporine effects actin rearrangement of PC3 and MDA-
MB231 cells 
PKCs reside in the cytosol in an inactive state. When activated they relocate to the 
plasma membrane or to subcellular sites (e.g. Golgi apparatus, or ER) to engage in 
various cellular functions, such as the rearrangement of the cytoskeleton and 
migration [571], [386]. Cancer cell migration is crucially dependent on the changes of 
the cell’s morphology endorsed by dynamic modifications of actin polymerization 
causing rearrangement of the cytoskeleton [579].  
Due to the low objective (10x) used in the previous experiment as well as 
limitations hindering our ability to decide the sort of changes happening inside the 
cells, we went on to stain the actin and visually assess the changes happening with 
a higher objective (63x). Phalloidin-iFlour 488 is a series of phalloidin conjugates that 
bind to actin filaments, also known as F-actin. Fixed monolayer of cells stained with 
phalloidin conjugates were visible with fluorescence microscopy at an 
excitation/emission= 493/517 nm.  
Results showed that cells treated with the three PKC inhibitors; 10 nM 
staurosporine, or 5 µM GF109203X, or 10 µM PKCζi without the stimulation with the 
chemokine did not have a substantial effect on the actin cytoskeleton rearrangement 
in both PC3 and MDA-MB231 cells (Figure 116). Even though staurosporine shows 
inhibitory activity against a wide spectrum of kinases, including PKC, no elongation 
to the cells was observed in the absence of the stimulus.  
Activation of cells with CXCL8 (10 nM) with and without PKC inhibitors, and 
its effect on inducing changes in the patterns of actin filaments rearrangement is 
reported. Comparison between the basal and CXCL8-activated cells did not show any 
substantial changes to the actin filaments. Pre-treatment of cells with GF109203X 
and PKCζi followed by stimulation with CXCL8 also did not show great changes to 
the rearrangement of the actin cytoskeleton. However, staurosporine treatment with 
CXCL8 activation immensely disrupted the cell structure. The disruption is 
characterised by thin elongated microfilament bundles along with a tangled network 
of cells overlapping with sticky endings of accumulating crosslinked actin filaments.  
Moreover, when MDA-MB231 cells were activated with CXCL10 (10 nM), 
nothing major to the morphology of the cells was noted. However, in the presence of 
CXCL10, staurosporine-treated cells formed visible actin stress fibres with peripheral 
microspikes or filopodia pointed with the red arrows (Figure 116). GF109203X-
treated cells appeared somehow more elongated too, while with PKCζi-treated did 
not look any different. 
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Figure 116. Fluorescence microscopy of actin polymerization in MDA-MB231 cells. 
Cells treated with CXCL8 (10 nM) or CXCL10 (10 nM) with or without PKC inhibitors- 
staurosporine (10 nM), GF109203X (5 µM), PKCζi (10 µM). Rapid elongation of cells 
forming sticky ending in a form of network appeared in CXCL8 and staurosporine treated 
cells. CXCL10 and staurosporine addition formed visible microspikes of filopodia, 
indicated by the red arrows. Cells were fixed and stained with Alexa-488 Phalloidin actin 
stain (green), and nucleus stain with DAPI (blue). Images are representative of the cell 
population of one experiment out of three independent repeats, acquired at 63x objective 
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In PC3 cells, the control and CXCL8 (10 nM) activated cells appeared to be 
similar in the cell morphology (Figure 117). Like before, cells were treated with PKC 
inhibitors and stimulated with CXCL8. Cells treated with staurosporine (10 nM) 
appeared to have accumulated protrusive endings forming sticky clusters at their 
leading edges, along with extensive stretching to the cell bodies with actin clumps 
spread throughout the cell margins. With GF109203X (5 µM) treatment, presence of 
dotty build-ups inside the cells was noticed.  Moreover, in both GF109203X and PKCζi 
(10 µM) treatment, cells appeared to have developed more membrane ruffles.  
Furthermore, comparing the control sample with CXCL10-stimulated cells 
showed that the latter exhibited modest appearance of membrane ruffles (Figure 
117). These membrane ruffles are characterized by the formation of actin rich 
membrane protrusions [580]. Staurosporine treatment showed a remarkable amount 
of actin-enriched branched lamellipodia and membrane ruffles and again cells were 
elongated and interlaced over each other. Finally, GF109203X and PKCζi did not 
induce notable changes to the actin cytoskeleton. 
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Figure 117. Fluorescence microscopy of actin polymerization in PC3 cells. Cells 
treated with CXCL8 (10 nM) or CXCL10 (10 nM) with or without PKC inhibitors- 
staurosporine (10 nM), GF109203X (5 µM), PKCζi (10 µM). Actin-enriched 
lamellipodia and membrane ruffles appeared at the endings of staurosporine treated 
cells in the presence of CXCL8 or CXCL10, pointed out with the red arrows. Cells 
were fixed and stained with Alexa-488 Phalloidin actin stain (green), and nucleus stain 
with DAPI (blue). Images representative of the cell population of one experiment out 
of three independent repeats, acquired at 63x objective using a Leica DMII 
fluorescence microscope and Leica imaging suite. 
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 PKC inhibitors affect the release of intracellular calcium in THP-1, 
MDA-MB231, PC3 and MCF-7 cells 
We have seen in chapter 3 that the stimulation of CXCR1-CXCR2 or CXCR3 
induces a rapid rise in the intracellular calcium. PKCs inhibitors were used to 
elucidate the importance of PKC in the release of intracellular calcium upon 
activation with CXCL8 or CXCL10. Cells incubated with PKC inhibitors for 30 mins 
and activated with 200 nM CXCL8 or 100 nM CXCL10 gave varying intracellular 
calcium release responses. 
MDA-MB231 cells activated with 200 nM CXCL8 showed no effect on 
intracellular calcium release with staurosporine (10 nM) or PKCζi (10 µM) pre-
treatment, but a slight reduction appeared with GF109203X (5 µM). Moreover, cells 
incubated with staurosporine (10 nM) or GF109203X (5 µM) followed by activation 
with 100 nM CXCL10 slightly reduced the release of calcium but not PKCζi (10 µM) 
(Figure 118). 
THP-1 cells treated with 10 nM staurosporine or 5 µM GF109203X 
significantly reduced the release of calcium upon activation with 200 nM CXCL8. 
There was also a similar trend with 100 nM CXCL10-activated cells, although not 
significant. PKCζi treatment reduced calcium release slightly but not as much as the 
two other inhibitors with both chemokines (Figure 119). 
MCF-7 cells treatment with 5 µM GF109203X and activation with CXCL8 
caused a significant reduction to the release of calcium. However, 10 nM 
staurosporine and PKCζi (10 µM) with CXCL8 (200 nM) or CXCL10 (100 nM) 
activation did not cause substantial changes to calcium release (Figure 120). 
PC3 cells were treated with 10 nm staurosporine, 5 µM GF109203X and 10 
µm PKCζi followed by activation with 200 nM CXCL8. From these experiments it was 
observed that there was significantly reduced intracellular calcium release when cells 
were incubated with staurosporine or GF109203X but no significance with PKCζi 
(Figure 121). Studies have noted that CXCL10 binding to its receptor CXCR3B is not 
associated with calcium flux, however, binding to CXCR3A was found to induce 
calcium mobilization [205], [230], [581]. In PC3 cells, the level of expression of either 
CXCR3A or CXCRB is not well determined. Therefore, we could not conclude the 
final outcome of calcium release upon induction with CXCL10.  
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Figure 118. Effect of PKC inhibitors on the intracellular calcium release of CXCL8 
or CXCL10 activated MDA-MB231 cells. a) None of the inhibitors: staurosporine (10 
nM), GF109203X (5 µM), or PKCζi (10 µM) caused a significant effect on calcium 
release upon activation with 200 nM CXCL8, although there was a slight reduction with 
GF109203X treatment. b) intracellular calcium measurement traces were taken from a 
representative experiment. c) although GF109203X and staurosporine slightly reduced 
the release of calcium in 100 nM CXCL10-activated MDA-MB231 cells but not PKCζi, 
no significant difference was noted. d) intracellular calcium measurement traces were 
taken from a representative experiment. 1% DMSO was added to the cells as a vehicle 
control. Data represents the mean ± SEM of at least three independent experiments. 
(One-way ANOVA with a Dunnett’s multiple comparisons test as post-test, n.s. = no 
significance p> 0.05). Data are expressed as the relative ratio of fluorescence emitted 
at 510 nm after sequential stimulation at 340 and 380 nm. 
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Figure 119. Effect of PKC inhibitors on the intracellular calcium release of CXCL8 
or CXCL10 activated THP-1 cells. a) staurosporine (10 nM) and GF109203X (5 µM) 
significantly reduced calcium release, and PKCζi (10 µM) had a slight reduction effect 
on 200 nM CXCL8-activated cells. b) intracellular calcium measurement traces were 
taken from a representative experiment. c) 100 nM CXCL10-activated THP-1 cells 
showed a similar decrease of calcium release, although not significant. d) intracellular 
calcium measurement traces are taken from a representative experiment. 1% DMSO 
was added to the cells as a vehicle control. Data represents the mean ± SEM of at least 
three independent experiments. (One-way ANOVA with a Dunnett’s multiple 
comparisons test as post-test, n.s. = no significance p > 0.05, * = p ≤ 0.05). Data are 
expressed as the relative ratio of fluorescence emitted at 510 nm after sequential 
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Figure 120. Effect of PKC inhibitors on the intracellular calcium release of 
CXCL8 or CXCL10 activated MCF-7 cells. a) GF109203X (5 µM) had significantly 
reduced the release of calcium in 200 nM CXCL8-activated MCF-7 cells, and 
staurosporine had a small effect on reducing calcium release but PKCζi did not have 
an effect. b) 100 nM CXCL10-activated MCF-7 calcium release was slightly reduced 
by staurosporine and GF109203X but not PKCζi, with no significant difference with 
any of the inhibitors. 1% DMSO was added to the cells as a vehicle control. Data 
represents the mean ± SEM of at least three independent experiments (One-way 
ANOVA with a Dunnett’s multiple comparisons test as post-test, n.s. = no 
significance p > 0.05, * = p ≤ 0.05). Data are expressed as the relative ratio of 
fluorescence emitted at 510 nm after sequential stimulation at 340 and 380 nm. 
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Figure 121. Effect of PKC inhibitors on the intracellular calcium release of 
CXCL8 activated PC3 cells. a) staurosporine (10 nM) and GF109203X (5 µM) 
significantly reduced calcium flux of 200 nM CXCL8-activated PC3 cells, but PKCζi 
(10 µM) had no effect. b) intracellular calcium measurement traces are taken from 
a representative experiment. 1% DMSO was added to the cells a vehicle control. 
Data represents the mean ± SEM of at least three independent experiments. (One-
way ANOVA with a Dunnett’s multiple comparisons test as post-test, n.s. = no 
significance p > 0.05, * = p ≤ 0.05). Data are expressed as the relative ratio of 
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 MTS cytotoxic assay to quantify the cytotoxicity of PKC inhibitors 
No cytotoxicity was reported when PKC inhibitors: 10 nM staurosporine, 5 µM 
GF109203X, and 10 µM PKCζi were incubated for 24 hrs with MDA-MB231, PC3 and 
THP-1 cells, as indicated in Figure 122. 
 
Figure 122. Toxicity of PKC inhibitors. The absorbance following incubation with 
staurosporine (10 nM), GF109203X (5 µM), or PKCζi (10 µM) incubated with a) 
THP-1, b) PC3, and c) MDA-MB231 cells for 24 hrs and MTS reagent for 2 hrs. 1% 
DMSO was added to the basal cells as a vehicle control. Data representative of the 
mean ± SEM of three independent experiments. (Kruskal-Wallis test, Dunn’s 
multiple comparisons test, n.s.= no significance p > 0.05). 
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 Discussion 
Overexpression of chemokine receptors is thought to be a contributing factor in 
providing navigational cues for cancer cells to metastasize [582]. Therefore, 
investigating the mechanisms of migration can give a better understanding on how to 
block cancer cells metastasizing. CXCL8 acting on its receptors, CXCR1 and CXCR2, 
within the tumour microenvironment was found to be associated with cancer migration 
and proliferation [131]. Also, CXCR3 is found to be expressed in lymphatic leukaemia, 
splenic marginal zone lymphoma and breast cancer cells [578], suggesting its 
correlation to tumour progression and metastasis [583]. Although many studies have 
been trying to address the main signalling pathways involved in cell migration, there 
is still a knowledge gap with regards to whether PKC signalling is a positive or 
negative factor in cancer metastasis. Our approach was to investigate the role PKC 
plays in the migration and morphology change of different cancer cells which have 
been activated by either CXCL8 or CXCL10. 
We studied the role of PKC family members in chemokine mediated migration 
by using small molecule inhibitors acting on different subtypes. We have already 
reported that PKC inhibition had no effect upon CCL3 migration in THP-1 cells [387]. 
However, Hamshaw et al. [389] found that PKC and PKD were important for the 
migration of CXCL12-activated PC3 cells. In addition, the migration of CXCL12-
stimulated MCF-7 cells was reported to be blocked by PKC inhibitors but not Jurkat 
cells [388]. Here, we observed that both CXCL8 and CXCL10 promote cells to migrate 
faster comparing with the untreated control, yet when we added PKC inhibitors, cells 
reacted differently based on the chemokine and PKC inhibitor used.  
Conventional (PKC α, β, γ), novel (PKC η, δ, ε), or atypical PKCζ isozymes 
are not important for CXCL8-induced MDA-MB231 and PC3 cells migration, but 
atypical PKCζ is crucial for THP-1 cells migration. The PKC inhibitor GF109203X- a 
less specific inhibitor of PKCα, β1, δ, and ε, staurosporine- inhibitor of PKCα, γ and 
η, as well as PKCζi did not affect the speed of migration of PC3 and MDA-MB231 
cells when activated with CXCL8. This was confirmed using Oris migration assays, 
where CXCL8-activated PC3 cells incubated with staurosporine, GF109203X, and 
PKCζi did not cause an effect on migration. Moreover, using these inhibitors in THP-
1 cell chemotaxis, we found that only PKCζi significantly reduced the number of cells 
migrating toward CXCL8. Guo et al. [584] reported that PKCζi blocked CSF-1 induced 
THP-1 chemotaxis and confirmed this with knocking down PKCζ with siRNA 
technique. Lie et al. [585] also found that PKCζ inhibition has reduced the chemotactic 
abilities of EGF-induced NSCLC cells. On the other hand, GF109203X had lowered 
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renal cancer cell migration using chemotaxis assay [586] and blocked CCL5-
mediated migration [587]. Additionally, in former studies we reported that knocking 
down PKCα in MCF-7 and Jurkat cells abrogated cells migration towards CXCL12, 
while PKCζ did not have an effect [388]. Taking it together, we conclude that atypical 
PKCζi block the migration of CXCL8 activated THP-1 cells, while PKCζi, GF109203X 
and staurosporine did not have an effect on the CXCL8-induced migration of PC3 and 
MDA-MB231 cells.  
In contrast, using the same set of inhibitors, we found that staurosporine (acts 
on PKC: α, γ, η), GF109203X (acts on PKC α, β, δ, ε) and PKCζi reduced the 
migration of CXCL10-activated PC3 cells. The migration speed of CXCL10-activated 
MDA-MB231 cells was also inhibited by GF109203X and PKCζi but not 
staurosporine. PKCζi was crucial for THP-1 cells chemotaxis, but GF109203X and 
staurosporine were not. Performing Oris migration assay on PC3 cells showed a 
lower migration rate of cells induced with CXCL10 and the PKC inhibitors. Although 
there was a trend that confirms the time-lapse migration assay results, yet they were 
fluctuating results demonstrated by high standard error (Figure 107b). This could be 
due to the migration pattern of PC3 cells, migrating to the sides of the Oris wells 
instead of the detection centre area where they would be detected.  
Mills et al. [388] speculated that due to the different behaviours of PKC 
inhibitors on MCF-7 and Jurkat cells migration, MCF-7 could be using the catalytic 
region of PKC because knocking down PKCα and PKCζ have totally abrogated the 
migration of the cells, while Jurkat cells could be using another PKC domain because 
of the varying actions it causes on migration. It could also be due to certain isoform 
levels being elevated in these cell lines, and therefore they would be more prone to 
be targeted to inhibition. For example, MDA-MB231 cells were found to have 
increased levels of PKCε and were suggested to be used as a biomarker for 
aggressive breast cancer [588]. Additionally, inhibition of PKCε was associated with 
the inhibition of breast cancer cells migration as well as a mediator of EMT [589]. 
Therefore, the role of PKCε could further be investigated by testing selective inhibitors 
targeting this isoform, which should allow for improved and precise therapeutic 
intervention.   
Cell migration is characterized by a series of morphological changes, 
endorsed by dynamic modifications of actin polymerization causing rearrangement of 
the cytoskeleton [491]. Accumulating evidence confirmed that PKC substrates 
phosphorylate many cytoskeletal proteins triggering dynamic alternations that lead 
cell adhesion and migration [386], [590], [591]. During the process of migration, actin 
filaments arrange in three-dimensional assemblies preparing for the next move [40]. 
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The leading edge of the cell will contain protrusive structures called lamellipodia and 
filopodia. Lamellipodia are cellular sheets branched of actin network serving as the 
mechanical force to move the cell forward. Filopodia are formed of tight parallel 
bundles of F-actin that shape like spikes to detect changes in the microenvironment. 
When activated, an elongation of the protrusion of the leading edge (containing the 
filopodia and lamellipodia) will lead cell movement. On the other hand, the contraction 
of the cells which also mediates the preparation of the cell to move is generated by 
stress fibres acting as contractile structures. They are formed of actin and myosin 
bundles, also known as actomyosin structures, generating contractile forces for cell 
migration and morphogenesis [456].  
Incubating cells with PKC inhibitors have presented some contradictory 
results dependent upon the chemokine used (Figure 123). Although staurosporine, 
GF109203X, and PKCζi did not cause any significant difference in the migration of 
CXCL8-activated PC3 and MDA-MB231 cells, staurosporine made a substantial 
change in the area, circularity or aspect ratio of both cell lines imaged using brightfield 
microscope. This was confirmed with observations of phalloidin-stained actin 
microfilaments with fluorescence microscopy generating a major actin disruption to 
the cells. Actin-enriched lamellipodia and membrane ruffles appeared at the tips of 
CXCL8-activated PC3 cells treated with staurosporine (Figure 117). MDA-MB231 
cells treated with staurosporine and activated with CXCL8 showed a tangled network 
of cells overlapping over each other, as well as stretching their cytoskeleton. Both in 
brightfield and fluorescence microscope, cells displayed long spindled shapes with 
thinning to the cells’ bodies exhibiting sticky endings with slender protrusions. Cell 
migration involving polymerization and depolymerisation of actin filaments in 
lamellipodia or membrane ruffles [456] were not affected by the changes 
staurosporine cause on both cell lines suggesting a different independent mechanism 
of action taking place. 
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Figure 123. Illustration of the effect of PKC inhibitors on CXCL8 or CXCL10-
activated MDA-MB231 or PC3 cells. Staurosporine inhibits PKCα, γ, and η, 
GF109203X inhibits PKC α, β, δ, and ε, and PKCζi inhibits PKCζ. ‘No’ denotes no 
effect, and ‘Yes’ denotes a significant effect on the cell migration speed or cellular 
morphology. 
 
CXCL10-activated cells were also not affected by PKCζi, but staurosporine 
and GF109203X caused some morphological changes to PC3 or MDA-MB231 cells. 
GF109203X significantly changed the aspect ratio of CXCL10-activated PC3 cells. 
Hamshaw et al. [389] found that GF109203X reduced the size of CXCL12-activated 
PC3 cells with an increase to the number of cellular protrusions. Another study found 
that overexpression of PKCε (one of the PKC isoforms inhibited by GF109203X) 
displayed a polarized shape change to fibroblasts resulting in the formation of long 
cellular membrane protrusions [592]. PKCε was found to be associated with Rac1 
activation [403] which is known for its role in migration and formation of lamellipodia 
[435], [546]. Indeed, PKCε expression was already confirmed in prostate cancer cells 
[403]. Another possibility for the morphology change assumed by GF109203X 
treatment is that RhoA could act downstream of PKC which leads to actin 
reorganisation. This was evident by Brandt et al. [593] who found that GF109203X 
blocked RhoA signalling in the vascular smooth muscle A7r5 cells. In addition, it was 
proposed that PKCε could induce EMT via downstream signals RhoC and STAT3, 
which mediate EMT regulation [588], [589], [594]. Moreover, the circularity of 
CXCL10-activated MDA-MB231 cells and aspect ratio of PC3 cells were challenged 
by staurosporine treatment where a rapid and dramatic disruption of actin stress fibres 
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with peripheral microspikes or filopodia formation in MDA-MB231 cells was observed. 
Ruffles accumulating at the membrane of CXCL10-activated PC3 cells treated with 
staurosporine were also observed. Collectively, although the morphological changes 
GF109203X and staurosporine induce on CXCL10-activated PC3 were associated 
with a reduction of the migration speed of the cells, this was not the case with CXCL8-
activated PC3 or MDA-MB231 cells.  
Staurosporine and GF109203X reduced the release of intracellular calcium in 
THP-1, MCF-7, MDA-MB231, and PC3 cells upon CXCL8 or CXCL10 induction either 
with a reduced trend or significantly, however, PKCζi did not have an effect on calcium 
release. This agrees with a study showing that staurosporine inhibit calcium influx 
from the external medium in antigen-induced RBL-2H3 cells [595]. Another study 
found that GF109203X inhibited the intracellular release of calcium in histamine-
induced DD1 MF-2 muscle cells [596]. However, Hamshaw et al. [389] and Goh. [434] 
showed that there was no reduction in calcium release upon incubation with PKC 
inhibitors and stimulation with CXCL12 in PC3 and MCF-7 cells. Therefore, the 
involvement of PKC isoforms in specific intracellular signalling pathways is dependent 
on the external stimulus activating them.  
Staurosporine is a competitive PKC inhibitor with a high binding affinity and 
low specificity. It targets PKCα which has emerged as a general stimulus of cell 
spreading and migration by regulating actin-associated protein [597]. The level of 
PKCα is elevated in PC3 [598] and breast cancer cells [599], therefore, blocking it 
with staurosporine might be the reason for the morphological changes observed 
earlier, although its effects cannot be explained merely by PKCα inhibition. Several 
studies have used staurosporine to induce cell apoptosis demonstrated by the change 
of cell morphology it causes and induction of JNK pathway. Olguín-Albuerne et al. 
[600] found that treating astrocyte cells with staurosporine causes morphological 
changes to the actin and tubulin and related astrocytes death dependent on NOX 
family members. Indeed, staurosporine is thought to promote apoptosis because of 
its inhibitory effect on the cell cycle [601] and it is related to the shape change of the 
cells. Staurosporine was also found to supress the proliferation of vascular endothelial 
cells but did not affect the migration of the cells [602]. However, in our study, we used 
staurosporine at a nanomolar concentration (10 nM) which was not found to cause 
cell toxicity using MTS assay (Figure 122). Hedberg et al. [603] have reported that 
using staurosporine at a nanomolar concentration induces rapid change in the actin 
cytoskeleton of different cell types in PKC-deficient cells arguing that staurosporine 
might not be PKC dependent. Yet, our data show that staurosporine did not promote 
a change in the cells morphology unless they were stimulated with the chemokine, 
246 | P a g e  
 
suggesting the role of PKC as a downstream signalling pathway involved in the 
specified cellular response. Thus, the chemokine, cell type and dose of staurosporine 
defines its effect on cell mortality, mobility and/or morphology, this is mostly due to its 
non-selectivity.  
In all, many questions remain to be answered; further investigation of PKC 
isoforms expression levels on the cells, as well as specific targeting of these isoforms 
could be an appropriate approach to establish a unifying understanding of how PKCs 
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 Chapter Conclusion 
In summary, the PKC family is a large one that could exhibit extensive range of effects 
on the cells [386] with each PKC isoform phosphorylating a spectrum of intracellular 
signalling proteins in distinct subcellular locations [604]. We conclude that 
1. Atypical PKCζ is important for the migration of CXCL8 or CXCL10-activated 
THP-1 cells and PC3 cells, whereas it is not important for CXCL8-stimulated 
PC3 or MDA-MB231 cells.  
2. Staurosporine and GF109203X decreased intracellular calcium release in 
CXCL8-activated THP-1, PC3 and MCF-7 cells. 
3. Staurosporine drastically changed the morphology of the cells, regardless of 
its impact on the cell migration, suggesting different mechanisms or signalling 
molecules involved in the process.  
Although these results reveal some of the roles of PKCs, but they also add to the 
complexity of this system, therefore requires further investigation on a larger number 
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6 Chapter 6: Final discussion and future 
work 
Migration of tumour cells is a fundamental process for the formation and progression 
of metastasis in malignant diseases. Chemokines binding to their cognate receptors 
could induce the migration of cancer cells. The expression of these chemokines and 
their effect could be cell-type specific [409], thus, it is challenging to be conclusive 
with the outcomes they generate on cancer cells. Also, the molecular signalling 
pathways involved in chemokine-driven cell migration remain to be fully 
characterised. The aim of this thesis was to investigate the role CXCL8 and CXCL10 
play in different cancer cell lines, as well as the main signalling pathways involved in 
the induction of migration. The approach taken was to test for chemokine receptor 
expression using immunofluorescence assay. Moreover, intracellular calcium release 
upon administration of exogenous chemokine was measured for receptor activation. 
Whether it was an adherent or non-adherent cell line, migration assays were chosen 
based on their reproducibility with the specified cell line. Therefore, we aimed to 
expand our vision in the importance of the chemokine system upon which we could 
utilize as a novel therapeutic target for chemokine-driven cancer progression.  
 Chapter 3 
To identify the involvement of CXCL8 and CXCL10 signalling in cancer metastasis, 
cognate receptors expression, intracellular calcium release, and the migratory 
behaviour were assessed in different cancer cell lines. Breast MCF-7 and MDA-
MB231, prostate PC3, and leukemic THP-1 cancer cells responded to exogenous 
CXCL8 application, while leukemic Jurkat cells did not. Emerging evidence within the 
past two decades acknowledged the success of preclinical trials in targeting CXCL8-
CXCR1/CXCR2 signalling axis [131]. Reparixin, a small molecule inhibitor of CXCR1 
and CXCR2 has made it to clinical trials for being safe and well-tolerated as a cancer 
stem cells targeting agent in patients with metastatic triple-negative breast cancer 
(NCT02370238) [476], [605], [606]. Reparixin appeared to be a good candidate for 
breast cancer patient having an acceptable toxicity profile identified in Phase I and II 
clinical trials. This adds to its already addressed effect in blocking cancer cell 
migration in in vitro studies demonstrated by others [162], [443], [445] and confirmed 
with our results in this thesis. Furthermore, SCH527123 (also known as Navarixin), 
was tested in Phase II clinical trials for chronic obstructive pulmonary disease 
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(NCT01006616) by blocking the migration of neutrophils to the diseased lungs. In 
combination with Pembrolizumab, Phase II trials (NCT03473925) are currently being 
held for patients with metastatic solid tumours (such as NSCLC). We found that 
Reparixin, SCH527123 as well as SB225002 are able to block the migration of THP-
1, MCF-7, MDA-MB231, and PC3 cells, highlighting the importance of the CXCL8-
CXCR1/2 signalling axis in cancer cell migration. Nevertheless, it was challenging to 
generate data using the Boyden chamber transwell assay or agarose spot assay, 
which could have been beneficial to identify the directionality towards the chemokine 
of cancer cells treated with the above antagonists. It is also crucial to take in to 
account the different patterns of cell migration within the 2D environments used. For 
example, MCF-7 cells migrate very slowly in comparison to MDA-MB231 and PC3 
cells when imaged using the time-lapse migration assay. In the Oris migration assay, 
PC3 cells migrated towards the edges rather than the centre, and this was the case 
with MDA-MB231 cells. Thus, there is still a need for robust and sensitive methods to 
identify chemokine-driven migration based on the cell line. 
 The migration ability of different cancer cells was also tested with CXCL10. 
Initially, CXCL10 receptor CXCR3 was found to be expressed in THP-1, MDA-MB231 
and PC3 cells. These cell lines showed higher migration rates in the presence of 
exogenous CXCL10. However, the robustness of the CXCL10/CXCR3 axis is 
challenged by the variant isoforms of CXCR3. CXCR3-A and CXCR3-B appear to 
have contradictive downstream signalling effects. We hypothesized that the previous 
cell lines have potentiated their migratory effect through CXCR3-A, which is 
acknowledged in the literature for being responsible for the induced cell migration 
[487]; and possess lower levels of CXCR3-B, having a lower inhibition effect on 
migration. Yet, further experiments looking into the dominant expression levels of both 
receptors, and the main receptor involved in the migration process could give us 
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 Chapter 4 
Chemokines binding to their cognate receptors induce the migration of cancer cells, 
however, the molecular signalling pathways involved in this process are not fully 
understood. The signalling pathways that are mediated by chemokines and their 
receptors are complex and require further investigation. We primarily used MDA-
MB231 and PC3 cells as a model to identify the pathways involved in CXCL8-
CXCR1/CXCR2 driven migration. There appeared to be few distinctions in the 
pathways that these cells use to migrate when activated with CXCL8 (shown in Table 
6). It is indeed evident that some chemokines may stimulate signalling pathways that 
others do not [388]. For example, while Pi3K did not seem to be important for T cells 
chemotaxis towards CXCL10 or CXCL11 [607], this signalling pathways was required 
for the chemotaxis of CXCL12-activated T-cells  [388], [608]. The data generated in 
this study have highlighted the signalling pathways that are crucial for CXCL8-
mediated cell migration in MDA-MB231 and PC3 cells. We found that upon CXCL8 
activation, Pi3K/AKT, Rho GTPases, DOCK1/2/5, Ras/Raf/MEK/ERK, FAK, Src, 
PKA, Arp2/3, PKC and PKD were important for MDA-MB231 and PC3 migration with 
slight distinctions (Figure 124). 
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Figure 124. Schematic representation of the signalling pathways thought to be 
involved in CXCL8 cancer cell migration. Various inhibitors were used to block the 
effect of these signalling molecules in order to establish an understanding of the 
crucial pathways associated with MDA-MB231 and PC3 cell migration upon activation 
with CXCL8. 
 
 Moreover, one of the impressive effects of chemokines on MDA-MB231 and 
PC3 cells are the morphological changes identified by rearrangement of the 
cytoskeleton, formation of integrin-mediated focal adhesions, extension and 
retraction of cells leading edges to execute the directional migration. The mechanism 
underlying the regulation or reorganisation of the cytoskeleton in cells polarization 
and migration involve a complex system of signal transduction molecules. Using a 
range of small molecule inhibitors, the characterisation of the cellular morphology 
changes was resembled by the alternation to the cell area, the circularity, and aspect 
ratio. We also visually assessed phalloidin-actin stained cells at higher microscope 
objective for changes in actin rearrangement. Although some of the inhibitors for the 
signal transduction molecules were able to inhibit cells migration, they may or may 
not have induced a substantial change in the cell morphology.  
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 Chapter 5 
PKC has been shown to regulate cell migration, adhesion and proliferation [609]. In 
order to identify a connection between PKC and tumour progression in breast, 
prostate and leukaemia cells, the effect of PKC on CXCL8 or CXCL10 mediated cell 
migration and morphology was analysed. We tested the speed of the migrating cells, 
morphology, and chemotaxis in the presences of different PKC isoforms inhibitors- 
GF109203X, staurosporine and PKCζi. We found that the migration of CXCL8-
activated PC3 and MDA-MB231 cells in the presence of conventional, novel, or 
atypical PKCs was not affected, but atypical PKCζ is crucial for THP-1 cells 
chemotaxis. The speed of CXCL10 induced PC3 and MDA-MB231 cells was 
significantly reduced in the presence of conventional, novel and PKCζ. THP-1 cells 
chemotaxis was again affected by PKCζ pseudosubstrate inhibitor. On the other 
hand, the cell area, circularity or aspect ratio were affected by staurosporine in CXCL8 
or CXCL10 induced cells, demonstrating the role of PKCα in the rearrangement of 
the cytoskeleton regardless of the effect on the migration. Consequently, this allows 
the speculation that different PKC isoforms induce different outcomes in cells 
migration and actin cytoskeleton rearrangement based on the chemokine receptor 
and/or the cell type. 
PKCζ is a member of the atypical PKC subfamily and has been vastly 
implicated in the regulation of cellular functions. Accumulating evidence using in vitro 
and in vivo systems highlight the critical role PKCζ plays in regulating intracellular 
signalling pathways. PKCζ is a well-known polarity protein, involving partition-
defective 6 (PAR6) and PAR3, regulating cell polarity, cell motility, and invasion [610]. 
For example, PKCζ controls the polarity of migrating astrocytes with formation of 
protrusions in the direction of the chemotactic gradient [611]. PKCζ knockout or 
knockdown in PC3 cells decrease lymphatic metastasis of prostate cancer by 
impairing the activation of AKT, ERK, and NF-кB signalling [612]. Indeed, PKCζ 
induce the aggressive phenotype of prostate cancer cells [613] as it is important for 
the cells migration and invasion where it forms the PAR6-PKCζ complex in the leading 
edge of membrane ruffles that aids in cell directional migration [610]. Inhibition of 
PKCζ has been associated with CXCL12 and EGF-induced chemotactic migration in 
breast cancer cells [614] and EGF-induced macrophages chemotaxis [584]. Another 
study suggested a role of stimulated PKCζ and CXCR4 expression in elevating the in 
vitro migration and invasion of hepatocyte growth factor-induced MDA-MB436 cells 
[615]. The migration of CXCL8-induced mesenchymal stromal cells was abrogated 
with PKCζ pseudosubstrate inhibitor [616]. In our group, we found that PKCζ was 
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important for the migration of CCL3-activated MCF-7 cells [498], CXCL12-activated 
MCF-7, Jurkat [388] and PC3 cells [389]. Moreover, in this thesis, we found that 
CXCL10-activated MDA-MB231 and PC3 cells as well as CXCL8 and CXCL10-
activated THP-1 cells utilize PKCζ for their migration. With such strong evidence 
demonstrating that PKCζ is crucial for the migration of multiple cancer cell types upon 
activation with different stimulus, it is tempting to conclude that the inhibition of PKCζ 
could decrease cancer spreading and metastasis. Further investigation of its role in 
vivo could potentially lead such pile of preclinical evidence to clinical trials.  
 Other PKC isoforms that were targeted using non-selective PKC inhibitors 
were staurosporine (acts on PKC: α, γ, η), GF109203X (acts on PKC α, β, δ, ε).  
Staurosporine induced actin remodelling dependent upon CXCL8 or CXCL10 
stimulation as well as blocked the migration of CXCL10-activated MDA-MB231 and 
PC3 cells. GF109203X also induced cytoskeleton changes in CXCL10-stimulated 
PC3 cells and blocked the migration of CXCL10-activated MDA-MB231 and PC3 
cells. These inhibitors could be targeting the elevated expression levels of PKCα in 
prostate [598] and breast cancer cells [599]. Additionally, PKCε expression was 
already confirmed in prostate cancer cells [403], hence the effect of GF109203X on 
PC3 cellular morphology and migration. However, due to these inhibitors not being 
selective, it is not conclusive which PKC isoform is the targeted one. Therefore, 
further work should be able to confirm which PKC isoforms are important for the 
migration of chemokine-activated cancer cells to help open a window for more precise 
therapeutic intervention. This could be accomplished by assessing the expression 
levels of PKC isoforms on a wide range of cell types and targeting the elevated levels 
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 Future Directions 
• Find alternative chemotaxis assays to determine the directed migration of 
adherent cells since Boyden chamber transwell assay and agarose spot 
assay were not proven to be reproducible for MDA-MB231, MCF-7 and PC3 
cells throughout this thesis. 
• We showed the expression levels of CXCR1 and CXCR2 using 
immunofluorescent assay. Flow cytometry analysis to determine cell surface 
expression of the receptors would be beneficial for deciding the antagonists 
required to block a specific effect associated with the overexpressed receptor. 
• The role of CXCL8 in cancer cell proliferation remains controversial. Some 
studies have found that CXCL8 does not promote cell proliferation in vitro 
[439], [617] and suppress cancer proliferation by promoting neutrophil 
recruitment [618]. While other studies found that CXCL8 was involved in 
upregulating cyclin D1 expression and Pi3K/AKT/mTOR stimulation in 
prostate PC3 and DU145 cells, where blocking CXCL8 expression abolished 
cells proliferation [294]. Based on the preliminary data generated in this thesis 
supporting a role of CXCL8 in promoting proliferating, it is worth investigating 
the signalling pathways involved in this process. Cell proliferation could be 
measured using MTT/MTS assays. 
• The distinct responses of carcinoma cells to CXCL10 may be due to either the 
cellular milieu or variations of CXCR3 isoforms (CXCR-A, CXCR-B, and 
CXCR-Alt), where the latter is thought to play a reciprocal role in cell migration 
[226]. There is a call for CXCR3 antagonists selective for each splice variant 
to grasp a better understanding of the role of CXCL10 in cell migration.  
• The role of PKC in the migration of different cancer cell lines was analysed 
using migration assays. Using an siRNA approach to knockdown the different 
PKC isoforms is required to confirm the conclusions. 
• The thesis looked at 21 different signal transduction molecules for their role in 
chemokine-driven cancer cell migration using small molecule inhibitors. 
Pi3K/AKT, Raf/MEK/ERK, p38 MAPK, Rho/Cdc42/Rac, DOCK1/2/5, Arp2/3, 
PKA/PKC/PKD, and Src/FAK, appeared to be important for the migration of 
PC3 and MDA-MB231 cells upon the activation with CXCL8. Confirmation of 
the exact roles of these signalling pathways could be achieved using 
chemically synthesized siRNA to specifically assess the importance of the 
different kinases. 
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